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Summary 
 
The initiation of inflammatory cytokine transcription by bacterial ligands is a central 
mechanism by which the immune system activates its first line of defense. Macrophage 
activation by the Toll-like Receptor 4 (TLR4) pathway is initiated with receptor binding of 
lipopolysaccharides (LPS) and culminates in a large-scale transcriptional response of the 
inflammatory gene program. Advancements in genome-wide screening technologies have 
made it possible to interrogate the regulatory landscape of signaling pathways such as those 
activated by TLR4.  Utilizing these high-throughput methods for the comprehensive 
characterization of pathway components, particularly for regulators that are involved in critical 
cellular processes such as transcription and translation, however, requires an approach that 
goes beyond the top scoring and previously characterized hits of genome-scale studies. To 
address this challenge, I developed the Throughput Ranking by Iterative Analysis of Genomic 
Enrichment (TRIAGE) method, a bioinformatic analysis model that facilitates the 
comprehensive identification of likely regulators by iterative sampling of pathway and network 
databases. I validated the TRIAGE approach by analyzing three previously published genome-
wide studies of regulators of early HIV infection and viral transcription. Analysis by TRIAGE 
showed significantly increased overlap and identified shared novel targets across the three 
studies. I further developed the TRIAGE analysis method as a globally accessible web-based 
resource. Applying TRIAGE analysis to three genome-scale studies of LPS treatment in 
macrophages of mouse and human cell lines, I identified an enrichment for regulators relating 
to alternative splicing and protein degradation. Using short read and long read RNA-seq of 
ligand-stimulated macrophages I further characterized the broad transcriptional variation 
induced by the LPS response and the novel and known transcript variants that define different 
macrophage activation states. These findings define an approach for comprehensive unbiased 
discovery of signaling pathway regulators from genome-scale datasets and suggest a model of 
macrophage activation involving proteasomal removal of negative regulators and remodeling 
of the macrophage state via a transcriptional shift in splice variant dynamics.   
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1 Introduction 
 
1.1  Innate immunity, macrophages, and inflammation 
1.1.1 The innate immune response 
An immune response is when a subset of cells within an organism synchronize their activity to 
eliminate or control a perceived threat. Immune responses vary in time, specificity, and 
memory, with different immune responses falling under different combinations of these 
criteria. A prevailing model of the mammalian immune system categorizes immune response 
types into two groups, adaptive and innate (C. A. Janeway et al., 1996). Adaptive is defined as 
immune responses that develop over time with increased specificity towards the targets of 
danger.  Adaptive immune responses also maintain recognition and responsiveness after the 
challenge has been eliminated. By contrast, innate immune activity is generalized as a response 
that cells can mount quickly and effectively but whose impact is less adapted to the specific 
challenge the organism encounters. In the innate immunity model, once the challenge has been 
controlled, the cells and tissue return to homeostasis with a secondary encounter of the 
challenge restarting the response same as it did with the first encounter. 
Many of the tenants of the adaptive vs. innate model of immunity have been challenged 
since its introduction. Cells such as dendritic cells have been shown to engage and cross 
between both branches of the response (Hammad & Lambrecht, 2011). Certain innate immune 
responses have been shown to have an element of training that changes the response with 
repeated exposure (Netea et al., 2016). The rapid responsiveness aspect of the innate immunity 
model, however, has remained central to our understanding of how mammalian immune 
systems operate. Organisms have had to evolve dedicated systems that can in a short time 
mount effective immune responses (Kimbrell & Beutler, 2001). This evolution had to happen 
in parallel with a system that prevents the engagement of these responses too frivolously. 
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Failure of that system leads to excessive or sterile inflammation which are the central 
pathogenesis of autoinflammatory and autoimmune diseases (Arakelyan et al., 2017). 
 
1.1.2 Macrophages: diversity & polarity 
One of the key components of innate immunity are macrophage cells. Macrophages survey 
their environment, respond to challenges, and repair tissue following an immune response.  
From the beginning of their discovery, two different behaviors were observed with 
macrophages. Some observed macrophages were fixed to certain tissue environments while 
others were seen to traffic through the blood stream (Gordon, 2016). This has led to a current 
understanding that categorizes macrophages into two groups, those that are tissue resident and 
those which circulate through the blood and are recruited to sites of challenge by the sensing 
of microorganisms or homing chemokines and cytokines. 
Early discoveries found that macrophages were derived from bone marrow cells (van 
Furth & Cohn, 1968). A proposed model for what differentiated the fixed versus migratory 
macrophages suggested that both macrophage types originated from bone marrow monocytes 
with tissue specific macrophages having low levels of the Ly6C marker and circulating 
macrophages having Ly6Chi (Geissmann et al., 2003; Lawrence & Natoli, 2011). Later work 
by a number of groups found that macrophages that are specific to certain tissue derive from 
fetal monocytes that originate in the yolk sac or fetal liver (Guilliams et al., 2013; Schulz et al., 
2012; Yona et al., 2013). In this model, tissue resident macrophages develop from fetal 
precursors and remain to survey the same tissue for the lifetime of the host, while recruited 
macrophages develop from bone marrow derived monocytes and circulate through the blood 
patrolling for sites or causes of immune challenge (Yona et al., 2013). Though the embryonic 
origin for some populations of self-sustaining tissue resident macrophages is now widely 
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accepted, emerging work suggests that tissue resident macrophages consist of diverse subsets 
of both embryonic and bone marrow origin (Epelman et al., 2014; Guilliams et al., 2018). 
Functionally, macrophages possess a range of seemingly opposing capacities. In the 
encounter of an immune challenge, macrophages activate microbicidal and apoptotic programs, 
whereas in the context of injury and in the aftermath of an immune response, they can promote 
tissue repair and a return to homeostasis. The two activation states can be induced in vitro by 
different stimuli. Treatment of macrophages by lipopolysaccharides (LPS) or interferon (IFN)-
g induces pro-inflammatory activity (Dalton et al., 1993), while treatment by interleukin (IL) 4 
or IL13 leads to the expression of anti-inflammatory cytokines (Stein et al., 1992). Early 
models defined this diversity of activation states into separate groups of classical activation 
(pro-inflammatory and pro-death) for the LPS/IFN-g treated macrophages and alternative 
activation (anti-inflammatory and pro-healing) for the IL4/IL13 treated macrophages (Edwards 
et al., 2006). This model was then replaced by a paradigm to parallel T cell activation and the 
model of Th1/Th2 responses. This saw the two activation paths in macrophages as part of a 
polarization of the cell to match the T cell states and defined the polarities as M1 (pro-
inflammatory) and M2 (anti-inflammatory) (Mills et al., 2000). 
Subsequent work, however, has challenged the idea that macrophage activation is 
determined by divergent polarization and limited to the binary states of pro- and anti- 
inflammatory. Work done in human cells found that an overly simplified M1/M2 polarity did 
not represent the full spectrum of observed functions, and that activation in different contexts 
can lead to more varied functions across the range of these macrophages polarities (Mosser & 
Edwards, 2008; Murray & Wynn, 2011; Xue et al., 2014).  
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1.1.3 The inflammatory response 
Though it is context and stimulus dependent, the most studied function of macrophages is their 
release of inflammatory cytokines as a pathogen fighting and immune protective response 
(Arango Duque & Descoteaux, 2014). The range of inflammatory cytokines secreted by 
macrophages include, but are not limited to, TNFa (B. Beutler et al., 1985), IL1 (Carmi et al., 
2009), IL6 (Hurst et al., 2001), IL12 (Trinchieri, 1994), and type I IFNs (Decker et al., 2005). 
These cytokines, together with a collection of chemokines, further recruit additional immune 
cells to sites of infection or tissue damage, induce apoptosis of infected cells, trigger the 
expression of anti-microbial proteins in targeted cells, and induce phagocytosis of pathogenic 
debris. Following the clearance of the immunological challenge, macrophages secrete a set of 
anti-inflammatory cytokines that regulate and resolve their pro-inflammatory activity 
(Chadban et al., 1998; Xiao et al., 2002).  
  
1.2 The PRR-ligand model; Toll-like receptor 4 and lipopolysaccharide 
1.2.1 PRRs 
As stationed or circulating surveyors of immunity, macrophages require a mechanism by which 
to selectively sense the presence of immune challenges. Since they lack the capacity of adaptive 
immune cells for clonal expansion and variability, it was not initially appreciated that 
macrophages can discriminate between different immunological threats and mount specific 
responses. Janeway was first to propose a model of innate immune cell sensing that relied on 
a set of a specific receptors termed Pattern Recognition Receptors (PRRs) (C. A. Janeway, Jr., 
1989). Subsequent work has identified numerous types of PRRs that are localized to different 
segments of the cell and whose receptors are specific for different groups of immune 
challenges.  The first such a PRR was the family of Toll-like receptors (TLRs) (Hoffmann, 
2003; Medzhitov et al., 1997) (described in more detail in section 1.2.3). TLRs are 
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transmembrane proteins that detect specific molecular patterns of microbes (see section 1.2.2 
on PAMPs) and initiate transcription of pro-inflammatory cytokines and type-I IFNs. 
Additional PRRs were subsequently identified with variations in their localization, pattern 
recognition, and downstream response induction. C-type lectin receptors (CLRs) are 
transmembrane receptors like TLRs but are relegated to the plasma membrane and 
predominately recognize fungal infections (Netea et al., 2006). NOD-like receptors (NLRs) 
recognize microbe motifs, but in contrast to TLRs are localized in the cytoplasm (Fritz et al., 
2006). A series of cytoplasmic localized receptors which recognize nucleic acids were also 
identified. RIG-I-like receptors (RLRs) (Hornung et al., 2006; Yoneyama et al., 2004) 
(including the melanoma-differentiation-associated gene 5 (MDA5) (Kato et al., 2006)), absent 
in melanoma 2 (AIM2)-like receptors (ALRs) (Bürckstümmer et al., 2009; Fernandes-Alnemri 
et al., 2009; Hornung et al., 2009), and cyclic GMP-AMP synthetase (cGAS)-stimulator of 
interferon genes (STING) (Ishikawa & Barber, 2008; Ishikawa et al., 2009; X. Li et al., 2013; 
L. Sun et al., 2013). Different cytosolic receptors recognize different forms of nucleotides. 
RLRs respond predominantly to viral RNA (though it can also respond to exposed bacterial 
RNA) (Hornung et al., 2006). cGAS-STING responds to cytosolic DNA (Ishikawa et al., 
2009). Initiation of inflammatory cytokine transcription and type-I IFNs is also not the only 
response initiated by PRRs. Some PRRs recruit super molecular complexes to specific 
locations in the cell. Activation of NLRs and ALRs also activate the inflammasome complex 
and lead to the maturation of Interleukin (IL)-1 and cell death (Franchi et al., 2012). An 
additional protein, Caspase-11 was found to be able to recognize intracellular endotoxins and 
activate a non-canonical inflammasome pathway (Hagar et al., 2013; Kayagaki et al., 2013). 
The diversity and specificity of these receptors support the original hypothesis by Janeway that 
the effectors of innate immunity have evolved sets of PRRs that recognize and discriminate 
between targets. Recent work has added the localization of receptors as additionally critical in 
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ensuring that the receptor’s responsiveness is not activated by the host, in addition to the 
receptor specificity as proposed by Janeway (Chow et al., 2015).  
 
1.2.2 PAMPs and DAMPs 
A necessary corollary to the PRR model proposed by Janeway was that pathogens contain 
pathogen-associated molecular patterns (PAMPs) and that these patterns are unique to 
pathogens and absent in the host organism. An additional criterion for PAMPs is that they 
involve components essential for pathogen function and survival to circumvent evolutionary 
pressure on the pathogen to easily change these factors (C. A. Janeway, Jr., 1989). This model 
aligned with Janeway’s earlier dictum of innate immunity, that it evolved to discriminate 
between self and non-self molecules of the host organism (C. A. Janeway, 1992). A 
contradictory model proposed by Matzinger and later confirmed by others found that even in 
the absence of a pathogen, signals associated with danger to the host cell or tissue, such as 
necrosis, can also activate the innate immune system (Matzinger, 1994; Scaffidi et al., 2002; 
Scheibner et al., 2006). These findings amended the category of triggers for innate immunity 
to include PAMPs and danger-associated molecular patterns (DAMPs). Further work also 
suggested the addition of another subcategory of molecular patterns associated with tissue 
trauma, termed alarmins (Bianchi, 2007). (It has been argued, however, that this category can 
be considered to fall under the category of DAMPs). Though these categories differ in the 
central dogma of innate immunity they profess, common to all of them is that the binding of a 
distinct molecular pattern with a complementary evolved receptor triggers and initiates innate 
immunity in different contexts and that the diversity of immunological challenges can be 
discriminated on the basis of specific receptor-ligand interactions.  
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1.2.3 LPS and TLR4 
Predating our understanding of receptors and ligands in innate immunity by almost a century, 
independent work by Pfeiffer and Centanni found that endotoxins -integral components of the 
outer membranes of gram-negative bacteria- were sufficient to induce the deleterious effects 
of bacteria (Vibrio cholerae and Salmonella typhi, respectively) (Centanni & Bruschettini, 
1894; Pfeiffer, 1892). These immunologically active endotoxins were later purified by Boivin, 
Lüderitz, and Westphal and identified as lipopolysaccharides, or LPS (Boivin & Mesrobeanu, 
1935; Lüderitz et al., 1971). The structure of LPS is comprised of three domains, a lipid 
component that is anchored to the bacterial cell wall called lipid A, a core oligosaccharide 
bound to lipid A by a 3-deoxy-d-manno-oct-ulosonic acid (Kdo) called the core component, 
followed by a variable chain of polysaccharide called the O-antigen (Figure 1.1A) (Erridge et 
al., 2002). The O-antigen, which is the outermost structure of LPS, is variable across different 
species of bacteria and it is how the presence or absence of a specific pathogen in the blood 
can be determined (i.e. “serological specificity”). The lipid A domain conserves some 
architecture across species including two phosphate groups and two acyloxyacyl moieties 
(though position and length can vary from species to species) and it is what gives LPS its 
endotoxic activity (Alexander & Rietschel, 2001; Raetz & Whitfield, 2002). LPS was also 
found to induce the expression of Tumor Necrosis Factor (TNF), an inflammatory cytokine, in 
macrophages (B. A. Beutler et al., 1985). Thus, LPS became the first characterized PAMP. 
Identifying the first PRR took a more circuitous path.  A Toll gene was first identified 
in Drosophila as critical for guiding spatial embryonic development (Hashimoto et al., 1988). 
Later work found that Toll -along with its ligand, spätzle, and its inhibitor, cactus- also 
functions as a receptor in the adult Drosophila anti-fungal response (Lemaitre et al., 1996). It 
was also observed that the activation dynamics of Toll in Drosophila bore a striking 
resemblance to the mammalian immune pathway induced through the IL-1 receptor (Gay & 
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Keith, 1991), suggesting that the immune signaling mechanisms of these pathways have been 
conserved across species. Searching for the Toll gene sequence in the human genome, 
Medzhitov identified the human homolog of Toll (Medzhitov et al., 1997). hToll and dToll 
both transcribe a transmembrane protein with an extracellular N-terminal leucine-rich repeat 
(LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain. Following the discovery 
of the human homolog of Toll many members of the Toll-like Receptor (TLR) family were 
identified (10 in human, 12 in mouse) (Beutler, 2004; Takeda et al., 2003). A mouse strain that 
was not responsive to LPS was later found to have a mutation in its Tlr4 gene (Poltorak et al., 
1998). Work done by Akira and colleagues later showed that the TLR4 receptor specifically 
binds LPS (Akira et al., 2001). The discovery by Akira marked the first characterized PAMP-
PRR combination. Many other receptor-ligand combinations followed (reviewed in Akira, 
Uematsu, & Takeuchi, 2006) . The TLR4-LPS interaction, consequently, became the protype 
receptor-ligand interaction in innate immunity and continues to be the most studied pathway 
in innate immune activation.  
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Figure 1.1 LPS domains and its binding to TLR4 dimers stabilized by MD-2 
Adapted from Alexander 2001 and Park 2009. 
 
 (A) The chemical structure of LPS and its domains. The immunostimulatory membrane 
anchored Lipid A domain includes covalently linked poly and oligosaccharides bound to 
glucosamine (GlcN) residues. The core domain is bound to the lipid domain by three Kdo 
and D-glycero-D-manno-heptose (Hep) sugars and separated by an inner and outer core. The 
core domain is connected to the O-specific chain which is variable and comprised of up to 
50 repeating motifs. (B) Top view of the stably dimerized structure of TLR4, MD-2 
following binding of LPS. TLR4 binds MD-2 at the primary interface. Binding to LPS (red) 
leads the TLR4-MD-2 heterodimer to dimerize with another TLR4-MD—2 structure by 
binding at the dimerization interface. (C) The “horseshoe” configuration of the stabilized 
TLR4 receptor following binding to MD-2 and LPS recognition. This configuration creates 
hydrophobic regions for the phosphate groups and lipid chains of LPS Lipid A domain to 
bind. 
A 
C B 
Structural domains of LPS 
Binding structure of LPS to stabilized TLR4 dimers 
Structure and binding of LPS and TLR4 
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1.3 TLR4 Pathway: signaling and regulation 
1.3.1 MyD88/Mal vs. TRIF/TRAM dependent signaling 
While TLR4 directly recognizes LPS, overexpression of TLR4 alone in embryonic kidney 293 
cells did not increase responsiveness to LPS (Akira et al., 2001) suggesting that a series of 
adaptors and downstream effectors are required to activate the TLR4 pathway. Accessory 
proteins CD14 and LPS Binding Protein (LBP) are required to bring LPS to the receptor 
(Fenton & Golenbock, 1998; Ulevitch, 1993; Wright et al., 1990). Prior to binding with LPS, 
TLR4 forms a complex with myeloid differentiation factor 2 (MD-2) which creates the 
hydrophobic pocket where LPS can bind (Figure 1.1B and C) (Park et al., 2009; Shimazu et 
al., 1999). Following the binding of LPS, TLR4-MD2-LPS stably dimerizes with another 
TLR4-MD2-LPS structure via binding of the two intracellular TIR domain regions of TLR4 
(Xu et al., 2000; H. Zhang et al., 2002). The dimerized version of TLR4, which spans across 
the cell or endosomal membrane, can then engage with macromolecular structures in the 
cytoplasm that have a binding affinity for the TIR domains of TLR4 (Bryant et al., 2015; Núñez 
Miguel et al., 2007; Song & Lee, 2012). 
On the cytosolic side of the dimerized TLR4 proteins, a cascade of signaling events 
occur to initiate the pro-inflammatory activity of the cell. The transcription factor nuclear factor 
kappa B (NFkB) was independently shown to be activated by LPS (Patrick A. Baeuerle & 
Baltimore, 1991). NFkB was also recognized early as a downstream effector of TLRs given its 
signaling similarity to the function of dorsal, a transcription factor acting downstream of Toll 
in Drosophila (Gay & Keith, 1991; Ghosh et al., 1990). How the activated form of TLR4 
culminates in the activation of NFkB has been the subject of extensive research.  
There are currently two known paths through which activated TLR4, depending on its 
localization, initiates downstream signaling inside the cell. TLR4 anchored in the cell 
membrane and activated by extracytosolic LPS engages through its TIR domain with myeloid 
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differentiation primary response protein 88 (MyD88) and its adaptor protein MyD88-adaptor-
like (MAL) (Fitzgerald et al., 2001; Medzhitov et al., 1998; Muzio et al., 1998). Following the 
binding with MAL, MyD88 recruits IL-1R-associated kinase (IRAK) family members through 
death domain (DD) interactions (Gottipati et al., 2008). This super-molecule does not bind in 
a 1:1 ratio, increasing evidence shows that these components come together to form a multiunit 
“myddosome” through which it engages its downstream effectors (Bryant et al., 2015; Gay et 
al., 2011). Following activation of the myddosome, TLR4 is internalized into endosomal 
vesicles, whereby the TIR domains of stably dimerized TLR4 bind with TIR domain-
containing adapter inducing IFN-β (TRIF) protein and TRIF-related adaptor molecule (TRAM) 
(K. A. Fitzgerald et al., 2003; Kagan et al., 2008; Oshiumi et al., 2003; Yamamoto et al., 2002). 
These two paths for initiating the cellular response of activated TLR4 are respectively known 
as the MyD88-dependent and MyD88-independent pathways.  
The divergent TLR4 response pathways engage different effectors and lead to a 
diversity of responses to LPS sensing. MyD88 and MAL signal though IRAK family proteins 
which activate the TNF-receptor associated factor 6 (TRAF6) (Keating et al., 2007; A. Liu et 
al., 2012; Verstak et al., 2014). TRAF6 acts as an E3-ubiquitin ligase which through a series 
of lysine-63 (K63) ubiquitin chains and the activation of mitogen-activated protein kinases 
(MAPKs) recruits the TGFb-activated kinase 1 (TAK1), TAK1-binding protein 2 (TAB2) and 
TAB3 (TAK1/TAB2/3) complex. The TAK1/TAB2/3 complex then activates the IκB kinase 
(IKK) complex (Deng et al., 2000; Ostuni et al., 2010) which through lysine-48 (K48) 
ubiquitination targets IκB for degradation by the proteasome (Whiteside et al., 1997). IκB is 
attached to NFκB and is what keeps it, in the absence of TLR4 activation, sequestered in the 
cytoplasm. Following the degradation of IκB, NFκB rapidly translocates to the nucleus where 
it binds DNA in its function as a transcription factor and mediates the expression of pro-
inflammatory genes (P. A. Baeuerle, 1995; Patrick A. Baeuerle & Baltimore, 1991; Ghosh et 
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al., 1998). The activation of TRAF6 and binding with TAK1/TAB2 also activates MAP3K 
which recruits the MAPK signaling cascade (Arthur & Ley, 2013; Takaesu et al., 2000). 
Engagement of the MAPK signaling cascade activates the MAPKs JNK and p38 (Sato et al., 
2005). JNK and p38 activate the transcription factors activator protein 1 (AP-1) and cAMP 
response element-binding protein (CREB), respectively, which further mediates expression of 
pro-inflammatory genes (Das et al., 2009; Kim et al., 2008). The TRIF-TRAM pathway (i.e. 
MyD88 independent pathway) activates TRAF3 which, through IκB kinase-ε (IKKε) and 
TANK-binding kinase-1 (TBK1), activates the transcription factor interferon regulatory factor 
3 (IRF3) which translocates to the nucleus (Katherine A. Fitzgerald et al., 2003). TRIF also 
activates the phosphatidylinositol 3-kinase (PI3K) which phosphorylates Akt which then 
modulates the expression of pro-inflammatory cytokines (Martin et al., 2003) (see section 1.3.2 
on negative regulation of TLR4 signaling). These different pathways activated downstream of 
TLR4 activation by LPS also show crosstalk (Cheng et al., 2015; Dorrington & Fraser, 2019) 
and downstream signal integration (Sakai et al., 2017). Together these pathways activate a 
constellation of transcription factors that initiate the full scale of pro-inflammatory 
transcription in response to LPS.  
 
1.3.2 Negative regulation of TLR4 signaling 
The cytoplasmic sequestration of NFκB by IκB, and the subsequent release and activation of 
NFkB upon stimulus-dependent IkB degradation, has served as a prototypic model for how the 
TLR4 response pathway is negatively regulated against constitutive activation. Additional 
proteins that function as inactivators of inflammatory effectors that  are then removed by 
degradation in response to sufficient stimuli of TLRs have been identified (Liew et al., 2005). 
Toll-interacting protein (TOLLIP) suppresses the kinase activity of IRAK and following LPS 
treatment TOLLIP is phosphorylated by IRAK1 and targeted for degradation, thus releasing 
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IRAK to complex with MyD88 (G. Zhang & Ghosh, 2002). Conversely, proteasomal 
degradation of positive effectors of TLR4 signaling in the absence of stimulus has also been 
observed. In the absence of robust TLR4 activation, the zing-finger protein A20 depresses 
TLR4 signaling by targeting for degradation the Ubiquitin-conjugating enzyme Ubc13 which 
is critical for building the ubiquitin chain of TRAF6 so that it can engage with the 
TAK1/TAB2/3 complex (Shembade et al., 2010; Wertz et al., 2004). In an interesting reversal 
of how many discoveries in TLR signaling arose from homology and comparison with 
Drosophila, the discovery of regulation by A20 in vertebrates led to the discovery of a similar 
model of regulation in Drosophila signaling by Toll/Imd (Chen et al., 2017). Alternative modes 
of negative regulation have also been identified such as the translocation of TLR4 to the 
lysosome via Rab7b where the receptor is assigned for degradation (Y. Wang et al., 2007), 
negative feedback of TLR4 activity via phosphoinositide 3-kinase (PI3K) (Laird et al., 2009), 
and deubiquitination of TRAF6 by the deubiquitinase cylindromatosis protein (CYLD) 
(Kovalenko et al., 2003) (in the presence of LPS stimulation CYLD is targeted for proteasomal 
degradation via Caspase 8 (O’Donnell et al., 2011)). These factors emphasize the interplay 
between positive effectors of the TLR4 response and negative regulators at different junctures 
in its signaling, and the central importance of signal induced protein degradation as a means of 
regulation. 
 
1.4 Transcription and alternative splicing in macrophages 
1.4.1 Escalation of core cellular processes define and drive the macrophage inflammatory 
state 
Transcriptional induction of the inflammatory cytokine TNFa was only the first of an 
extensive panel of genes that LPS treatment was found to induce (B. Beutler et al., 1985). 
Simultaneously, many additional transcription factors beyond NFκB have been found to be 
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activated in response to TLR4 engagement (Guha & Mackman, 2001; Sweet & Hume, 1996). 
The genes whose expression is effected by LPS have been extended from the hundreds 
initially identified (Nau et al., 2002), to over a thousand genes (Bjorkbacka et al., 2004). 
While a robust transcriptional response is to be expected in the activation of an altered cell 
state, Liu and colleagues found that the scale of macrophage gene expression change in 
response to LPS+IFNg was 1-2 orders of magnitude greater than other treatments and cell 
fate inductions in the same cell type (H. Liu et al., 2018) (Figure 1.2). In parallel to these 
findings, work has been emerging to elucidate the mechanisms of how the macrophage shifts 
its metabolic program to meet the energy needs of this large scale transcription induction 
program (Kelly & O'Neill, 2015). In addition to activating a switch to glycolytic metabolism 
(Krawczyk et al., 2010), recent findings have suggested that LPS treatment also directly 
engages and increases the production of specific pro-glycolytic metabolites (Infantino et al., 
2011; Michelucci et al., 2013; Tannahill et al., 2013). These findings emphasize the large-
scale signaling shift in many of the core cellular processes activated by TLR4 during and 
inflammatory response. 
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A key cellular process not discussed so far, which is relevant in the context of robust 
transcriptional induction, is alternative splicing. Alternative splicing is a process of exon 
excision and inclusion of mRNA by the spliceosome and controlled by cis and trans acting 
proteins on the mRNA (Black, 2003). Estimates of human protein coding genes that undergo 
alternative splicing range from 60% (Modrek & Lee, 2002), to upwards of 90% when looking 
at multi-exonic genes that have two or more known isoforms (Lee & Rio, 2015). At the 
proteomic level it is estimated that alternative splicing expands the number of proteins that can 
be generated from the human genome by a factor of 10 (Nilsen & Graveley, 2010). It would 
be expected that in macrophage transitions, alternative splicing events could play a critical role 
in the determination of fate and activation states. A surprising finding, however, came from 
Lin and colleagues who did a transcriptome-wide analysis of alternative splicing in 
macrophage polarization and found that alternative splicing was highly and preferentially 
deployed in M1 activation (pro-inflammatory, the one associated with the LPS treatment) and 
only minimally so in M2 macrophage determination (Lin et al., 2016). The escalated 
deployment of alternative splicing in the activation of inflammation was similarly observed by 
A B 
Figure 1.2: Elevated transcription in LPS treated macrophages. 
From H. Liu et al., 2018  
 
(A) Diagram of differentiation and polarization of human primary monocytes (Mo) to 
macrophages (Mϕ) in culture.  (B) Venn diagrams with numbers of differentially expressed 
genes with fold change ≥2 (q-value ≤0.05) for GM-CSF and M-CSF treated macrophages 
versus monocytes (left), and for the four polarizations (right).  
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Liu and colleagues who found that in macrophages treated with LPS+IFNg, alternative splicing 
events exceeded by an order of magnitude the number of events observed following other cell 
fate and activation treatments of monocytes (H. Liu et al., 2018) (Table 1.1). These findings 
suggest that, in addition to the known core cellular processes (proteasomal degradation, 
elevated transcription, and glycolytic metabolism) used by macrophages in their rapid 
transition from homeostatic surveyors to activators of inflammation, alternative splicing is 
likely to also play a key role. 
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Cell Type Culture Treatment 
Exon 
Inclusion 
events  
Exon 
Skipping 
events  
Human 
primary 
monocytes  
Mo  GM-CSF  2574  1794  
  Mo  M-CSF  2264  1433  
  GM-CSF  LPS/IFNγ  448  357  
  M-CSF  IL4  34  27  
  M-CSF  IL1β  25  13  
  M-CSF  IL10  17  12  
THP-1 cell line  THP-1  PMA3D  305  267  
  THP-1  PMA5Dr  349  211  
  THP-1  VD3  1142  519  
  PMA3d  LPS/IFNγ  224  131  
  PMA3d  IL4/IL13  133  75  
 
  
Table 1.1 Comparison of differential alternative splicing events in monocyte (Mo) and 
macrophage treatments. 
From H. Liu et al., 2018  
 
Liu and colleagues compared the number of alternative splicing events observed in 
monocyte derived and immortalized macrophages under various differentiation and 
stimulus conditions. While the differentiation transitions (GM-CSF and M-CSF) led to the 
highest number of alternative splicing events in monocyte derived macrophages, among the 
stimulus treatments LPS/IFNγ led to the highest number of alternative splicing events. 
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1.4.2 Dynamic regulation of signaling by alternative splicing, in macrophages and other 
contexts 
Alternative splicing has been previously shown to have a regulatory role in TLR4 signaling 
through variants of critical effectors such as MyD88, IRAK1, MD2, and TLR4 itself. MyD88s, 
an alternatively spliced variant of MyD88 that lacks its critical intermediate domain, binds 
IRAK1 but fails to induce IRAK phosphorylation, thus acting as a negative inhibitor of 
MyD88-dependent signaling (Burns et al., 2003; Janssens et al., 2002). As compared to healthy 
donors, patients with acute respiratory distress syndrome (ARDS) have been shown to have 
higher ratios of MyD88l -the complete and functional version- to the splice variant MyD88s 
(Blumhagen et al., 2017). IRAK1 was also found to have a splice variant that has a dominant 
negative effect on TLR4 signaling. IRAK1c lacks exon 11 of the IRAK1 gene and fails to 
induce phosphorylation, thus truncating TLR4 signaling at the myddosome formation stage 
(Rao et al., 2005). A similarly truncated variant that negatively impacts TLR4 signaling was 
described for the TLR4 accessory protein MD-2. The alternatively spliced MD-2s variant lacks 
exon 2 of the MD-2 gene and fails to induce a stable ligand binding pocket for LPS when 
complexing with TLR4 (Gray et al., 2010). A splice variant of TLR4 itself has also been 
identified. Soluble mTLR (smTLR4) includes an additional exon that adds a stop codon after 
exon 2 and inhibits activation by LPS. smTLR4 was also found to be expressed as a result of 
LPS stimulation suggesting that this might be used as way to terminate TLR4 signaling during 
the inflammatory resolution phase (Iwami et al., 2000; Jarešová et al., 2007). Patients with 
rheumatoid arthritis were found to have several splice variants of the A20 gene (Yoon et al., 
2013), though it remains to be seen whether alternative splicing of A20 is also a regulatory 
mechanism of TLR4 signaling in healthy patients. 
The TLR4 pathway related examples listed above all involve switching between a 
functional variant and alternatives that lack comparative function and stability. In some cellular 
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contexts, alternative splicing was observed to have a regulatory effect by switching to 
attenuated variants. In other cellular contexts, however, alternative splicing has been shown to 
have regulatory capacity that goes beyond switching between functional and non-functional 
variants. Alternation in splicing can also produce variants with different positive signaling 
results. The inhibitor of apoptosis protein (IAP) survivin was shown to have two variants that 
are both functional, but differ in their localization within the cell, suggesting that alternative 
splicing can be used to direct a protein to different localizations in different contexts (Mahotka 
et al., 2002). It remains to be discovered whether macrophage activation is also regulated by 
alternative splicing in such a manner. 
 
1.4.3 The spliceosome network of proteins drives specificity in different contexts 
Alternative splicing events are understood to be guided by transcript sequences and RNA 
binding proteins that differentially promote the inclusion or exclusion of exons and introns. 
There are cis-regulatory sequences known as exonic splicing enhancers (ESE) and intronic 
splicing enhancers (ISE) which promote exon and intron inclusion, respectively. Exonic 
splicing silencer (ESS) and intronic splicing silencer (ISS) are cis-regulatory elements that 
promote exon and intron repression, respectively (Black, 2003; Yabas et al., 2015). There also 
trans-acting factors which include the serine-arginine (SR) rich proteins and heterogeneous 
ribonucleoprotein particle (hnRNP) proteins which recruit the spliceosome to different splice 
sites to promote, in the case of SR proteins, splice site usage and, in the case of hnRNPs, splice 
site skipping (Mayeda et al., 1999; Jun Zhu et al., 2001) (Figure 1.3). All of these factors are 
targets for regulation of signaling in innate immunity (Fang et al., 2017; Grohar et al., 2016; 
Yabas et al., 2015). The spliceosome complex itself has recently be shown to also be able to 
dynamically regulate splicing and for its regulatory impact to not simply be relegated to 
whether it is or isn’t recruited to specific sites by ancillary regulators. Work by Papasaikas and 
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colleagues found that the spliceosome, far from being a rigid and universal structure, consists 
of a network of persistent and transient proteins that are engaged for complete or just parts of 
the splicing reaction, respectively. More surprisingly, silencing by siRNA of persistent or 
transient components affected alternative splicing in qualitatively different ways (Papasaikas 
et al., 2015). These findings suggest that the selective engagement of the core spliceosome 
proteins also plays a role in regulation by alternative splicing. This conclusion is supported by 
an earlier finding by De Arras and colleagues that inhibition of Sf3a1 and Sf3a2, two genes 
transcribing proteins essential for spliceosome function, diminished IL-6 production in LPS 
treated macrophages (De Arras et al., 2013). More recent work by Liu and colleagues found 
that muscleblind like splicing regulator 1 (MBNL1) is specifically essential for the monocyte 
to macrophage transition (H. Liu et al., 2018). The independent findings by Papasaikas, De 
Arras, and Liu emphasize the role core splicing factors can play in selective regulation in 
different contexts. 
Figure 1.3: Cis and Trans regulatory mechanisms for alternative splicing. 
From Yabas et al., 2015  
 
Mechanism of alternative splicing of pre-mRNAs. The cis-regulatory elements that control 
alternative splicing are composed of unique nucleotide sequences. The exonic splicing 
enhancers (ESE) and intronic splicing enhancers (ISE) (dark blue) respectively promote exon 
inclusion (light blue boxes), while exon repression requires the exonic splicing silencer (ESS) 
and intronic splicing silencer (ISS) elements (brown). The trans-acting factors that promote 
exon inclusion are the Serine (S)-Arginine (R) SR rich proteins while hnRNP proteins can 
promote exon skipping. In the diagram the middle exon can be included to give rise to a 
polypeptide with 3 exon units, while the alternatively spiced polypeptide skips the variable 
exon to yield a protein with 2 exon units. 
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1.4.4 Splicing aberrations and inflammatory dysregulation in myelodysplastic syndromes  
Beyond the in vitro findings mentioned in the previous section, mutations in core spliceosome 
factors have also been shown to play a key role in the pathogenesis of disease. Myelodysplastic 
syndromes (MDS) are a group of diseases whose pathogenesis is associated with altered 
proliferation and differentiation of bone marrow cells. Though the pathogenesis and disease 
phenotype is quite diverse across patients, it often involves cytokine and immune system 
abnormalities, ring sideroblasts, anemia, and bone marrow dysplasia (Tefferi & Vardiman, 
2009). Early work has shown that anemia and ring sideroblast – two of the pathogenic 
categories of MDS – is often associated with patients having a mutation in the Splicing Factor 
3b Subunit 1 (SF3B1) gene (Visconte et al., 2012). Further studies found that mutations in 
SF3B1 are often associated with MDS (Arber et al., 2016). Two additional splicing related 
genes, U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) and Serine And Arginine Rich 
Splicing Factor 2 (SRSF2), were also found to have mutations in subset of MDS patients 
(Papaemmanuil et al., 2013).  
Moreover, recent studies have begun to show dysregulated TLR signaling in patients 
with MDS. One study found that downstream signalers of TLR4 are overexpressed in patients 
with MDS (Velegraki et al., 2013), another study found broad dysregulation of TRAF6 – a 
critical signal mediator in TLR signaling- in patients with MDS (Culver-Cochran & 
Starczynowski, 2018). These parallel findings suggest that the pathogenesis of MDS may be 
correlated with the dysregulation of TLR4 signaling by aberrant alternative splicing, though 
the mechanism by which these mutations lead to this dysregulation, and how it deviates from 
normal TLR4 signaling, remains to be elucidated. 
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1.5 Genome-wide perturbation studies of the TLR4 response to LPS 
1.5.1 Categorizing the canonical TLR4 pathway 
As a corollary to the outlined incremental insights so far to the canonical TLR4 signaling 
pathway, various schema have been proposed to integrate the myriad of effectors, mediators, 
and regulators shown so far to bridge LPS recognition with pro-inflammatory transcription. 
The Kyoto Encyclopedia for Genes and Genomes (KEGG) curates a TLR signaling pathway 
that includes 104 members (KEGG) with only the essential effectors downstream of TLR4 
included (Figure 1.4A). Sun and colleagues took a more methodical approach by curating 
known and putative effectors in TLR signaling, and running them through a targeted RNA 
interference (RNAi) screen in human and mouse macrophages treated with a panel of TLR 
ligands (J. Sun et al., 2016). The canonical TLR pathway that emerges from their study includes 
126 genes, with some being shared and many being specific for different TLR ligands. Within 
the same ligand treatment, some effectors were also shown to be species-specific in their 
requirement (Figure 1.4A). Sun and colleagues propose a model of TLR signaling that includes 
the spectrum of TLR signaling factors segmented into three modules (Figure 1.5A-B), the 
encoder module which includes the TLR receptors and their proximal signaling adaptors (such 
as MyD88/MAL and TRIF/TRAM), the transmission module (including factors such as NFκB, 
MAPK and PI3K/Akt), followed by the decoder module (which includes the transcription 
factors and cytokines). Working in dendritic cells (DC), Mertins and colleagues aimed to do a 
similar analysis by curating known TLR signaling components and looking for “orphaned” 
effectors (Mertins et al., 2017). (Orphaned in the sense that their matching kinases haven’t been 
identified.) Combining ss (SILAC)-based phosphoproteomics and computational network 
analysis, they compiled a list of 161 genes associated with LPS responsiveness. Breaking down 
the network into three groups; “seeds”, “intermediates”, and “transcriptional regulators” 
(Figure 1.5C-D), these groups map similarly to the “encoder”, “transmission” and “decoder” 
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model that Sun et al. proposed. These similar models summarize the understanding of innate 
immune activation that has emerged from the accrued findings so far, that it comprises a 
recognition-to-signaling-to-transcription system. These two studies also highlight different 
blindspots in the currently curated models. The weighted-network work by Mertins highlights 
how the itemized identification of different factors has left gaps in our understanding of how 
many of these effectors interact and how these factors coalesce into a functional signaling 
network. The comparative work by Sun, on the other hand, highlights how insights gained from 
dispersed species and cell types may come up short when extrapolated into a cohesive 
vertebrate TLR signaling pathway. To elucidate a more complete model of innate immune 
activation by TLR4 signaling, both of these considerations must be taken into account. 
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Figure 1.4: Canonical TLR signaling pathway in human and mouse. 
From KEGG, Sun et al., 2016. 
 
The canonical TLR pathway from the KEGG pathway database, overlaid with species 
specific dependency found by Sun et al., 2016. 
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Figure 1.5: Models of the canonical TLR signaling pathway. 
From Sun et al., 2016, Mertins et al., 2017  
 
(A) Schematic by Sun et al., 2016 of signal flow in the TLR pathway (B) 126 canonical TLR 
signaling genes curated by Sun et al., 2016. (C)  The computational framework for integrative 
analysis of the functional and physical proteomics  applied by Mertins et al., 2017  for analysis 
of canonical TLR signaling  (D) A TLR signaling transduction network proposed by Mertins 
et al., 2017 that connects 27 seeds (blue) to 95 transcriptional regulators (red) through the top 
60 intermediate (yellow) nodes. 
Network models of the TLR signaling pathway 
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1.5.2 High-throughput assays to identify novel regulators in immune cells 
The regulatory insights and discoveries outlined so far have all contributed to the incremental 
reconstruction of the canonical TLR4 signaling pathway. A necessary complement to that 
approach, however, has been the use of unbiased genome-scale studies. RNA interference 
(RNAi) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 assays 
make it possible to target the expression of specific genes in the genome (Cong et al., 2013; 
Fire et al., 1998; Jinek et al., 2012). Libraries of short interfering RNA (siRNA) or guide RNAs 
that cover the complete (or near complete) human or mouse genome make it further possible 
to expand these technologies to high-throughput assays and identify novel candidates in a  
comprehensive and unbiased manner (Berns et al., 2004; Boutros et al., 2004; Shalem et al., 
2014; T. Wang et al., 2014). In attempting to expand our insight into the regulatory mechanisms 
of TLR4 signaling, it is critical to fully utilize these genome-level approaches so that novel 
regulators of the pathway can be discovered and signaling gaps can be filled in. 
Adapting these gene perturbation systems to macrophages cells, however, faces a 
critical obstacle. Both platforms rely on exogenous RNA delivery to guide the perturbation 
mechanism to their target (Shalem et al., 2014; Silva et al., 2004). This presents a challenge in 
the context of studying immune cells, specifically in the context of TLR signaling, as some 
TLRs - as a form of host defense (especially against viruses)- bind and respond to the presence 
of exogenous RNA (Alexopoulou et al., 2001; Heil et al., 2004). To circumvent this challenge, 
Li and colleagues used a systematic approach to identify an siRNA delivery system that avoids 
activating the cells’ intrinsic immune response (N. Li et al., 2015). Using that system, Li and 
colleagues also developed two reporter cell lines in human and mouse macrophage-like cells 
that can be used for high-throughput assays of TLR4 activation. In the mouse cell line, they 
introduced two reporters associated with downstream effectors of TLR4. A green fluorescent 
protein (GFP) fused to the relA NF-κB transcription factor driven by its endogenous promoter 
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and a secondary reporter cassette that includes the TNFa promoter driving expression of the 
single exon red fluorescent protein mCherry. The first reporter enables by high content imaging 
the tracking of NF-κB cytosol-to-nuclear translocation, while the second reporter enables the 
tracking of initiated TNFa transcription through the red fluorescence channel. In human cell 
lines, Li and colleagues used a dual luciferase reporter system, including a firefly luciferase 
driven by the human TNFa promoter and a renilla luciferase driven by a ubiquitin promoter. 
The former is used as a readout for TNF transcription and the latter is used as a normalization 
control (Figure 1.6). It should be noted that treatment with LPS did not lead to increased 
activation of ubiquitin driven renilla luciferase, enabling its use as a normalization control 
(Figure 1.6G). Renilla activation showed a slight decrease in some wells treated with LPS 
compared to untreated, though that may be driven by the lower cell count in some of the LPS 
treated wells. Utilizing these platforms, Li and colleagues (Ning Li et al., 2017) and Sun and 
colleagues (J. Sun et al., 2017) completed genome-wide analysis of the LPS induced response 
in mouse and human macrophages, respectively (Figure 1.7).  
Using a different cell and perturbation system, Parnas and colleagues published a 
genome-wide CRISPR study in mouse dendritic cells treated with LPS (Parnas et al., 2015). 
Critical differences exist in the design and assay of the Parnas study and the three LPS studies 
done in macrophages by Li and Sun. Parnas and colleagues used bone marrow derived cells 
from mice that were then differentiated into dendritic cells as opposed to macrophages, and 
used a CRISPR library instead of the RNAi platforms used by Li and Sun. These four studies, 
collectively, present the first chance to study the TLR4 signaling pathway in a comprehensive 
way and expand our insights into its regulatory program (see chapter 3 and chapter 6). 
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Figure 1.6: Reporter cell lines for tracking TLR4 activation in human and mouse 
macrophages. 
From Ning Li et al., 2015  
 
(A) Design of a dual-promoter lentiviral vector for expression of TLR pathway reporters. (B 
+ C) Gene cassettes in the mouse RAW G9 reporter clone containing Bb) the mouse rela 
promoter driving expression of a GFP-relA fusion protein and (C) the mouse tnf promoter 
driving expression of an mCherry protein. (D) Cytosol-to-nuclear translocation of the GFP-
relA fusion in RAW G9 cells up to 40 min after treatment with 10 ng/ml LPS (E) Increased 
tnf promoter-driven mCherry expression in RAW G9 cells up to 16 hr after treatment with 10 
ng/ml LPS (F) Gene cassettes in the human THP1 B5 reporter clone containing the human 
UBC promoter driving constitutive expression of renilla luciferase and the human TNF 
promoter driving TLR ligand-inducible expression of firefly luciferase. (G) Luminescence of 
the UBC promoter driven Renilla luciferase in Renilla knock down THP1 cells and WT 
untreated and treated cells.   
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1.5.3 Finding regulators beyond the highest scoring and annotated hits of omic studies 
As reported findings from the high-throughput studies of the response to LPS, the 
aforementioned Sun, Li and Parnas studies selected insights from the highest scoring hits and 
enrichments that their respective screens identified. The RNAi screen in macrophages led to 
the characterization of species-specific roles for different IRAK family proteins in human and 
mouse macrophages (J. Sun et al., 2016) and the genome-wide CRISPR study in mouse 
dendritic cells by Parnas implicates a role for components of the oligosaccharyltransferase 
(OST) complex in the LPS-induced expression of TNFα (Parnas et al., 2015). Beyond these 
specific findings, however, the vast scope of insights generated by these genome scale studies 
remain largely unexplored.  
The gap between the genome-scale of measurements in high-throughput studies, and 
the modest number of reported candidates and insights that the studies culminate in, is not 
unique to the studies of the LPS response. Many hits from high throughput studies lack 
extensive annotation and also lack clear direction for how to contextually follow up on them 
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Figure 1.7: A siRNA screening pipeline for human and mouse macrophage activation. 
From Sun et al., 2016 
 
Workflow for the RNAi screen using six siRNA sequences per gene distributed in separate 
regions of a 384-well plate. Reporter cell lines were assayed for their responses to simulation 
with LPS, and the effects of individual gene perturbations were measured 
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(Manly et al., 2004). Prioritization of candidates from high-throughput screens is further 
constrained by the high rates of false positives that these studies, especially using RNAi, have 
been associated with (Aguirre et al., 2016; A. L. Jackson & Linsley, 2004; Mohr et al., 2010). 
In prioritizing hits for further validation, researchers must find a balance between prioritizing 
candidates based on potential biological relevance and the feasibility to follow up on numerous 
gene candidates (Finkbeiner et al., 2015). These considerations contribute to a bottlenecking 
of screen data hit selection that is often most strongly guided by the a posteriori knowledge of 
the authors over the ranking and statistical results from the screen (Lotterhos et al., 2016). This 
phenomenon also explains what can be described as the “quantum leap” in reports of high-
throughput studies, when the analysis leaps - with sparse analytical justification- from 
considering statistically prioritized lists of candidates to a handful of hits that are selected for 
further validation. While many insights and discoveries from high-throughput studies have 
been made through this approach, to fully realize the potential of these efforts to elucidate 
robust regulatory pathways, unbiased and comprehensive candidate prioritization approaches 
that address these challenges are necessary. 
 
1.5.4 Score based hit selection: false positives, false negatives, and setting a cutoff  
A basic approach towards unbiased hit prioritization from high-throughput studies relies on 
using a normalized scoring method that assigns a ranking to each candidate based on its score. 
Readout scores generated by high-throughput assays reflect a mix of biological variability and 
technical variation that contribute to each target’s score. A commonly used corrective approach 
is the Z-score method (originally called Z-factor (J. H. Zhang et al., 1999)) which assigns a 
score to each target based on its score’s deviation from the mean of scores for all the targets in 
the assay (Birmingham et al., 2009), thus correcting for the technical variability intrinsic to the 
assay. Variations on the Z-score approach have been developed to adjust for outliers and batch 
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and plate variability, such as robust Z-score (using median and median absolute deviation in 
place of the mean and standard deviation) and normalizing based on the score distribution of 
each plate as opposed to the complete assay (Birmingham et al., 2009; B. Dutta et al., 2016; 
Tseng et al., 2012). The challenge of the Z-score approach, however, is that it is dependent on 
the setting of a cutoff that defines the absolute score above which all candidates are considered 
hits and below which all candidates are considered non-hits (Boutros & Ahringer, 2008). The 
setting of a single cutoff is associated with an intrinsic compromise between decreasing the 
false positive rate while increasing the false negative rate or vice versa (Malo et al., 2006). On 
one hand, setting of a stringent cutoff for hit selection (such as the top 1% of hits or less) 
reduces the number of false positives amongst candidates but greatly increases the number of 
false negatives (i.e. targets assigned as non-hits that are biologically significant but may have 
a readout that is either less sensitive or obscured by the technical variation of the experimental 
design). Conversely, setting a more lenient cutoff goes hand-in-hand with the inverse error rate, 
the number of false negatives is reduced but the false positive rate is greatly increased. An 
additional impact of the more lenient cutoff strategy for hit selection is that it makes the follow 
up lower-throughput experiments less efficient, as a high number of candidate hits will fail to 
validate by secondary screening. The efficiency consideration drives many studies to rely on 
more stringent cutoffs and err on the side of a low false positive rate. This approach, however, 
leaves unexplored a large portion of potential candidates. When aiming to comprehensively 
characterize a signaling network it is critical to interrogate the lower scoring putative hits as 
well. Analysis by Rosenbluh and colleagues of genomic and proteomic studies to characterize 
the signaling network of β-catenin-active cancers found that many critical novel signaling 
components were in the lower scoring segments of the assay scores that are missed by a 
stringent cutoff (Rosenbluh et al., 2016). This finding emphasizes the need for an unbiased hit 
selection strategy that captures more of the lower scoring potential hits. Furthermore, the 
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artificial rigidity of a single cutoff, be it stringent or lenient, crucially obscures the more 
complex reality whereby targets identified by the screen exist on a spectrum of confidences 
with novel biological insights distributed across the range of assay scores. To more fully utilize 
the potential of high-throughput studies in characterizing novel regulatory mechanisms and 
candidates, an approach to hit prioritization that circumvents these challenges is needed. 
 
1.6 Limited overlap in hits from comparative high-throughput studies 
1.6.1 Overlap in reported hits of parallel studies is limited across fields 
In considering the results from multiple genome-wide studies characterizing the TLR4 
response to LPS, it is also critical to recognize that comparative analysis of high throughput 
studies in different systems have often had limited concordance. From microarray assays to 
gene-perturbation studies, analysis of published datasets from varying omics platforms 
repeatedly show modest overlap with limited statistical significance across parallel studies 
(Bhinder & Djaballah, 2013; Ein-Dor et al., 2006).  High-throughput gene perturbation studies 
of similar biological phenomena that have surprisingly limited overlap have been found in 
studies of Influenza (Watanabe et al., 2010) and Human Immunodeficiency Virus (HIV) 
(Hirsch, 2010).  
The unexpected heterogeneity of hits from related high-throughput studies has been 
broadly attributed to the varying experimental conditions of different research settings 
affecting the ranking of hits and thus obfuscating the true biological variability being measured 
(Ramasamy et al., 2008). Independent meta-analysis by Bushman and Hao of the Influenza and 
HIV studies found that the lack of overlap is largely driven by the false-negative rates in the 
hit selection methods of the comparative studies (Bushman et al., 2009; Hao et al., 2013). These 
insights further suggest that developing correctives for broader identification of hits beyond 
highest scoring targets is critical for robust and reproducible results from high-throughput 
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studies. It also suggests that an increase in the number of hits shared across parallel studies can 
be used as a metric for false negative correction.  
 
1.6.2 Measuring significance of overlap by number of shared hits or by statistical 
enrichment 
Robustly measuring the overlap of hits across two or more studies can be done in two ways. 
The number of shared hits can be counted and the result taken as a measure of the true-positive 
hits identified by the two studies (Rhodes et al., 2002). This approach is often referred to as 
“vote counting” when used to prioritize individual targets that appear as hits in more than one 
study (Ramasamy et al., 2008). While the approach of directly counting the number of shared 
hits does not address the number of false-positives each set of hits has and the false negatives 
the set excludes, it is still an important tool in assessing the sensitivity of high-throughput 
studies.  
An alternative approach is a statistical test for how much the overlap across the two sets 
exceeds the null (i.e. the assumption that overlap between unrelated studies will be no greater 
than a random sampling of hits of equal size).  A frequently deployed test for convergence and 
non-random overlap is the hypergeometric test, also known as the one sided Fisher’s Exact 
Test (FET) (Birmingham et al., 2009; R.A. Fisher, 1925; T. Nguyen et al., 2015). The 
hypergeometric test measures the statistical significance of the overlap of two groups selected 
from two independent sets. In the case of comparing high-throughput studies the two 
independent sets would correspond to the two genome-scale studies and the two groups being 
compared correspond to the sets of hits selected from each group. This measurement relies on 
three critical numbers, m which is the number of shared members across the two sets, n1 and 
n2 which are the sizes of the two selected sets of hits, and n which is the group of candidates 
from which the set of hits was selected from (Fury et al., 2006) (Figure 1.8). Since the total 
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number of candidates measured in genome-scale studies are near similar across comparative 
studies, improvements in the statistical enrichment of agreement across parallel omic studies 
can be driven by either an increase in the number of shared hits (bigger m) or a decrease in the 
size of candidates selected as hits (smaller n1 and n2). Given the relative and complementary 
strengths of the two ways to measure shared enrichment – the number of shared hits which is 
driven by a decrease in false-negative rate and significance of overlap which is strongly driven 
by reduction in the false-positive rate - both measurements are critical proxies for assessing 
improved hit selection methods. 
  
m 
n1 n2 
n 
Figure 1.8: Schematic of measurements calculated by the 
hypergeometric test of statistical enrichment.  
 
A schematic of the different components being measured 
when calculating the statistical significance by the 
hypergeometric test. n1 and n2 correspond to the two selected 
hit sets. m is the set of shared hits between the two selected 
sets. n is the set from which the hits are selected from in both 
groups. 
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1.6.3 Comparative studies of HIV dependency factors as example of hit selection challenge 
in high-throughput studies 
An example often referred to in the literature of the high discordance of hit selection from high-
throughput assays are a set of three independent studies looking at the essential proteins 
required for early infection of HIV, also known as HIV Dependency Factors (HDFs) (Hirsch, 
2010; Jian Zhu et al., 2014). Published within months of each other, Brass et al. (Brass et al., 
2008), König et al. (König et al., 2008), and Zhou et al. (Zhou et al., 2008) used genome-scale 
RNAi studies to identify host factors that were required by the virus for effective early stage 
infection of the host cell. The three siRNA studies for HDFs have been the subject of a number 
of subsequent meta-analysis studies (Bushman et al., 2009; Hirsch, 2010; Jian Zhu et al., 2014) 
and the three set comparisons serve as a validating example of the widespread challenge of the 
limited overlap found across related genome scale studies.  
Since these studies have already been published in their entirety they can also be used 
as test data sets to evaluate how different hit selection approaches change the metric of overlap 
across screens. Various attempts have been made at developing benchmarking or synthetic 
datasets that can be used to evaluate the accuracy, sensitivity, and specificity of different hit 
selection approaches (Geistlinger et al., 2020; Mathur et al., 2018; T.-M. Nguyen et al., 2019; 
Roder et al., 2019). The setting of a gold standard dataset by which different prioritization 
methods can be compared remains one of the critical challenges in the bioinformatics of high-
throughput data (Khatri et al., 2012; Mathur et al., 2018; Mitrea et al., 2013). As the comparison 
of different benchmarking methods is beyond the scope of this thesis, the comparative analysis 
of the three HIV studies can serve as an alternative proxy for evaluating the accuracy of new 
methods. A more sensitive hit selection method applied to all three studies would lead to greater 
overlap of hits between the studies while an approach with higher specificity would lead to 
more statistical significance in the overlap of the comparative studies. 
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1.7 Bioinformatic solutions for robust hit selection from high-throughput 
studies 
1.7.1 Gene-set and pathway centric analysis of high-throughput hits 
Suites of bioinformatic tools have been suggested as auxiliary analysis methods to buttress the 
prioritization of hits from high-throughput studies beyond scores and ranking (Birmingham et 
al., 2009; Tseng et al., 2012). These advancements have shifted the practices for hits 
prioritization in primary high-throughput studies from the original one-step scoring and cutoff 
approach (Boutros & Ahringer, 2008) to more complex analysis “pipelines” that integrate 
enrichment and network bioinformatics to prioritize or deprioritize hits for follow-up 
secondary screening (B. Dutta et al., 2016; Huang et al., 2008).  
A widely used bioinformatic approach is the application of enrichment analysis that 
selects hits not based on original scores but rather based on the enrichment of predetermined 
“gene sets”.  Enrichment analysis, also called pathway analysis, has been proposed as a way to 
correct for false positives (Creixell, 2015), as randomly selected false-positive hits are less 
likely to come from the same pathway. Various grouping methods have been proposed as a 
way to apply the enrichment analysis approach, such as using preset Gene Sets (Subramanian 
et al., 2005), Eigengenes based on coexpression and correlation patterns (Langfelder & 
Horvath, 2007), Metagenes based on the clustering and dimensionality reduction of 
coexpression data (Brunet et al., 2004), and pathway structures based on curated gene lists of 
known shared function (Kanehisa & Goto, 2000). Curated pathway databases such as the Kyoto 
Encyclopedia for Genes and Genomes (KEGG) provide updated and easy to interpret pathway 
gene groups (Kanehisa et al., 2017) and are in wide use for high-throughput data analysis.  
The analysis method by which to apply the knowledge from these databases has gone 
through a critical evolution over the past ten years. The first generation of pathway analysis 
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methods relied on calculating the representation of pathway hits in a given list by use of a 
statistical calculation such as the Fisher’s Exact Test or χ2 test (L. D. Fisher, 1993; Ronald 
Aylmer Fisher, 1960). These approaches to interpretation and prioritization of high throughput 
screens by pathway analysis have been generally summarized as Over Representation Analysis 
(ORA), wherein the number of hits that are also found in the predetermined pathway gene set 
are compared to what you would expect to find according to the null hypothesis (Beißbarth & 
Speed, 2004; Goeman & Bühlmann, 2007). Enrichment and prioritization by ORA also have a 
set of limitations that an emerging class of second-generation pathway analysis approaches 
seek to address. Chief among these limitations is the way that the ORA enrichment evaluates 
the presence or absence of a pathway gene as a binary of either being in the set or being outside 
the set. Statistical calculation by ORA also treats all genes as being independent from each 
other and does not consider how their expression correlate inside versus outside the set. 
Functional Class Sorting (FCS) methods emphasize coordinated changes in the group of gene 
from the predetermined set (i.e. pathway or functional group). Statistical approaches such as 
the Kolmogorov-Smirnov statistic and the Wilcoxon rank sum function factor in the correlation 
among the genes in the pathway and look at the scores of all the pathway genes, not just the 
“hits” (Barry et al., 2005; Subramanian et al., 2005). ORA and FCS approaches, however, rely 
on the assumption that all genes in a pathway are equal indicators of enrichment. A third 
generation of enrichment analysis approaches were developed that consider the topology of a 
pathway and not merely the list of genes that make up its components. Utilizing curated and 
annotated databases such as Reactome (Joshi-Tope et al., 2003) or KEGG (Kanehisa et al., 
2017) topology-based (TB) approaches such as ScorePAGE (Rahnenführer et al., 2004), 
PathNet (Bhaskar Dutta et al., 2012), and CePA (Gu et al., 2012) consider the relationships, 
functions, overlap, and -crucially- the centrality of different proteins in each pathway in 
assigning weights to the enrichment. 
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The reliance on pathway databases as a way to prioritize hits from high-throughput 
studies, however, comes with significant analytical tradeoffs irrespective of the chosen analysis 
method. For example, pathway databases do not cover the complete genome. An analysis I did 
of the KEGG database found that only 36% of human protein coding genes are curated in at 
least one pathway of biological processes (Figure 1.9). Exclusive reliance on pathway 
databases for high-throughput hit selection therefore limits the number of novel genes that can 
be identified, obviating one of the most important rationales for performing unbiased genome-
scale screens.  
Despite the plethora of alternative solutions, ORA remains widely used in the routine 
reporting of high-throughput studies (Dong et al., 2016). The appeal of this enrichment 
approach, in addition to filtering out low likelihood hits, lies partially in its intuitive 
interpretability; seeing the mechanisms and biological processes that a new dataset points 
towards is an easier launching ground from which to generate hypotheses about mechanisms, 
rather than trying to interpret a long list of often obscure gene names. This feat, however, is 
achieved by an abstraction of the data that removes the output from the units it was designed 
to measure and ultimately aims to validate. Current best practices in pathway analysis relegate 
these forms of high-throughput screen interpretation as “exploratory add-ons” (Sedeno-Cortes 
& Pavlidis, 2014) and highlight the challenge of converting insights on the combined gene set 
level back to individual gene analyses that can be followed up experimentally (Mooney & 
Wilmot, 2015). A challenge remains to utilize the gene set enrichment analysis in a way that 
still provides a path to the characterization of specific genes and mechanisms novel to the 
context being investigated. 
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1.7.2 Network database approaches to hit selection of high-throughput studies 
Complementary to the pathway analysis filtering approach, the utilization of protein-protein 
interaction (PPI) databases have been proposed as a way to prioritize lower scoring hits from 
high-throughput studies and expand the dataset (B. Dutta et al., 2016; Tu et al., 2009; L. Wang 
et al., 2009). Based on combined curated and unbiased omic scale studies, PPI databases have 
broader coverage (>80%) of the genome than curated databases (Figure 1.10). In the network 
analysis approach, PPI databases such as the Search Tool for the Retrieval of Interacting Genes 
(STRING) (Szklarczyk et al., 2010), are used to find lower scoring candidates that have 
predicted interactions with higher scoring hits. The hit selection set is then expanded to include 
the lower scoring interacting hits.   
 Integrating the network information from interaction databases into a prioritization 
pipeline for high-throughput studies can be done by different approaches. The simplest to apply 
is the Direct Neighbor approach whereby proteins that have a direct predicted interactions with 
candidates of interest are considered part of the network (Oti et al., 2006). As the Direct 
Neighbor approach casts a very wide net alternative and more discriminating approaches to 
expanding candidate lists by use of network database knowledge have been created. The 
network propagation method uses a diffusion approach which has the benefit of penalizing 
nodes (in this case proteins) that have very high rates of predicted interactions (Cowen et al., 
2017). Other approaches incorporate concepts from graph theory and information theory such 
as considering the mutual dependency between two nodes and collapsing layers of information 
into kernel matrices to be collectively considered (Yu et al., 2013). Where more multi-level 
datasets are available, network prioritization using more sophisticated statistical and machine 
learning methods such as linear regression and random forest have yielded more discriminating 
results (L. Wang et al., 2018; W. Zhang et al., 2017). 
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Similar to the various criteria for pathway analysis discussed in the previous section, 
the first generation of network analysis methods still remains in wide use, as shown by the 
popularity of databases like STRING which employs a direct neighbor method.  Expansion of 
the lists of candidates from a high-throughput functional study by any of the above network 
approaches is often in the first steps of candidate prioritization. A network analysis approach 
to hit selection decreases the rate of false negatives as it expands the hit selection set to more 
hits. Network analysis, however, also amplifies the noise in the hit selection set as false-
positive candidates in the original high scoring set of hits also expand to include their predicted 
interactions.  
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Genes annotated to one or 
more pathways of a 
biological process 
Figure 1.9: Percentage of protein coding human genes annotated into pathways by 
KEGG. 
 
KEGG database collected on May 11, 2019, filtered for pathways relating to biological 
processes. 
Human protein coding genes as defined by HGNC as of June 29, 2018 
Proteins with one or 
more interactions 
annotated in STRING 
Figure 1.10: Percentage of protein coding human genes with at least one associated 
interaction in the STRING database. 
 
STRING database collected on October 3, 2018, filtered for interactions of 400 
confidence score or higher 
Human protein coding genes as defined by HGNC as of June 29, 2018  
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1.7.3 Gene-level vs. pathway-level insights in omics output and visualization 
Comparing the different analytical advancements in high throughput hit prioritization by 
unbiased scoring, pathway analysis, and network analysis highlights their complementary 
contributions to error correction, interpretability, and novel candidate identification. While 
frequently applied in parallel, there is currently no outlined framework for how to integrate 
their analytical contributions. This presents a critical challenge in applying robust hit selection 
to studies such as RNAi high throughput assays of the macrophage response to LPS. 
 
1.7.4 Developing web-based versus Rscript solutions for high-throughput hit selection 
A solution to the challenges of hit prioritization as outlined above would have implications for 
hit prioritization in other high-throughput studies, and would be of use to the screening 
community outside of the field of innate immunity. Critical to the utility of a bioinformatic 
analysis pipelines is its adaptation to platforms that broaden its access. Access and 
dissemination of bioinformatic solutions largely fall under two categories, making the code 
available through public repositories where users can download the code or, alternatively, 
adapting the code into a user-friendly web interface that is publicly accessible. These two 
approaches both have advantages and tradeoffs. Using a software repository platform has the 
advantage of ensuring the user that their data is safe as the code they are running only runs 
locally on the machines of their choosing. It also further expands the possibility for advanced 
developers to adapt the analysis pipeline to the specific analysis of their project. A consequence 
of this path is that it limits the access to only those with a basic-to-strong proficiency of working 
with the computational language and platform, further creating a gulf between the 
informaticians and the experimentalists running the assays. Building an interactive web 
application circumvents the accessibility challenge and substantially broadens the community 
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of potential users. This benefit, however, comes with intrinsic tradeoffs, most prominently the 
risk of data security for the users who have to upload their data to a server they do not control. 
Of lesser concern, but still critical to consider, web applications are less adaptable and offer 
more confined solutions to pre-set problems, thus limiting the applicability of the pipeline. 
These considerations are critical to consider when designing novel bioinformatic frameworks. 
 
1.8 Aims 
In this thesis my aim is to develop and present better ways to utilize, prioritize, and interpret 
data from high-throughput studies and to apply these insights to genome-scale studies of the 
response to LPS signaling in macrophages.  
 
Building on the knowledge outlined in this introduction, my work herein focuses on five aims: 
 
Aim 1: To understand how regulatory candidates selected by ancillary bioinformatic and 
secondary validation approaches improved on hits selected based on simple ranking from high-
throughput studies (Chapter 3). I use the three siRNA studies of the response to LPS and the 
three studies of HIV Dependency Factors (HDFs) to compare overlap and enrichment of hits 
selected based on bioinformatic validation versus score ranking methods.  
 
Aim 2: To test the improvements and trade-offs of pathway and network based hit prioritization 
methods for high throughput studies, and to develop an optimized approach that brings together 
their combinatorial benefits (Chapter 4). I use the three studies of HDFs as my testing data sets, 
the KEGG and STRING databases for my respective pathway and network databases, and 
hypergeometric and random permutation tests for statistical evaluation. 
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Aim 3: To develop the new analysis approach from aim 2 into a publicly available interface so 
that it can be utilized for analysis of different genome-scale datasets (Chapter 5). I use the 
Shiny R platform to design the interface and add features for combined network and pathway 
visualization and data exploration. 
 
Aim 4: To apply the developed framework from aim 3 to the analysis of the three siRNA studies 
of the response to LPS, and to identify novel regulatory mechanisms of macrophage activation 
(Chapter 6). I use the analysis methods developed in the previous chapters and follow up the 
findings with studies using chemical inhibitors targeting the cellular processes identified by the 
analysis. 
 
Aim 5: To broadly characterize post-transcriptional dynamics and alternative splicing in the 
macrophage response to LPS by RNA-seq (Chapter 7). I use short and long read RNA-seq 
approaches of four macrophage cell types treated with LPS. 
  
   47 
2 Materials and Methods 
2.1 Datasets 
2.1.1 Three genome-wide siRNA studies of the response to LPS 
The genome-scale siRNA studies of the macrophage response to LPS used in this thesis were 
published in (J. Sun et al., 2017) and (Ning Li et al., 2017).  
 
2.1.2 Genome-wide CRISPR study of the response to LPS in mouse 
The CRISPR based genome-wide study of the LPS response in bone marrow derived dendritic 
cells used in this thesis was published by (Parnas et al., 2015). The dataset with complete Z 
scores and FDR was generously shared by Aviv Regev. 
 
2.1.3 Three genome-wide siRNA studies of HIV Dependency Factors 
The three genome-wide siRNA studies of essential proteins in early HIV infection were 
published by (Brass et al., 2008); König et al. (2008); (Zhou et al., 2008). The complete datasets 
of scores and metadata of these studies were generously shared by Amy Espeseth (Zhou et al 
screen), Abraham Brass (Brass et al screen), and Sumit Chanda (König et al screen). 
 
2.1.4 RNA-seq of WT and UBL5 KD macrophages treated with LPS 
Wild type THP1 cells and UBL5 knockdown cells (expressing a UBL5 specific shRNA) were 
differentiated into a macrophage-like state with 5ng/ml phorbol-12-myristate-13-acetate 
(PMA, from Sigma, P1585) for 72 hours. Following differentiation cell were treated with 
100ng/mL LPS for 0h, 0.5h, 1h, 2h, and 4h. Total RNA for each sample was prepared using 
the TRIzol reagent (Invitrogen Cat# 15596026) and using the manufacturers protocol for 
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isolating RNA. Two biological replicates were generated for each time point and each 
condition.  
The RNA-seq was run on an Illumina HiSeq2000 at a sequencing depth of 2x150bp 
reads, at around 20-30 million reads per sample. The results were mapped using STAR aligner 
as described by Dobin et al. (2013). The data was then analyzed for differential exon usage by 
DEXseq as described by Anders et al. (2012). 
 
2.2 Databases 
2.2.1 KEGG database for pathway enrichment 
The KEGG database was downloaded from the KEGG Application Program Interface (API), 
as described previously (Kanehisa et al., 2017). For the analysis described in this thesis, the 
KEGG data was downloaded on May 11, 2019. 
Pathway lists were filtered for pathways that are related to biological processes (and 
excluding the ones related to disease) by only selecting pathways with PathwaysIDs of 05000 
or less. EntrezIDs were added to the NCBI gene symbols in the KEGG database by the 
org.Hs.eg.db: R package (Marc Carlson (2018). org.Hs.eg.db: Genome wide annotation for 
Human. R package version 3.7.0.) and the org.Mm.eg.db: R package (Marc Carlson (2018). 
org.Mm.eg.db: Genome wide annotation for Mouse. R package version 3.7.0.). The annotated 
pathway enrichment document was formatted into a matrix of gene IDs and pathway identifiers 
(Figure 2.1) to be subset into 2x2 matrices for competitive enrichment analysis as previously 
described (Goeman & Bühlmann, 2007). 
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EntrezID GeneSymbol PathwayID PathwayName 
10 NAT2 232 Caffeine metabolism 
10 NAT2 983 Drug metabolism - other enzymes 
10 NAT2 1100 Metabolic pathways 
100 ADA 230 Purine metabolism 
100 ADA 1100 Metabolic pathways 
1000 CDH2 4514 Cell adhesion molecules (CAMs) 
10000 AKT3 1521 
EGFR tyrosine kinase inhibitor 
resistance 
10000 AKT3 1522 Endocrine resistance 
10000 AKT3 1524 Platinum drug resistance 
10000 AKT3 4010 MAPK signaling pathway 
10000 AKT3 4012 ErbB signaling pathway 
10000 AKT3 4014 Ras signaling pathway 
10000 AKT3 4015 Rap1 signaling pathway 
10000 AKT3 4022 cGMP-PKG signaling pathway 
10000 AKT3 4024 cAMP signaling pathway 
10000 AKT3 4062 Chemokine signaling pathway 
10000 AKT3 4066 HIF-1 signaling pathway 
10000 AKT3 4068 FoxO signaling pathway 
10000 AKT3 4071 Sphingolipid signaling pathway 
10000 AKT3 4072 Phospholipase D signaling pathway 
10000 AKT3 4140 Autophagy - animal 
  
Figure 2.1: Format of pathway enrichment file from KEGG. 
 
Pathway membership data was downloaded from the KEGG database and formatted 
into a matrix of gene IDs (EntrezID, GeneSymbol) matched with their membership 
group name (PathwayID, PathwayName). 
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2.2.2 STRING database for biological network interactions 
The STRING database was downloaded from the STRING API as described by (Szklarczyk et 
al., 2010). The 9606.protein.links.full.v10.5 was downloaded for human interactions and the 
10090.protein.links.full.v10.5 for mouse interactions. Inferred interactions from other species 
were not included. The network downloads were separated based on the evidence source of 
their interactions. The evidence source categories followed the STRING database 
categorizations; neighborhood, co-occurance, fusion, co-expression, experiments, databases, 
and text mining. The different evidence source network files were then split into three groups 
based on their evidence scores, 0.15-0.4 as low confidence, 0.4-0.7 as medium confidence, and 
0.7-1 as high confidence. The files were then converted into the igraph format using the igraph 
R package (Csardi G, Nepusz T: The igraph software package for complex network research, 
InterJournal, Complex Systems 1695. 2006. http://igraph.org). For the analysis described in 
this thesis, the STRING data was downloaded on October 3rd, 2018. Each analysis was 
performed using a single master igraph that was generated by combining the igraphs of the 
relevant criteria (evidence source and scores). The networks were used to prioritize lower 
scoring hits by using the direct neighbor functional approach as previously described (L. Wang 
et al., 2009). 
 
2.2.3 Gene and protein ID conversion 
Gene to protein ID conversions were done using the biomaRt R package (Mapping identifiers 
for the integration of genomic datasets with the R/Bioconductor package biomaRt. Steffen 
Durinck, Paul T. Spellman, Ewan Birney and Wolfgang Huber, Nature Protocols 4, 1184-1191 
(2009).) EntrezID to GeneSymbol ID conversions were done using the org.Hs.eg.db: R 
package (Marc Carlson (2018). org.Hs.eg.db: Genome wide annotation for Human. R package 
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version 3.7.0.) and the org.Mm.eg.db: R package (Marc Carlson (2018). org.Mm.eg.db: 
Genome wide annotation for Mouse. R package version 3.7.0.) 
 
2.2.4 Human and mouse protein coding gene lists 
Lists of human protein coding genes were accessed from the HUGO Gene Nomenclature 
Committee (HGNC) website, using the 
HGNC_genes_with_protein_product_EntrezID_geneSymbol list. Lists of protein coding 
genes in mouse were downloaded from the Mouse Genome Informatics (MGI) database, using 
the MGI_MRK_Coord.rpt download and filtering for Marker Type = protein coding gene. 
 
2.2.5 Mouse and human gene orthologues 
Gene ID orthologous were curated from the biomarRt R package (Mapping identifiers for the 
integration of genomic datasets with the R/Bioconductor package biomaRt. Steffen Durinck, 
Paul T. Spellman, Ewan Birney and Wolfgang Huber, Nature Protocols 4, 1184-1191 (2009).) 
using the mouse_human_orthologs_biomart download, last accessed on January 23, 2019. Hits 
within the three LPS screens that did not have an orthologue listed were checked in the NCBI 
Gene database, if an orthologue was listed it was added to the list. If a gene was listed as having 
a one-to-many orthologue mapping from human to mouse the GeneCards database (Stelzer et 
al., 2016) was consulted and the orthologue with the highest similarity score was used as a 
match for the gene.  
 
2.2.6 Canonical TLR pathway genes 
A list of canonical TLR pathway genes was curated by combining the canonical gene list from 
(J. Sun et al., 2016) and (Mertins et al., 2017). The combined list includes 186 genes in human 
and mouse IDs.  
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2.3 Statistics 
2.3.1 Hypergeometric test for pathway enrichment 
Hypergeometric distributions to calculate the significance of shared enrichments (across 
screens and for pathway analysis) were done by generating contingency matrices of shared and 
non-shared hits and then analyzing by a one sided Fishers’ Test with the alternative hypothesis 
set to “greater than” and the null being no shared enrichment. This approach has been 
previously described as the “competitive enrichment” test or over representation analysis 
(Khatri et al., 2012). 
  
2.3.2 Normalization of high-throughput readouts 
Normalization of scores from high-throughput studies was performed using the Z score 
approach described in (Birmingham et al., 2009). Where plate information was available, 
scores were normalized to plate mean, otherwise scores were normalized to overall mean of 
the data set. 
 
2.3.3 Cell viability correction 
Cell viability correction for candidates from high-throughput studies was different for different 
studies and based on available data as follows:  
 
THP1 -TNF -α screen: the ubiquitin promoter driven renilla luciferase readout was used as a 
normalization factor which can correct for cases where siRNAs target genes that affect general 
transcription, and also cases where specific gene knockdown affected the cell number and 
viability of the sample. The TNF promoter driven firefly activity provided a measure of the 
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TLR4 ligand induced TNF activation. The ratio of firefly to renilla luminescence (R1/R2) was 
used as a cell viability/general transcription corrected readout of TNF promoter activity. 
(Reporter cell line described in section 2.5) 
 
Raw G9 – NF-κB and Raw G9 – TNF-α screen: The NF-κB and TNF-α screens in RAW G9 
cells were provided with cell count number for each target. In the screening assay two imaging 
fields were collected from each well providing imaging data for approximately 300-400 cells 
per well. Gene candidates that had less then 50 cells per image were removed. (Reporter cell 
line described in section 2.5) 
 
Zhou et al HDF Screen: The study calculated a Percent Cell Viability measure for each gene 
target. The values were normalized using a normal distribution and gene candidates with a cell 
viability score of -2 or less were flagged. 
 
Brass et al HDF Screen: The study included cell count number for each gene target. The counts 
were log10 normalized and then given a plate-by-plate Z-score normalization. Gene candidates 
with a cell viability score of -2 or less were flagged. 
 
König et al HDF Screen & Parnas et al CRISPR-LPS Screen: Data shared with us for these 
studies already had a cell viability correction applied to their readout scores. 
 
2.4 Bioinformatics 
2.4.1 Iterative analysis of pathway and network enrichment (TRIAGE) 
 
Iterative analysis in excel 
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To integrate and iterate pathway and network analysis when prioritizing screen hits I began by 
utilizing the Comprehensive Analysis for RNAi Data (CARD) platform (B. Dutta et al., 2016). 
CARD is a publicly available website that curates and combines established algorithms and 
methods for high-throughput data pre-processing and filtering. CARD takes uploads from 
RNAi screens and provides a platform for data normalization and setting a cutoff. Following 
data normalization, the user can select from a series of further analysis steps including pathway 
analysis and network analysis. CARD uses a direct neighbor approach in network analysis. The 
user provides two cutoffs, one for “hits” and one for “non-hits” that can be prioritized based or 
predicted interactions from selected databases. For pathway analysis, CARD uses a Fisher’s 
Exact Test for enrichment of pathways from different databases (KEGG, Reactome, Gene 
Ontology). CARD generates a series of graphs and tables based on the different analysis that 
the user selected. These analyses can be downloaded as separate excel files. 
 A critical first question to address in the design of an integrated and iterative analysis 
approach, is whether the iterative analysis ultimately converges on a single set of selected hits 
such that the cycles of iteration can terminate. As an initial attempt to test the convergence of 
the iterative approach, and for an early model of TRIAGE analysis, I relied on the CARD 
analysis features. I used data from the THP1-TNF-α screen (see section 2.1.1). Each step of the 
iterative analysis was run as a separate new project in CARD, with the results downloaded and 
reformatted as the input for the next step in the analysis. The step by step processes were as 
follows. 
Preliminary Step: Prior to uploading the screen to CARD the candidates from the 
screen were divided into three groups and prepared as an input file for CARD.  
1. Hits from the screen that were above the RNAiCut recommended threshold (Kaplow et 
al., 2009) (or, alternatively a very conservative threshold), that had also passed analysis by 
CARD for low likelihood of being an Off-target effect (Marine et al., 2012) and had not been 
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ruled out by expression analysis as being absent in the cell line used, were assigned as “top 
hits” by placing a value of 1 in the “Replicate1” column of the input file. 
2. Hits that were above the chosen threshold but had been flagged by either Off-target 
analysis or Expression Analysis, and hits that were below the threshold but had a Z-score of -
1 or lower were assigned as “medium confidence hits” by placing a value of 0.5 in the 
“Replicate1” column of the input file. 
3. All other candidates in the screen were assigned as “non-hits” by placing a value of 0 
in the “Replicate1” column of the input file 
 
Step 1: The input file was uploaded to CARD using the “No normalization” setting of the “load 
data” tab.  Pathway Analysis (using KEGG) was then run by setting a cutoff of 0.9. (A cutoff 
of 0.9 was chosen to ensure that all the hits assigned a score of 1 are selected as CARD uses a 
“greater than” approach to its input.) The results were locally downloaded.  
 
Step 2: Using the output file “KEGG.enrichment.csv” the pathways with a p-value of 0.05 or 
less were selected. The generated list of pathways was used to filter a comprehensive list of all 
the pathway names from KEGG with their associated member gene names generating a list of 
genes associated with the selected pathways. The newly generated list of gene names from 
significantly enriched pathways was cross-referenced with the original input file from the 
screen. In a new column titled “Replicate1” gene names that had a score of 0.5 or higher in the 
input file that were also in the pathway generated list of genes were assigned a score of “1”. 
Genes that had a score of 0.5 or higher that were not in the pathway list were assigned a score 
of 0.5. Genes that had a score of 0 in the input file were given the same score of 0 throughout 
the analysis. This is the “contractive step”, the hit list is contracted to consist only of hits that 
make up the strongly represented pathways and processes in the set. 
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Step 3: The document with the newly assigned scores was uploaded to a new project in CARD 
using the “no normalization” option in the “load data” tab. Network analysis was performed 
using the combined network databases provided by CARD (HPRD, BioGRID, BIND) with the 
cutoff for hits set at 0.9 and the cutoff for non-hits set at 0.4. The analysis was locally 
downloaded. 
 
Step 4: Using the “NormalizedDataAll.csv” file from the CARD analysis download in step 3, 
gene names that had a “NetworkDegree” value of greater than 0 and an input score in step 2 of 
0.5 or greater were assigned a value of 1 in a new “Replicate1” column. All other gene names 
were assigned the same value as they were given in step 2. This is the Expansion step, where 
the set is expanded to include any hit with a predicted network interaction with any gene in the 
“contractive set” from step 2. This also completed the end of the first iteration.  
 
Step 5: The new document is uploaded to CARD and put through steps 2-4 as the second 
iteration. 
 
Step 6: After the iteration is complete, the gene names that are assigned a value of 1 at the end 
of the current iteration are compared with the gene names that were assigned a value of 1 at 
the end of the previous iteration. If the lists are not the same, the iteration is repeated by going 
through steps 5-6 again. If the lists are the same (i.e. the analysis has “converged” on a single 
set and additional iterations will keep yielding the same results) the analysis terminates. 
 
Step 7: Once the analysis terminates the hits that are assigned as having a value of 1 in the final 
iteration are chosen as the newly selected hits from the screen. 
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 Applying the above approach to the THP1-TNF-α study led to the analysis going 
through 4 iterations, after which the data converged on a set of hits with each subsequent 
iteration. These analyses provided initial validation of the method and supported the analysis 
principle that, through iterative analysis of pathway and network enrichment, a dataset of high-
confidence and medium confidence hits converges on a single set of hits. The cumbersome 
processes, however, generally took upward of two days for each screen. To further develop 
and robustly test the TRIAGE analysis design, it was critical to develop a more streamlined 
and automated computational approach to iterative analysis. 
 
Iterative analysis in R 
 
Computational analysis in this thesis was done in the R environment (R Core Team (2013). R: 
A language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/. Genomic analysis software was supported 
by the BioConductor platform (Gentleman et al., 2004). To build the TRIAGE analysis pipeline 
in R, all components were built as separate functions and then integrated together into a master 
function. Below is a summary of the individual steps taken followed by their integration into 
an iterative function. 
 
Importing and standardizing databases:  The downloads from pathway databases and network 
databases (KEGG and STRING) were mapped to common IDs (EntrezIDs, see section 2.2.3 
of this chapter for ID conversion). The network database was converted to a set of igraphs 
(section 2.2.2) and the pathway database was converted to a two-column table of pathway name 
and pathway members. This enabled efficient mapping between hit datasets and databases.  
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Pathway enrichment function: A pathway enrichment function was created that creates a 
contingency matrix for each pathway name in the pathway database and a list of IDs separated 
into “hits” and “non-hits”. Using a one sided Fisher’s exact test, the p-values, FDR, and 
Bonferroni correction of enrichment for each pathway name is generated.  This analysis loops 
over all the unique pathway names in the pathway database table. The pathway function is 
provided with a significance cutoff (<0.055). The function uses the significance to separate the 
pathway names that passed the threshold of significance for the list of pathway names and 
creates a list of selected pathways. Using the list of selected pathways, a vector of unique gene 
IDs that are members of the selected pathways is created. When using a dataset with a single 
cutoff (hits vs. non-hits), the intersect of the pathway member IDs and hits IDs is sub selected 
as a new set of hits. When using a dataset with two cutoffs (high confidence hits, medium 
confidence hits, and non-hits), only the high confidence hits are used as the “hits” for 
determining pathway enrichment. After the vector of pathway associated genes is created, a 
vector of the union of high confidence and medium confidence hits is generated. The intersect 
of the new vector of hits and the vector of pathway genes is taken as the new set of hits. 
 
Network enrichment function: A generated igraph of the selected network database parameters 
is matched with a list of high confidence hits and medium confidence hits. A new igraph is 
created based on the intersect of the list of hits with the database igraph. A two-column table 
of each of the two IDs (“nodes”) from each predicted interaction (“edge”) is created. The list 
is then matched with a list of the high confidence hits. To find the medium confidence hits that 
have predicted interactions with high confidence hits, edges that have a match with the high 
confidence list of hits in at least one of their nodes are kept while nodes without a match in 
either of its edges are filtered out. A new vector of unique IDs is generated from the filtered 
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table and the union of the vector and the high confidence list of hits are assigned as the new set 
of high confidence hits. 
 
Iterative analysis function: The iterative function was built by first creating a pipeline where 
the pathway enrichment function is applied to the input of a screen containing gene IDs in three 
groups (high confidence, medium confidence, and non-hits). The output of the pathway 
analysis steps is then reshaped to match the required input for the network analysis step. 
Following the network analysis output, the new hit characterizations are assigned as the new 
input column for pathway analysis. A “confidence category” column keeps track of what 
confidence level each hit was at the first input while a “proxy score” column updates the level 
of hit confidence each gene is assigned within each iteration. A separate data frame is created 
where the selected enrichment pathways from the pathway function are tabulated.  
 To halt the iterative loop when the analysis starts generating the same set of high-
confidence hits across iterations, the script uses a while function relying on a variable nested 
in an if function. Briefly, the variable “counter” is assigned as TRUE at the start of the analysis. 
An additional variable (“iteration”) counts what iteration of the analysis is currently running.  
The analysis function is wrapped within a “while” function that only runs the analysis while 
counter = TRUE. Following an iteration of pathway and network analysis, an if function 
evaluates if the iteration count is greater than 1. If true, the if function evaluates if the table of 
IDs with associated proxy score of this iteration match the table of IDs with associated proxy 
scores from the previous iteration. If the condition is true the “counter” variable is assigned as 
counter = FALSE. This leads to the termination of the function. Otherwise, the counter variable 
remains TRUE and the condition of the while loop is met to commence a new iteration of the 
analysis. When the analysis is complete a data frame with all the input IDs, the confidence 
category each ID was assigned at input, the proxy score for each iteration, and whether the ID 
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was assigned as a “hit” by the final iteration is generated. An additional data frame with the 
pathway enrichments from the final iteration, each pathway name matched with the intersect 
of member IDs with the list of hits IDs is also generated. 
 Repeated tests with different datasets have all resulted in the analysis converging to a 
single set of hits after a finite number of iterations. When testing randomized datasets, however, 
a number of datasets (out of more than five thousand tested) led to the set oscillating between 
different sets after a few iterations. To ensure the termination of the iterative analysis even in 
these rare cases, an additional condition was added to the above described test. The results of 
each iteration after iteration ≥ 3 are compared to the results of all the previous iterations. If a 
result is repeated it is indicative of an oscillating pattern. The analysis then finds the iteration 
within the repeated pattern that has the largest hit set and then terminates the analysis and 
assigns that iteration as the final output. (R code excerpted in Inset 2.1) 
 
Adaptable TRIAGE function:  
 
To make TRIAGE a more adaptable framework for iterative analysis with different datasets 
and databases, a R script version of TRIAGE was written using the inputs as variables. The 
TRIAGE function relies on calling two separate analysis functions, the pathway enrichment 
function (Inset 2.2) and the network analysis function (Inset 2.3). The master TRIAGE function 
applies the pathway and network functions iteratively, and the results are tested for when the 
analysis converges on a single set (Inset 2.4). 
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1. ##-- Measure if there is an iterating pattern   
2.     converge.sequence <- 0   
3.        
4.     if (iteration >=3) {   
5.       highconf.length <- c(length(append.hits.df[[ID.column]][append.hits.df[[Network
.iteration.name]]== "HighConf"]))   
6.          
7.       for ( t in 1:iteration){   
8.         if (identical(append.hits.df[[Network.iteration.name]], append.hits.df[[paste
0("NETWORK.iteration_", iteration-t)]])){   
9.           converge.sequence <- t   
10.           break   
11.         } else {   
12.           highconf.length <- c(highconf.length, length(append.hits.df[[ID.column]][ap
pend.hits.df[[paste0("NETWORK.iteration_", iteration-t)]] == "HighConf"]))   
13.         }   
14.       }   
15.     }   
16.        
17.     ##-- See if Iteration is converging on output    
18.        
19.     if((iteration != 1 && identical(append.hits.df[[Network.iteration.name]], append.
hits.df[[paste0("NETWORK.iteration_", iteration-1)]]))    
20.        || (converge.sequence > 0    
21.            && (length(append.hits.df[[ID.column]][append.hits.df[[Network.iteration.n
ame]]== "HighConf"]) == max(highconf.length))    
22.        ))  {   
23.       ##-- Set counter to false   
24.       counter <- FALSE   
25.     } else {   
26.       ##-- Update itertion number   
27.       iteration <- iteration + 1   
28.     }   
Inset 2.1: R code to ensure termination of iterative analysis. 
 
Set of selected hits are compared to the set of selected hits at all previous iterations 
(lines 7-8). If the set of selected hits is identical to the set in the previous iteration 
(line 19) or if the set of hits oscillates between a defined set of hits and the current 
iteration gives the largest set (lines 20-21) the counter is set to FALSE (line 24) 
leading the analysis to terminate and select the current iteration as the final output. 
R code for termination of iterative analysis  
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1. ########## ENRICHMENT 2 Tier FUNCTION ----   
2.    
3. ###** Requirments **###   
4. ## screen.datafame: A dataframe of the screen    
5. ## ID.column: A column within the screen.dataframe for the identifiers of the targets (EntrezID, GeneSymbol, etc.)    
6. ## criteria.column: A column within the screen.dataframe of the criteria for being considered a hit    
7. ## highconf.criteria: A criteria each target has to meet to be considered a "high confidence" hit.   
8. ## midconf.criteria: A criteria each target has to meet to be considered a "mid confidence" hit.   
9. ## criteria.setting: Whether you should be using "equal", "greater than or equal", or "less then or equal". Should be i
n the format of "equal", "greater", or "less"   
10. ## enrichment.dataframe: A dataframe to be used for pathway membership in the format of a column of IDs (should be same
 as ID column in screen.dataframe in ID type and column title) and a column of which group they are part of of. (each I
D~group relationship should be in its own seperate row)   
11. ## enrichment.title: Name of the column with the names of the enrichment groups the targets are members of.   
12. ## stat.test: name of of the statistical test to be used for measuring enrichment confidence. Should be in format of ei
ther "pVal", "FDR", or "Bonferroni"   
13. ## test.cutoff: A numeric value which a less than the value in stat.test will be considered a significant enrichment.   
14.    
15.    
16. ###** Output **###   
17. ## a list with 2 dataframes   
18. ## 1: the screen.dataframe with an appended column listing each ID if it is part of a significantly enriched enrichment
 ("Yes") and was either high or medium confidence in the input, if it is not ("No"), or if it is missing from the enric
hment.dataframe ("Missing")   
19. ## 2: a dataframe listing all the enrichmen groups with number of members, number of hits, ID of hits, p value, FDR, an
d Boneferroni of enrichment.   
20.    
21. ENRICHMENT.2tiers.function <- function(screen.dataframe, ID.column, criteria.column, highconf.criteria, midconf.criteri
a, criteria.setting, enrichment.dataframe, enrichment.title, stat.test, test.cutoff){   
22.      
23.   ##--Assign Dataframes   
24.   #Get dataframe of hits and assign temp column names   
25.   hits.df <- screen.dataframe[, c(which(colnames(screen.dataframe) == ID.column), which(colnames(screen.dataframe) == c
riteria.column))]   
26.   names(hits.df) <- c("ID.temp", "criteria.temp")   
27.      
28.   #Get dataframe of enrichment and assign temp names   
29.   enrich.df <- enrichment.dataframe[, c(which(colnames(enrichment.dataframe) == ID.column), which(colnames(enrichment.d
ataframe) == enrichment.title))]   
30.   names(enrich.df) <- c("ID.temp", "enrich.temp")   
31.      
32.   ##--Get high confidence, medium confidence hits and non hits matrix   
33.   if (criteria.setting == "equal") {   
34.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
35.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
36.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used for g
raph subsetting later   
37.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
38.   } else if (criteria.setting == "greater") {   
39.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= highconf.criteria)])   
40.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= midconf.criteria && hits.df$criteria.temp 
< highconf.criteria)])   
41.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used for g
raph subsetting later   
42.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
43.   } else if (criteria.setting == "less") {   
44.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= highconf.criteria)])   
45.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= midconf.criteria && hits.df$criteria.temp 
> highconf.criteria)])   
46.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used for g
raph subsetting later   
47.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
48.   } else {   
49.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
50.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
51.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used for g
raph subsetting later   
52.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
53.     message("criteria.setting not properly defined. Using 'equals to' default")   
54.   }   
55.      
56.   ##-- subset hits and non.hits list to only those that intersect with what is in the enrichment dataframe   
57.   subset.hits <- intersect(highconf.hits, enrich.df$ID.temp)   
58.   subset.all.hits <- intersect(all.hits, enrich.df$ID.temp)   
59.   subset.non.hits <- intersect(union(non.hits, midconf.hits), enrich.df$ID.temp)   
60.      
61.   ##- subset enrichment list for enrichments that have members in the screen.dataframe list and get a list of unique na
mes   
62.   enrich.filter <- enrich.df[which(enrich.df$ID.temp %in% hits.df$ID.temp), ]   
63.   enrich.unique <- unique(as.character(enrich.filter$enrich.temp))   
64.      
65.      
66.   ##- add create columns and rows for all the pathways   
67.   p.val <- enrich.group.members.number <- enrich.hit.number <- enrich.hit.IDs <- rep(NA,length(enrich.unique))   
68.      
69.      
70.   ##-- populate the columns with the values for each enrichment group   
71.   
(Cont.) 
R code for pathway enrichment 
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72.     
73.   #- Fischer's Test (greater then)   
74.   for(i in 1:length(enrich.unique))                                               
75.   {   
76.     enirchment.members <- enrich.filter$ID.temp[which(as.character(enrich.filter$enrich.temp) == enrich.unique[i])]   
77.     contingency <- matrix(NA,nrow = 2, ncol = 2)   
78.     contingency[1,1] <- length(intersect(enirchment.members, subset.hits)) # pathway.genes.hits   
79.     contingency[1,2] <- length(intersect(enirchment.members, subset.non.hits)) # pathway.genes.non.hits   
80.     contingency[2,1] <- length(setdiff(subset.hits, enirchment.members)) # non.pathway.hits    
81.     contingency[2,2] <- length(setdiff(subset.non.hits, enirchment.members)) # non.pathway.non.hits   
82.     p.val[i] <- fisher.test(contingency, alternative = "greater")$p.value   
83.     enrich.group.members.number[i] <- contingency[1,1] + contingency[1,2]   
84.     enrich.hit.number[i] <- contingency[1,1]   
85.     enrich.hit.IDs[i] <- paste(unique(enrich.filter$ID.temp[match(intersect(enirchment.members,subset.hits), enrich.fil
ter$ID.temp)]),collapse = ", ")   
86.   }   
87.      
88.   p.val.FDR <- p.adjust(p.val,method = "BH") #Correction for multiple testing   
89.   p.val.FWER <- p.adjust(p.val,method = "bonferroni") #Bonferroni Correction   
90.      
91.      
92.   #- print number of enrichment groups being calculated   
93.   message(paste0("unique enrichment groups being measured: ", length(enrich.unique)))   
94.      
95.   ##-- Create enrichment results dataframe   
96.      
97.   enrichment.results <- data.frame(Enrichment = enrich.unique,    
98.                                    pVal = p.val,   
99.                                    pValFDR = p.val.FDR,   
100.                                    pValBonferroni = p.val.FWER,    
101.                                    EnrichmentMembers = enrich.group.members.number,    
102.                                    EnrichmentHitNumber = enrich.hit.number,    
103.                                    EnrichmentHitID = enrich.hit.IDs)   
104.      
105.   enrichment.results <- enrichment.results[with(enrichment.results, order(enrichment.results$pValBonferroni,enrichment.
results$pValFDR,enrichment.results$pVal)),] #order dataframe from lowest to highest value of statistical test   
106.      
107.   ###--
- Assign individual IDs in the screen.dataframe if they are hits based on the enrichment analysis and the provided cuto
ff   
108.      
109.   ##-- Get list of enrichment that are siginificantly enriched for   
110.   if (stat.test == "pVal") {   
111.     sig.enrichment <- as.character(enrichment.results$Enrichment[which(enrichment.results$pVal < test.cutoff)])   
112.   } else if (stat.test == "FDR") {   
113.     sig.enrichment <- as.character(enrichment.results$Enrichment[which(enrichment.results$pValFDR < test.cutoff)])   
114.   } else if (stat.test == "Bonferroni") {   
115.     sig.enrichment <- as.character(enrichment.results$Enrichment[which(enrichment.results$pValBonferroni < test.cutoff)
])   
116.   } else {   
117.     sig.enrichment <- as.character(enrichment.results$Enrichment[which(enrichment.results$pVal < test.cutoff)])   
118.     message("Statisitical test not properly defined. Unsing pVal as default")   
119.   }   
120.      
121.   #- list of hit IDs in significantly enriched enrichments   
122.   sig.enrich.hitIDs <- intersect(unique(enrich.filter$ID.temp[which(enrich.filter$enrich.temp %in% sig.enrichment)]), s
ubset.all.hits)   
123.      
124.   #- list of IDs that are not members of the significantly    
125.   if(length(sig.enrich.hitIDs > 0)){   
126.     nonhits.sig.enrich.IDs <- setdiff(enrich.filter$ID.temp, sig.enrich.hitIDs)   
127.   } else {   
128.     nonhits.sig.enrich.IDs <- enrich.filter$ID.temp   
129.   }   
130.      
131.   ##-
- append column to screen.dataframe of whether the row ID is annotated in the enrichment.dataframe and if it is or isn'
t part of a significantly enriched group   
132.   temp.enrich.IDs <- matrix("Missing", nrow(hits.df))   
133.   temp.enrich.IDs[hits.df$ID.temp %in% sig.enrich.hitIDs] <- "Yes"      
134.   temp.enrich.IDs[hits.df$ID.temp %in% nonhits.sig.enrich.IDs] <- "No"   
135.      
136.   screen.dataframe$Enrichment.hit <- temp.enrich.IDs   
137.      
138.      
139.      
140.   ###--- Define return objects   
141.   enrichment.output <- list(screen.dataframe, enrichment.results)   
142.      
143.   ####---- Return   
144.   return(enrichment.output)   
145.      
146. }  
Inset 2.2: R code for stand-alone pathway enrichment function. 
 
The R script enables the selection of hits from a dataset with high confidence and 
medium confidence hits based on competitive pathway enrichment. The R script can 
be used with any user provided pathway membership resource and the user can select 
the preferred statistical test and cutoff. 
R code for pathway enrichment (continued) 
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1. ########## NETWORK FUNCTION ----   
2.    
3. ###** Requirments **###   
4. ## screen.datafame: A dataframe of the screen    
5. ## ID.column: A column within the screen.dataframe for the identifiers of the targets (EntrezID, GeneSymbol, etc.). 
   
6. ## criteria.column: A column within the screen.dataframe of the criteria for being considered a high confidence hit,
 medium confidence hit, and low confidence/non hit.   
7. ## highconf.criteria: A criteria each target has to meet to be considered a "high confidence" hit.   
8. ## midconf.criteria: A criteria each target has to meet to be considered a "mid confidence" hit.   
9. ## criteria.setting: Whether you should be using "equal", "greater than or equal", or "less then or equal". Should b
e in the format of "equal", "greater", or "less".   
10. ## network.igraph: an igraph of the network to be used for network analysis (network igraph must use the same ID typ
e as screen.dataframe)   
11.    
12.    
13. ###** Output **###   
14. ## The input screen.dataframe with two appended columns   
15. ## Network.analysis: A column with information on whether it was an "InputHighConfidenceHit" or "NetworkAnalysisAdde
d", if neither than "0" is assigned.   
16. ## Network.hit: A column on wether based on network enrichment the row ID is a hit, with designations "Yes" and "No"
   
17.    
18. NETWORK.function <- function(screen.dataframe, ID.column, criteria.column, highconf.criteria, midconf.criteria, crit
eria.setting, network.igraph){   
19.      
20.   ##-- necessary libraries   
21.   library("igraph")   
22.      
23.   ##--Assign Dataframes   
24.   #Get dataframe of hits and assign temp column names   
25.   hits.df <- screen.dataframe[, c(which(colnames(screen.dataframe) == ID.column), which(colnames(screen.dataframe) =
= criteria.column))]   
26.   names(hits.df) <- c("ID.temp", "criteria.temp")   
27.      
28.   ##--Get high confidence, medium confidence hits and non hits matrix   
29.   if (criteria.setting == "equal") {   
30.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
31.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
32.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used fo
r graph subsetting later   
33.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
34.   } else if (criteria.setting == "greater") {   
35.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= highconf.criteria)])   
36.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= midconf.criteria && hits.df$criteria.te
mp < highconf.criteria)])   
37.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used fo
r graph subsetting later   
38.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
39.   } else if (criteria.setting == "less") {   
40.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= highconf.criteria)])   
41.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= midconf.criteria && hits.df$criteria.te
mp > highconf.criteria)])   
42.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used fo
r graph subsetting later   
43.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
44.   } else {   
45.     highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
46.     midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
47.     all.hits <- union(highconf.hits, midconf.hits) # a seperate matrix of high and low confidence hits to be used fo
r graph subsetting later   
48.     non.hits <- setdiff(as.matrix(hits.df$ID.temp), all.hits)   
49.     message("criteria.setting not properly defined. Using 'equals to' default")   
50.   }   
51.      
52.   ###--- Format igraph   
53.   set.seed(123)   
54.      
55.   ##-- Select subgraph that matches list of IDs in screen  ----> This will be the geneal all encompasing network   
56.   G <- upgrade_graph(network.igraph)   
57.   OverallDegree <- degree(G)   
58.   screen.IDs.for.network.analysis <- intersect(hits.df$ID.temp, V(G)$name)   
59.   Graph <- induced.subgraph(G, screen.IDs.for.network.analysis)   
60.      
61.   ##-- Select subgraph that matches list of IDs in high confidence AND mid confidence hits ----
> This will be the network of all "hits"   
62.   Subset.allhitIDs.for.network.analysis <- intersect(all.hits, V(G)$name)   
63.   allhits.SubGraph <- induced.subgraph(G, Subset.allhitIDs.for.network.analysis)   
64.   allhits.SubGraph <- induced.subgraph(allhits.SubGraph, names(which(igraph::degree(allhits.SubGraph) > 0)))   
65.   allhits.SubGraph.IDs <- V(allhits.SubGraph)$name   
66.      
67.   ##-- Removes edges that don't connect a high confidence hit.   
68.      
69.   graph.edges.allhits.names <- get.data.frame(allhits.SubGraph, what = "edges")   
70.   indices.to.remove <- intersect(which((graph.edges.allhits.names$from %in% highconf.hits) == FALSE),    
71.                                  which((graph.edges.allhits.names$to %in% highconf.hits) == FALSE))   
72.      
73.   if(length(indices.to.remove) > 0){   
74.     graph.edges.allhits.names <- graph.edges.allhits.names[-indices.to.remove, ]   
75.   }   
76.      
77.    
(Cont..) 
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78. ##-- Get net list of added High confidence hits   
79.   new.highconf.SubGraph <- graph.data.frame(graph.edges.allhits.names, directed = FALSE, vertices = NULL)   
80.      
81.   ##--Combine this list with the original high confidence hits   
82.   new.highconf.IDs <- union(V(new.highconf.SubGraph)$name, highconf.hits)   
83.      
84.   ###-- Create columns to append to screen.dataframe   
85.   hits.df$Network.analysis <- 0   
86.   hits.df$Network.analysis[match(new.highconf.IDs, hits.df$ID.temp)] <- "NetworkAnalysisAdded"   
87.   hits.df$Network.analysis[match(highconf.hits, hits.df$ID.temp)] <- "InputHighConfidenceHit"   
88.   hits.df$Network.hit <- "No"   
89.   hits.df$Network.hit[match(new.highconf.IDs, hits.df$ID.temp)] <- "Yes"   
90.      
91.   ##-- append to the screen.dataframe input   
92.   screen.dataframe.out <- screen.dataframe   
93.   screen.dataframe.out$Network.analysis <- hits.df$Network.analysis   
94.   screen.dataframe.out$Network.hit <- hits.df$Network.hit   
95.      
96.    
97.      
98.   ###--- Return the appended data frame inside a list   
99.   network.output <- list(screen.dataframe.out)   
100.   return(network.output)   
101.      
102. }    
Inset 2.3: Rcode for stand-alone network analysis function. 
 
The R script enables the selection of hits from a dataset with high confidence and 
medium confidence hits based on direct neighbor interactions. The R script can be 
used with any user provided interaction network. 
R code for enrichment by network analysis (continued) 
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1. ########## TRIAGE FUNCTION ----   
2.    
3.    
4. ###** Libraries **###   
5. library('dplyr')   
6. library('data.table')   
7. library('igraph')   
8.    
9.    
10. ###** Requirments **###   
11. ## screen.datafame: A dataframe of the screen    
12. ## ID.column: A column within the screen.dataframe for the identifiers of the targets (EntrezID, GeneSymbol, etc.)    
13. ## criteria.column: A column within the screen.dataframe of the criteria for being considered a hit    
14. ## highconf.criteria: A criteria each target has to meet to be considered a "high confidence" hit.   
15. ## midconf.criteria: A criteria each target has to meet to be considered a "mid confidence" hit.   
16. ## criteria.setting: Whether you should be using "equal", "greater than or equal", or "less than or equal". Should be i
n the format of "equal", "greater", or "less"   
17. ## enrichment.dataframe: A dataframe to be used for pathway membership in the format of a column of IDs (should be same
 as ID column in screen.dataframe in ID type and column title) and a column of which group they are part of of. (each I
D~group relationship should be in its own seperate row)   
18. ## enrichment.title: Name of the column with the names of the enrichment groups the targets are members of.   
19. ## stat.test: name of of the statistical test to be used for measuring enrichment confidence. Should be in format of ei
ther "pVal", "FDR", or "Bonferroni"   
20. ## test.cutoff: A numeric value which a less than the value in stat.test will be considered a significant enrichment.   
21. ## network.igraph: an igraph of the network to be used for network analysis (network igraph must use the same ID type a
s screen.dataframe)   
22.    
23.    
24. ###** Output **###   
25. ## Output is a list of 3 dataframes   
26. ## [[1]] input dataframe plus 'TRIAGE.hit' column,    
27. ## [[2]] dataframe of high confidence and medium confidence designation at each iteration,    
28. ## [[3]] dataframe of final TRIAGE enrichments   
29.    
30.    
31. TRIAGE.2tiers.function <- function(screen.dataframe, ID.column, criteria.column, highconf.criteria, midconf.criteria, c
riteria.setting, enrichment.dataframe, enrichment.title, stat.test, test.cutoff, network.igraph) {   
32.      
33.   ###--- Save original inputs   
34.   input.screen.dataframe <- screen.dataframe   
35.   input.ID.column <- ID.column   
36.   input.criteria.column <- criteria.column   
37.   input.highconf.criteria <- highconf.criteria   
38.   input.midconf.criteria <- midconf.criteria   
39.   input.criteria.setting <- criteria.setting   
40.   input.enrichment.dataframe <- enrichment.dataframe   
41.   input.enrichment.title <- enrichment.title   
42.   input.stat.test <- stat.test   
43.   input.test.cutoff <- test.cutoff   
44.   input.network.igraph <- network.igraph   
45.      
46.      
47.      
48.   ###--- Define input high confidence hits, medium confidence hits, and background   
49.   #Get dataframe of hits and assign temp column names   
50.   hits.df <- screen.dataframe[, c(which(colnames(screen.dataframe) == ID.column), which(colnames(screen.dataframe) == c
riteria.column))]   
51.   names(hits.df) <- c("ID.temp", "criteria.temp")   
52.      
53.   ##-- Get high confidence, medium confidence hits and non hits matrix of the inputs   
54.   if (criteria.setting == "equal") {   
55.     input.highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
56.     input.midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
57.     input.all.hits <- union(input.highconf.hits, input.midconf.hits) # a seperate matrix of high and low confidence hit
s to be used for graph subsetting later   
58.     input.non.hits <- setdiff(as.matrix(hits.df$ID.temp), input.all.hits)   
59.   } else if (criteria.setting == "greater") {   
60.     input.highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= highconf.criteria)])   
61.     input.midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp >= midconf.criteria && hits.df$criteria
.temp < highconf.criteria)])   
62.     input.all.hits <- union(input.highconf.hits, input.midconf.hits) # a seperate matrix of high and low confidence hit
s to be used for graph subsetting later   
63.     input.non.hits <- setdiff(as.matrix(hits.df$ID.temp), input.all.hits)   
64.   } else if (criteria.setting == "less") {   
65.     input.highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= highconf.criteria)])   
66.     input.midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp <= midconf.criteria && hits.df$criteria
.temp > highconf.criteria)])   
67.     input.all.hits <- union(input.highconf.hits, input.midconf.hits) # a seperate matrix of high and low confidence hit
s to be used for graph subsetting later   
68.     input.non.hits <- setdiff(as.matrix(hits.df$ID.temp), input.all.hits)   
69.   } else {   
70.     input.highconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == highconf.criteria)])   
71.     input.midconf.hits <- as.matrix(hits.df$ID.temp[which(hits.df$criteria.temp == midconf.criteria)])   
72.     input.all.hits <- union(highconf.hits, input.midconf.hits) # a seperate matrix of high and low confidence hits to b
e used for graph subsetting later   
73.     input.non.hits <- setdiff(as.matrix(hits.df$ID.temp), input.all.hits)   
74.     input.message("criteria.setting not properly defined. Using 'equals to' default")   
75.   }   
76.    
(Cont.)   
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77.   ###--- Begin setting the first iteration variable to 1    
78.   iteration <- 1   
79.      
80.   #- Create dataframe for appending the dataframe through each iteration step   
81.   append.hits.df <- hits.df   
82.   names(append.hits.df)[which(colnames(append.hits.df) == "ID.temp")] <- input.ID.column  ## Necesary to rename the ID 
column to original name so that it aligns with the ID.column of the enrichment dataframe   
83.      
84.   ####---- Set up a counter for while loop till iteration converge   
85.   counter <- TRUE   
86.      
87.   while (counter == TRUE) {   
88.        
89.     ###--- Enrichment step ----> Contracting the hits set   
90.        
91.     enrichment.step <- ENRICHMENT.2tiers.function(screen.dataframe, ID.column, criteria.column, highconf.criteria, midc
onf.criteria, criteria.setting, enrichment.dataframe, enrichment.title, stat.test, test.cutoff)   
92.        
93.     ##-- create enrichment output dataframe   
94.     #- Get datframe from enrichemnt step   
95.     enrichment.output.df <- enrichment.step[[1]]   
96.        
97.     ##-- Append Data frame to be used for Network function input   
98.     append.hits.df <- data.frame(append.hits.df, temp = "", stringsAsFactors = FALSE)   
99.     Enrichment.iteration.name <- paste0("ENRICH.iteration_", iteration)   
100.     names(append.hits.df)[names(append.hits.df) == "temp"] <- Enrichment.iteration.name   
101.     append.hits.df[[Enrichment.iteration.name]][enrichment.output.df$Enrichment.hit == "Yes" & (append.hits.df[[ID.colu
mn]] %in% input.all.hits)] <- "HighConf"   
102.     append.hits.df[[Enrichment.iteration.name]][enrichment.output.df$Enrichment.hit != "Yes" & (append.hits.df[[ID.colu
mn]] %in% input.all.hits)] <- "MedConf"   
103.        
104.        
105.     ###--- Network step ----> Expanding the hits set   
106.        
107.     ##-- Set Network Function input parameters   
108.     screen.dataframe <- append.hits.df   
109.     ID.column <- ID.column   
110.     criteria.column <- Enrichment.iteration.name   
111.     highconf.criteria <- "HighConf"   
112.     midconf.criteria <- "MedConf"   
113.     criteria.setting <- "equal"   
114.     network.igraph <- network.igraph   
115.        
116.        
117.     ##-- Run NETWORK function   
118.        
119.     network.output <- NETWORK.function(screen.dataframe, ID.column, criteria.column, highconf.criteria, midconf.criteri
a, criteria.setting, network.igraph)   
120.     network.output.df <- network.output[[1]]   
121.        
122.     ##-- Append Data frame to be used as Enrichment input or final output   
123.     append.hits.df <- data.frame(append.hits.df, temp = "", stringsAsFactors = FALSE)   
124.     Network.iteration.name <- paste0("NETWORK.iteration_", iteration)   
125.     names(append.hits.df)[names(append.hits.df) == "temp"] <- Network.iteration.name   
126.     append.hits.df[[Network.iteration.name]][network.output.df$Network.hit == "Yes" & (append.hits.df[[ID.column]] %in%
 input.all.hits)] <- "HighConf"   
127.     append.hits.df[[Network.iteration.name]][network.output.df$Network.hit != "Yes" & (append.hits.df[[ID.column]] %in%
 input.all.hits)] <- "MedConf"   
128.        
129.     ##-- Set Enrichment Function input parameters for next iteration   
130.     screen.dataframe <- append.hits.df   
131.     ID.column <- input.ID.column   
132.     criteria.column <- Network.iteration.name   
133.     highconf.criteria <- "HighConf"   
134.     midconf.criteria <- "MedConf"   
135.     criteria.setting <- "equal"   
136.     enrichment.dataframe <- enrichment.dataframe    
137.     enrichment.title <-  enrichment.title   
138.     stat.test <- stat.test   
139.     test.cutoff <- test.cutoff   
140.        
141.     ##-- Print message on completion of iteration   
142.     message(paste("iteration ", iteration, " Complete"))   
143.        
144.     ##-- Measure if there is an iterating pattern   
145.     converge.sequence <- 0   
146.        
147.     if (iteration >=3) {   
148.       highconf.length <- c(length(append.hits.df[[ID.column]][append.hits.df[[Network.iteration.name]]== "HighConf"])) 
  
149.          
150.       for ( t in 1:iteration){   
151.         if (identical(append.hits.df[[Network.iteration.name]], append.hits.df[[paste0("NETWORK.iteration_", iteration-
t)]])){   
152.           converge.sequence <- t   
153.           break   
154.         } else {   
155.           highconf.length <- c(highconf.length, length(append.hits.df[[ID.column]][append.hits.df[[paste0("NETWORK.iter
ation_", iteration-t)]] == "HighConf"]))   
156.         }   
157.       }   
158.     }   
159.       
(Cont.)  
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160. ##-- See if Iteration is converging on output    
161.        
162.     if((iteration != 1 && identical(append.hits.df[[Network.iteration.name]], append.hits.df[[paste0("NETWORK.iteration
_", iteration-1)]]))    
163.        || (converge.sequence > 0    
164.            && (length(append.hits.df[[ID.column]][append.hits.df[[Network.iteration.name]]== "HighConf"]) == max(highco
nf.length))    
165.        ))  {   
166.       ##-- Set counter to false   
167.       counter <- FALSE   
168.     } else {   
169.       ##-- Update itertion number   
170.       iteration <- iteration + 1   
171.     }   
172.        
173.   }   
174.   ####---- end of while loop, Print message on completion of TRIAGE iteration   
175.   message(paste("TRIAGE iterations complete, number of iterations: ", iteration))   
176.      
177.      
178.      
179.      
180.   ####---- Create TRIAGE output dataframes   
181.   input.plus.triage.df <- input.screen.dataframe   
182.   input.plus.triage.df$TRIAGE.hit <- network.output.df$Network.hit   
183.      
184.   hits.by.iteration.df <- append.hits.df   
185.   names(hits.by.iteration.df)[which(colnames(hits.by.iteration.df) == "criteria.temp")] <- input.criteria.column   
186.      
187.   triage.enrichment.df <- enrichment.step[[2]]   
188.      
189.   ##-- Create List of outputs   
190.   triage.output <- list(input.plus.triage.df, hits.by.iteration.df, triage.enrichment.df)   
191.      
192.   #- Print message on list content   
193.   message("list contents: \n [[1]] input dataframe with 'TRIAGE.hit' column, \n [[2]] dataframe of high confidence and 
medium confidence designation at each iteration, \n [[3]] dataframe of final TRIAGE enrichments")   
194.      
195.      
196.   ####---- return list   
197.   return(triage.output)   
198. }   
199.     
Inset 2.4: R code for TRIAGE function. 
 
The R script enables the selection of hits from a dataset with high confidence and 
medium confidence hits using the iterative TRIAGE analysis. The R script calls the 
enrichment function and network function from Inset 2.1 and 2.2, respectively. The 
analysis can be performed using the user’s choice of pathway database and 
interaction network.  
R code for TRIAGE analysis (continued) 
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The list of input variables that can be selectively assigned in the adaptable TRIAGE function 
in R and their required formats are: 
screen.datafame: A data frame of the screen.  
ID.column: A column within the screen.dataframe for the identifiers of the targets (EntrezID, 
GeneSymbol, etc.). 
criteria.column: A column within the screen.dataframe of the criteria for being considered a 
hit. 
highconf.criteria: A criteria each target has to meet to be considered a "high confidence" hit. 
midconf.criteria: A criteria each target has to meet to be considered a "mid confidence" hit. 
criteria.setting: Whether the function should be using "equal", "greater than or equal", or "less 
than or equal" when assessing if confidence criteria is met. criteria.setting input should be in 
the format of "equal", "greater", or "less". 
enrichment.dataframe: A data frame to be used for pathway membership in the format of a 
column of IDs (should be same as ID column in screen.dataframe in ID type and column title) 
and a column of which group they are part of. (each ID~group relationship needs to be in its 
own separate row). 
enrichment.title: Name of the column with the names of the enrichment groups the targets are 
members of. 
stat.test: Name of the statistical test to be used for measuring enrichment confidence. Needs to 
be in the format of either "pVal", "FDR", or "Bonferroni". 
test.cutoff: A numeric value which a less than value in stat.test will be considered a significant 
enrichment. 
network.igraph: an igraph of the network to be used for network analysis (network igraph must 
use the same ID type as screen.dataframe). 
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 The user provided variables are then used to apply the iterative function as in the 
previous paragraph. The adaptable version of TRIAGE broadens the possibility for its 
application beyond the use of the specific databases and settings it was originally designed 
with. The TRIAGE function provides an output in the format of a R script list that contains 
three data frames: 1) the input data frame plus a 'TRIAGE.hit' column. 2) A data frame of high 
confidence and medium confidence designation at each iteration of the analysis. 3) A data 
frame of final TRIAGE enrichments from the provided enrichment data frame. 
 
2.4.2 Web based interface of TRIAGE (Shiny) 
The TRIAGE web interface was designed to run on a set of intuitive user inputs and provide 
the user with results of TRIAGE analysis and the ability to explore and download the results 
(Figure 2.2). Creation of the public facing web page based on R script was done using the Shiny 
application (Winston Chang, Joe Cheng, JJ Allaire, Yihui Xie and Jonathan McPherson (2019). 
shiny: Web Application Framework for R. R package version 1.3.2. https://CRAN.R-
project.org/package=shiny). Briefly, the different sets of outputs were separated into different 
“tabs” with an additional tab added for input. Inputs required from the user were separated into 
“selectedInputs” (organism, pathway, network, interaction confidence for network analysis), 
“conditionalPanel” (selecting interaction network confidence source), “fileInput” (uploading 
input file),  “textInput” (high-conf cutoff value, mid-conf cutoff value), “checkboxInput” (add 
genome background), and “actionButton” (run analysis, reset analysis). The inputs are assigned 
to variables that are then matched to variables in the TRIAGE function.  
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Figure 2.2: Shiny application for TRIAGE analysis. 
 
Schematic of the Shiny application of the TRIAGE analysis interface. The application can 
be run either as a stand-alone application or accessed from an internet browser. The 
analysis relies on a set of user inputs (uploaded gene list with scores, cutoffs to be used, 
and selecting pathway and network database parameters). The application applies 
TRIAGE analysis to the uploaded data. The application tracks only the IP address and 
location of connection. No data of the analysis or uploaded screen is collected or stored 
by the application. The analysis output provides a download zip folder of analysis as well 
as an interactive interface for network and pathway exploration. 
IP address 
Country 
location 
TRIAGE application access and analysis pipeline  
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A set of warning messages were built in if lists of hits yield no results in pathway and 
network analysis (a warning message suggests lowering cutoff criteria and re-running the 
analysis). Additional warning messages were built in for organism mismatch and lack of gene 
ID recognition. To visualize the progress of the analysis for the user a progress bar appears and 
fills to 1/3 of the bar when the analysis is ready to begin and to half of the bar after the first 
iteration. After each iteration the progress bar fills one third of the remaining space of the bar. 
When the analysis is complete the progress bar fills to the end and the input tab switches to the 
Enriched Pathways tab for a review of the results.  
To create the hyperlinks for each enriched pathway with mapped on hits on KEGG 
pathway maps a link2KEGGmapper function is generated following an analysis on TRIAGE. 
The link2KEGGmapper function generates a list of gene names mapped to the organism 
abbreviation and assigned colors based on input provided confidence level. A web path is 
created for each pathway and added to the end of the https://www.kegg.jp/kegg-
bin/show_pathway?%s0%s web address. This generates a unique URL for each pathway based 
on the list of high confidence and medium confidence hits in its membership to match the URL 
generated by the KEGG mapper and ID color feature 
(https://www.genome.jp/kegg/tool/map_pathway3.html).  
For the table of pathway enrichment an enrichment score (EnirchScore) for each 
pathway was calculated. The score is a measure of the robustness of the pathways enrichments 
by the number of genes represented in the TRIAGE dataset. The EnrichScore also evaluates 
how many of the genes driving the pathway enrichment were assigned as high confidence in 
the input (HighScoreGenes). The total EnrichScore is calculated as !	 !"#$%&%'
$%&%'(&)*#+,*-
+
!".+/012%$%&%'
!"#$%&%'
$ /	2 .  
To generate the appended columns of “InteractingGenes” and 
“NetworkGenePathways” for the TRIAGE gene hits tab, an igraph of the selected hits is 
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generated based on the network input parameters provided by the user and filtered into a sub-
igraph for each hit. The interacting genes are then cross-referenced with the pathway input 
parameters selected by the user and the list of pathway memberships of the interacting genes 
are tabulated, counted, and added to the “NetworkGenePathways” column. The download tab 
on the interface was created as a reactive page. As files are added to the directory with 
additional analysis steps, the download page updates with a list of file names in the current 
directory. For ease of use the download files are put in a zip file format. 
The application is hosted by the National Institute of Allergy and Infectious Disease 
(NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) at the following 
URL: https://triage.niaid.nih.gov. The analysis is run behind two internet security firewalls and 
all requests are handled using encrypted connections (Figure 2.3). Using these encrypted 
connections ,only the browser from the IP address where the request originated from can access 
the data generated and uploaded. After a connection ends the directory with the upload and 
analysis files are deleted from the server.  
 
2.4.3 Interactive pathway and network exploration (JavaScript, jsons, d3.js) 
Interactive visual interfaces were built by integrating the JavaScript language into the R Shiny 
platform. Communication across the platforms were done by creating JavaScript files in R 
using the jasonlite R package (Jeroen Ooms (2014). The jsonlite Package: A Practical and 
Consistent Mapping Between JSON Data and R Objects. arXiv:1403.2805 [stat.CO] URL 
https://arxiv.org/abs/1403.2805.) and then fed into d3.js file (Bostock et al., 2011). 
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Figure 2.3: Data security measures for accessing the TRIAGE interface. 
 
Access by external users to TRIAGE interface pass through two secure firewalls. The 
incoming request first passes through the NIH web hosting firewall after which the analysis 
and TRIAGE application go through the NIAID firewall where the analysis is hosted. 
Migrations to external websites outside of the firewall (i.e. the KEGG interface) are 
accompanied with a warning message for the user. 
TRIAGE interface security infrastructure 
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 To create the hierarchical edge bundling maps of selected pathways and TRIAGE hits, 
an igraph of all the selected hits is generated. A vector of all the selected pathway names and 
additional group “novel hits” is also created. To filter the network map, first the edges are 
filtered based on membership in the selected pathways or interaction with an edge in one of 
the selected pathways. Second, nodes are filtered based on having the two edges in different 
groups in the vector of selected pathways and novel hits (this removes intra-group nodes). The 
nodes are assigned color grouping based on the edge that is in a pathway group.  
 The interactive interface for network exploration was built using a combination of 
Shiny and Java based features.  Lists of clicked paths in Shiny were converted to object notation 
lists for Java. Communication between the json file where the clicks are tracked and the shiny 
interface where the clicks are received was done using d3.js. A d3.js input and output file is 
created for each directory to communicate between the formats (jsons for Java, csv for Shiny). 
Visual parameter controls of the graph on the interface are created using the Shiny slider 
function. A window in the interface maps the node selected by the cursor to the selected 
network data frame and populates the field with interaction confidence and evidence source 
information on the selected node. A log of clicked edges and nodes is formatted into a csv 
format that is added to the download directory in TRIAGE and appears in the reactive 
“download” tab. 
 
2.4.4 IPA 
Pathway analysis and visualization by IPA were performed using the QIAGEN Ingenuity 
Pathway Analysis application (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). 
 
   76 
2.4.5 rMATS 
rMATS analysis was performed using the rMATS analysis package as described by Shen et al. 
(2014). 
 
2.4.6 SQANTI 
SQANTI analysis was performed using the SQANTI analysis pipeline as described by 
Tardaguila et al. (2018). 
 
2.5 Cell Culture 
2.5.1 Immortalized human and mouse macrophage cell-lines 
RAW264.7 cells were maintained in DMEM, 10% FBS, 20mM Hepes, and 2mM glutamine. 
THP1 cells were maintained in RPMI1640, 10% FBS, and 2mM glutamine (containing 
500ug/ml G418 for THP1 B5 line). THP1 cells were differentiated into a macrophage-like state 
with 5ng/ml phorbol-12-myristate-13-acetate (PMA, from Sigma, P1585) for 72 h. 
 
2.5.2 RAW264.7 G9 cell line 
The RAW264.7 G9 cell line is described in (N. Li et al., 2015). The cell line expresses 
enhanced green fluorescent protein (EGFP)-tagged RelA and TNF- promoter (-1229nt to -
27nt)-induced mCherry. 
 
2.5.3 THP1 – B5 cell line 
The THP1 – B5 cell line is described in (N. Li et al., 2015). The cell line expresses firefly 
luciferase driven by the human TNF-a promoter combined with renilla luciferase driven by a 
ubiquitin promoter. 
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2.5.4 UBL5 knockdown cell line 
shRNAs targeting human UBL5 were designed using the Hannon Lab online tool 
(http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA) and cloned into the 
pEN_miRc2 vector (Shin et al., 2006). The knockdown efficiency was tested in 293T cells by 
transient co-expression of shRNAs with a YFP-IFIT1 fusion protein. The most efficient 
shRNA, targeting the following sequence in human UBL5; shRNA#1: 
CGGGATGAACCTGGAGCTTTAT, was subcloned to the pDS_FBneo plasmid and 
production of retrovirus and generation of stable cell lines were carried out as described 
previously (X. Zhu et al., 2007). Stable knockdown of UBL5 was confirmed using qPCR 
(Figure 2.4). 
 
2.5.5 Bone marrow derived macrophages 
Bone marrow progenitors isolated from sex-matched wild-type C57BL/6J mice (Jackson 
Laboratories) were differentiated into bone marrow derived macrophages (BMDMs) during a 
6 day culture in complete Dulbecco’s modified Eagle’s medium (DMEM + 10% FBS, 100 
U/ml penicillin, 100 U/ml streptomycin, 2 mM L-Glutamine, 20 mM HEPES) supplemented 
with 60 ng/ml recombinant mouse M-CSF (R and D systems). One day prior to stimulation, 
cells were rinsed with cold PBS, then scraped from plates using a cell lifter. 2mL of cells in 
complete DMEM at a concentration of 7.5x105 cells/mL were then plated in 6 well plates and 
allowed to rest overnight at 37 ̊ C, 5% CO2, 95% relative humidity prior to stimulation.  
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Figure 2.4 Efficacy of UBL5 knockdown in THP1 Cells.  
 
Percent UBL5 mRNA expression of THP1 cells treated with a control shRNA (sh-
Luciferase) and THP1 cells with UBL5 knockdown. Experiment was done in 
triplicates. ** = p < 0.01, two-tailed t test. 
Stable knockdown of UBL5 in THP1 cells 
** 
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2.5.6 Primary human macrophages 
Human blood derived monocytes were propagated in RPMI media with 10% FBS, 10 mM 
HEPES, and Betamercaptoethanol in 5% CO2 at 37°C. Human peripheral blood monocyte 
samples from screened, healthy donors were obtained under the NIH Clinical Center IRB-
approved protocol 99-CC-0168 from the NIH Department of Transfusion Medicine. Human 
primary monocytes were differentiated with 10 ng/ml GM-CSF (R&D) for 7 days.  
 
2.6 Assays 
2.6.1 LPS treatment 
LPS was from Enzo life science (used to be Alexis Biochemicals, Salmonella minnesota R595 
TLRgrade, ALX-581-008-L002) and was used to treat the cells at a concentration of 100 ng/ml, 
unless otherwise noted. 
 
2.6.2 Cytotoxicity 
Cytotoxicity in the inhibitor experiment were determine by the release of LDH using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega G1780) and used according to the 
manufacturer’s instructions. Cells were plated at 2.0x105 cells per well and done in triplicates. 
Florescence was measured with the FLUOstar Omega Filter-based multi-mode microplate 
reader. 
 
2.6.3 Splicing inhibition by Madrasin 
Madrasin was from Sigma (Cat# SML 1409-5MG). To get the compound in solution, 5mG of 
Madrasin was diluted in 3.212mL DMSO to create a 5 mM stock. Cells were plated at 2.0x105 
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cells per well and treated with 50ng/mL of inhibitor (except where noted differently as in the 
response curve assay) suspended in phenol red free media. Inhibitor was kept on for 4 hours in 
37°C. Inhibitor plus media was removed and replaced with fresh media including LPS. 
 
2.6.4 Proteasomal inhibition by MG132 
MG132 was from Sigma (Cat# M7449-1ML).   The cell was pre-treated with 10 μM MG132 
for 4 hrs before LPS stimulation.   
 
2.6.5 mCherry readout of TNF-a promoter activation 
Raw 264.7 reporter cells were plated into a 96-well plate at 2x105 cells/200μL/well with phenol 
red-free DMEM supplemented with 10% Hyclone® FCS, 2mM L-glutamine and 20mM 
HEPES, and then cultured overnight. The fluorescent intensity of mCherry expressed in the 
cells was measured at 584/620BP12 nm (excitation/emission filter) with the FLUOstar Omega 
Filter-based multi-mode microplate reader. 
 
2.6.6 PCR 
Total RNA was extracted with the RNeasy Mini Kit (QIAGEN). cDNA was reverse transcribed 
from 1μg RNA using the BioRad Reverse Transcription kit. PCR reactions were performed in 
an Applied Biosystems Veriti 96 Well Thermocycler with the following thermal cycles 95°C 
for 3 min, (95°C for 15 s, 55°C for 15 s, 72°C for 30 s) × 35 cycles. The samples were run on 
2% agarose gels.  
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2.6.7 qPCR 
Total RNA was extracted with the RNeasy Mini Kit (QIAGEN). cDNA was reverse transcribed 
from 1μg RNA using the BioRad Reverse Transcription kit. 200 ng RNA equivalent of cDNA 
was used per reaction with gene specific primers and FAM conjugated probes (IDT DNA) and 
qPCR Solaris mix (Dharmacon/Life Technologies). qPCR reactions were performed in a 
BioRad PCR thermocycler (BioRad CFX Real-Time Systems) with the following thermal 
cycles 95°C for 15 min, (95°C for 15 s, 60°C for 60 s) × 40 cycles. The Ct values were analyzed 
with BioRad software. Primers used in all PCR and qPCR reactions are listed in table 2.1. 
 
Target Oligonucleotide  
Human TNF-α, Forward (sense) CCAGGGACCTCTCTCTAATCA 
Human TNF-α, Reverse (antisense) TCAGCTTGAGGGTTTGCTAC 
Human TNF-α, FAM Probe AGTGACAAGCCTGTAGCCCATGTT 
Mouse TNF-α, Forward (sense) CCCTCCAGAAAAGACACCATG 
Mouse TNF-α, Reverse (antisense) GTCTGGGCCATAGAACTGATG 
Mouse TNF-α, FAM Probe ACCGATCACCCCGAAGTTCAGTAGA 
Human HPRT, Forward (sense) CTGGAAAGAATGTCTTGATTGTGG 
Human HPRT, Reverse (antisense) CTTGCGACCTTGACCATCTT 
Human HPRT, FAM Probe AGACTTTGCTTTCCTTGGTCAGGCA 
Mouse HPRT, Forward (sense) TCCTCCTCAGACCGCTTT 
Mouse HPRT, Reverse (antisense) TTCCAAATCCTCGGCATAATGA 
Mouse HPRT, FAM Probe CCCAGCGTCGTGATTAGCGATGAT 
Human b-actin, Forward (sense) TGAAGTCTGACGTGGACATC 
Human b-actin, Reverse (antisense) ACTCGTCATACTCCTGCTTG 
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IRAK1 S1, Forward (sense) TGGTCAGAGGGCTGTGAAGAC 
IRAK1 A1, Reverse (antisense) AGCCAGACCTGCTTGCAGTG 
IRAK1 S2, Forward (sense) TTGAGAAGCACCCAGAGCAC 
IRAK1 A2, Reverse (antisense) TGGAGTCAAGTGCCAGGAG 
IRAK1 S3, Forward (sense) CGCAGATTATCATCAACCC 
IRAK1 A3, Reverse (antisense) CATCAGCTCTGAAATTCATCAC 
TMED7-TICAM2 S1, Forward (sense) TGACAACGCCAAGCAGTG 
TMED7-TICAM2 A1, Reverse (antisense) ACAAAGGTGGGTCTTCTCCAAC 
TMED7-TICAM2 S2, Forward (sense) TGAGGGACTGTCCAAGAAAG 
TMED7-TICAM2 A2, Reverse (antisense) AATCGATGACAGACTTCAGAGC 
TMED7-TICAM2 A3, Reverse (antisense) CTGTGAGTCAGGGGTTAATG 
TMED7-TICAM2 S3, Forward (sense) CTGGGCCAGAAAGGAAGAC 
TMED7-TICAM2 A4, Reverse (antisense) TCCTGGACTTGTATCCACACTG 
Table 2.1 Primer design for PCR assays. 
 
2.6.8 RNA extraction 
Cells were plated in 10cm dish at 4.0x107 cells per plate. Following LPS stimulation at the 
relevant time point media was removed. Cells were washed twice with PBS. 1mL of lysis buffer 
(100:1 Buffer RLT, b-mercaptoethanol) was added to the plate to lyse the cells. Plates were 
kept in -80°C till RNA extraction assay.  Total RNA was extracted with the RNeasy Mini Kit 
(Qiagen, 74106) following the manufacturer’s instruction. 
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2.6.9 Western Blot 
THP1 cells were lysed in radioimmunoprecipitation assay buffer (Sigma, R0278) containing a 
protease inhibitor cocktail (Roche). Cell lysates were quantified by protein assay (Bio-Rad), 
and equal protein amounts were resolved with a 4 to 12% Bis-Tris Gel/MOPS Running Buffer 
System (Invitrogen) and transferred to nitrocellulose membranes. The membranes were 
analyzed by Western blotting with the following antibodies: Anti-IkBa (CST, Cat#: 4814), 
anti-phosphor-Erk (CST, Cat# 9106S), anti-MAPK p38, phospho (Thr180/Tyr182) (Cell 
Signaling, Cat# 4511). 
 
2.6.10 Short read RNA-seq 
3 replicates of each condition were prepared and tested for RNA integrity number (RIN) of 9.6 
or higher. Samples were pooled and sequenced on HiSeq using Illumina TruSeq Stranded 
mRNA Library Prep and paired-end sequencing. Reads of the samples were trimmed for 
adapters and low-quality bases using Trimmomatic software before alignment with the 
reference genome (hg38 for human and Mouse - mm10 for mouse) and the annotated 
transcripts using STAR. Gene expression quantification analysis was performed for all samples 
using STAR/RSEM tools. 
 
2.6.11 Long read RNA-seq 
Representative samples for all conditions were selected from the short-read RNA-seq sample 
preparation and sequenced by PacBio Whole-Genome De Novo Sequencing. Readouts were 
analyzed by the SQANTI analysis pipeline. 
  
   84 
  
   85 
3 Global analysis of three genome-scale siRNA studies of the LPS response in 
macrophages 
 
3.1 Introduction 
As I have argued in chapter 1, the sheer scale of the transcriptional response to LPS suggests 
that critical regulatory mechanisms of the TLR4 signal transduction pathway remain to be 
discovered. Robust hit selection from high-throughput gene-perturbation studies provides a 
means through which novel regulatory candidates can be identified. Hit selection that goes 
beyond a handful of familiar or highest scoring hits, however, faces significant challenges of 
false positives and missed hits. In this chapter I show how comparative analysis of genome-
scale studies of the LPS response reflects the challenges of robust hit selection from high-
throughput screens. I further demonstrate the ways in which current ancillary hit selection 
approaches succeed or fail to correct for the biases and error rates in high scoring hits. These 
analyses provide a roadmap for what novel bioinformatic solutions should seek to solve.  
To go through these steps, I start with an analysis of the three genome-scale siRNA 
studies in macrophages by Li and Sun (Ning Li et al., 2017; J. Sun et al., 2017). I apply 
normalization and cell toxicity corrections to generate a comparative list of high scoring 
putative positive and negative regulators (section 3.2). I show how enrichment of canonical 
TLR pathway genes in the highest scoring hits from each study reflect the assay and readout 
design of each study (section 3.3). Comparing the highest scoring hits across the three studies 
of LPS, I show how the limited overlap suggests high rates of both false positives and false 
negatives in the current hit selection sets (section 3.4). The limited overlap is similarly observed 
when comparing the hit selection sets from the three siRNA screens and the hits selected by 
another genome-scale CRISPR/Cas9-based screen of the LPS response (section 3.5). To 
compare the overlap of reported hits from high-throughput studies and how they relate to the 
highest scoring hits from those studies, I also analyze three studies of HDFs for HIV (section 
3.6). I show how current hit selection approaches from high-throughput studies have the 
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strongest impact on false positive correction when compared to hits selected purely by screen 
score. I also demonstrate that the described alternative approaches to hit selection still lack a 
correction mechanism to promote lower scoring hits that are likely potential regulators of the 
process being studied (section 3.7). Finally, I summarize the steps I took to methodically 
analyze the data from the high-throughput studies of the LPS response to identify the 
limitations of current approaches.   
 
3.2 Normalization and hit selection from three siRNA studies identifies 
extensive lists of putative regulatory targets for macrophage activation 
To begin a global analysis of regulatory candidates of the TLR4 signaling pathway, I utilized 
recently generated datasets in the Fraser lab from three genome-scale siRNA studies of the LPS 
response in macrophages. These datasets, with input from the analysis I describe here, were 
subsequently published in Scientific Data (see publications arising from this thesis). The three 
studies included the THP1 TNF-α study described by Sun et al. 2017 (J. Sun et al., 2017), and 
the Raw G9 TNF-α and Raw G9 NFκB studies described by Li et al. 2017 (Ning Li et al., 
2017). (A detailed description of these three studies are in the introduction to this thesis, section 
1.5.2). To select the highest scoring hits from each screen I first applied robust normalization 
to the readout scores. I used a robust Z score approach which normalizes the data distribution 
as deviations from the mean on a plate by plate basis (reviewed in section 1.5.4 and described 
in Dutta et al, 2016 (B. Dutta et al., 2016)). Ensuring that low readouts from the assay are not 
driven by a low number of surviving cells (potentially driven by the essentiality of gene 
targeted by the siRNA) required different approaches in different studies. To correct for cell 
viability (or general perturbation of transcription) in the THP1 study, I divided the readouts 
from the TNF-α promoter-driven firefly luciferase reporter by the ubiquitin promoter-driven 
renilla luciferase readouts, thus ensuring the samples with low cell counts have the firefly 
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luciferase readout corrected.  In the RAW G9 cells I used a cutoff of 50 cells within the imaging 
field from the high content imaging assay to remove candidates that fell below it. (I describe 
the respective cell viability correction methods in detail in section 2.3.3).  These analyses 
generated three datasets with normal distributions centered around a mean of 0 (Figure 3.1A).  
Following score normalization and cell viability correction I applied a ranking to each 
gene target based on its score. To interpret the readouts from the assays as putative regulators 
of the TLR pathway, siRNA targets with high ranking negative scores were considered 
candidates with a positive regulatory role in LPS signaling, siRNA targets with high ranking 
positive scores were considered candidates for a putative negative regulatory role. For initial 
hit selection I used the top 2.5 percentile in both directions to assign as high scoring hits. This 
approach led to a Z-score cutoff of -2.00 with 453 hits for putative positive regulators from the 
THP1 TNF-α screen, a cutoff of -1.86 with 418 hits for the RAW G9 NF-κB hits, and a cutoff 
of –1.46 with 419 hits for the RAW G9 TNF-α screen (Figure 3.1B). In the opposite direction 
this approach assigned a cutoff of 1.575 with 453 hits for putative negative regulators from the 
THP1 TNF-α screen, a cutoff of 2.022 with 418 hits for the RAW G9 NF-κB negative 
regulators hits, and a cutoff of 2.397 with 418 hits for the RAW G9 TNF-α screen (Figure 
3.1C). The parameters, controls, and results from normalization applied to the three screens are 
tabulated in Table 3.1. 
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Figure 3.1: Normalization and hit selection from 3 genome-wide studies of the macrophage 
response to LPS. 
 
(A) Normalized distribution of the readout scores for the THP1-dual luciferase study (left), RAW 
G9 – GFP tagged NF-κB assay (center), and RAW G9 – mCherry tagged TNF-α assay (right). (B) 
Selecting negative scoring targets as putative positive regulators by assigning a cutoff for Zscores 
in the top 2.5% of negative scores. (C) Selecting positive scoring targets as putative neagtive 
regulators by assigning a cutoff for Zscores in the top 2.5% of positive scores.  
A.  Normalized distribution  
B.  Putative positive regulators 
C.  Putative negative regulators 
Hit selection from 3 siRNA studies of the response to LPS 
THP1 - TNF-α study  RAW G9 - TNF-α study  RAW G9 - NF-κB study  
THP1 - TNF-α study   RAW G9 - TNF-α study  RAW G9 - NF-κB study  
THP1 - TNF-α study   RAW G9 - TNF-α study  RAW G9 - NF-κB study  
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 THP1 TNF- α Raw G9 TNF- α RAW G9 NF-κB 
Library GE Dharmacon 
Human siGENOME 
SMARTpool 
siRNA Library 
Refseq27 
Dharmacon 
siGENOME 
siRNA mouse 
library 
Dharmacon 
siGENOME 
siRNA mouse 
library 
Gene Targets 18,110 16,870 16,870 
Essential-Gene 
Correction 
Ubiquitin promoter-
driven renilla 
luciferase activty 
Cell Count > 50 Cell Count > 50 
Negative Controls 2 Non-Targeting 
Control (NTC) 
2 NTC, Ppib 2 NTC, Ppib 
Positive Controls TLR4, IRAK1, 
IKBKG, MAP3K7, 
Renilla siRNA 
Tlr4, Myd88, 
Ikbkg, Irak1, 
siGFP siRNA 
Tlr4, Myd88, 
Ikbkg, Irak1, 
siGFP siRNA 
Assay Readout firefly/renilla dual 
luciferase assay 
mCherry High 
Content Imaging 
GFP High Content 
Imaging 
Positive Regulator 
Cutoff 
-2 -1.86 -1.46 
Positive Regulator Hits 453 418 419 
Negative Regulator 
Cutoff 
1.575 2.022 2.397 
Negative Regulator Hits 453 418 418 
3.3 Shared and divergent enrichment for canonical members of the TLR4 
pathway in hits from three LPS studies 
Using the bioinformatic platform Ingenuity Pathway Analysis (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) I analyzed the 
selected hits from the three screens to measure their enrichment for canonical components of 
the TLR signaling pathway. The analysis (Figures 3.2-3.4) showed robust enrichment for 
critical nodes in the TLR signaling pathway in all three studies. The enrichment of expected 
essential effectors in the downstream LPS response represented in the high scoring selected 
hits set, such as MyD88 and NF-κB related genes, highlight the efficacy of the three screens. 
The divergence in effector enrichments between the three screens also relate to the differences 
Table 3.1 Normalization and hit selection from three siRNA studies of the 
macrophage response to LPS. 
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in the screen assays. For example, components of the TAK1/TAB complex, whose downstream 
effectors do not rely on NF-κB, appear as more critical in the two screens using the TNF-α 
readout, while core NFkB components are more prominent hits in the screen using the NF-κB 
readout (Figure 3.2-3.4). (An unexpected result was the appearance of IKKß as negative 
regulator in the screen using the NF-κB readout (Figure 3.3), though it may be due to an off-
target effect.) 
 
3.4 Overlap across parallel screens of the response to LPS is significant but 
limited 
As described in chapter 1 (section 1.6.2), measuring the commonality of hits from convergent 
high-throughput studies has been suggested as a path towards finding targets with increased 
degrees of confidence (Rhodes et al., 2002). This enrichment can also be measured statistically 
using the hypergeometric test for how much the overlap across the two sets exceeds the null 
(Birmingham et al., 2009; R.A. Fisher, 1925; T. Nguyen et al., 2015). To characterize the 
statistical enrichments and the number of shared hits between the three studies of the LPS 
response, I applied the hypergeometric test as well as determining the degree of overlap. The 
enrichment of hits across studies were all of statistical significance in the hits from the positive 
regulator steps, however, the absolute number of shared hits was still quite limited as compared 
to the size of the screened gene sets (Figure 3.5A). The enrichment of negative regulator hits 
across studies did not meet significance in the two THP1 to RAW G9 study comparisons 
(Figure 3.5B). This result, however, was not as surprising since the assays used for the three 
studies employed close to saturating doses of the LPS ligand (N. Li et al., 2015), leaving limited 
scope to observe an increased response. Despite crossing thresholds of significance, however, 
the paucity of shared hits across these related studies is further highlighted when looking at the 
<10 hits shared between all three screens (Figure 3.6). These comparisons suggest that the hits 
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selected only by highest rank from the three studies contain multiple false positives and false 
negatives.  
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Enrichment of TLR pathway genes in high scoring hits 
from the THP1 TNF-α study  
Figure 3.2: Enrichment of canonical toll-like Receptor pathways genes in hits from 
THP1 TNF-α genome-wide screen. 
 
Overlaying highest scoring positive (green) and negative (red) regulators from the 
THP1-dual luciferase study over the canonical pathway map curated by Ingenuity 
Pathway Analysis (IPA, Qiagen) 
Putative Positive Regulators    Putative Negative Regulators 
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Enrichment of TLR pathway genes in high scoring hits 
from the Raw G9 NF- κB study  
Figure 3.3: Enrichment of canonical toll-like Receptor pathways genes in hits from 
Raw G9 NF- κB genome-wide screen.  
 
Overlaying highest scoring positive (green) and negative (red) regulators from the RAW 
G9 – GFP tagged NF-κB study over the canonical pathway map curated by Ingenuity 
Pathway Analysis (IPA, Qiagen) 
Putative Positive Regulators    Putative Negative Regulators 
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Enrichment of TLR pathway genes in high scoring hits 
from the Raw G9 TNF-α study  
Figure 3.4: Enrichment of canonical toll-like Receptor pathways genes in hits from 
Raw G9 TNF-α genome-wide screen.  
 
Overlaying highest scoring positive (green) and negative (red) regulators from the 
RAW G9 – mCherry tagged TNF-α study over the canonical pathway map curated by 
Ingenuity Pathway Analysis (IPA, Qiagen) 
Putative Positive Regulators    Putative Negative Regulators 
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THP1   
TNF-α  
RAW G9 
NF-κB 
THP1   
TNF-α  
RAW G9 
NF-κB 
RAW G9 
TNF-α 
RAW G9 
TNF-α 
17 21 73 436 401 432 398 345 344 
THP1   
TNF-α  
RAW G9 
NF-κB 
THP1   
TNF-α  
RAW G9 
NF-κB 
RAW G9 
TNF-α 
RAW G9 
TNF-α 
9 8 29 444 409 445 410 389 389 
A.    Putative Positive Regulators 
B.   Putative Negative Regulators 
Figure 3.5: Enrichment and significance of overlap across high scoring hits from three 
siRNA screens of the macrophage response to LPS.  
  
(A) 3 pairwise comparisons of the overlap between high scoring positive regulators for the 
THP1-dual luciferase study and RAW G9 – GFP tagged NF-κB study (left), pairwise 
comparison of high scoring positive regulators for the THP1-dual luciferase study and the 
RAW G9 – mCherry tagged TNF-α study (center), and pairwise comparison of high scoring 
positive regulators for the RAW G9 – GFP tagged NF-κB study and the RAW G9 – mCherry 
tagged TNF-α study (right). (B) Similar analysis as in A using high scoring negative 
regulators from the three studies.  
Overlap across high scoring hits from LPS siRNA 
screens 
   96 
 
  
SPI1 
COPB1 
NXF1 
SPAG1 
KAT7 
ARCN1 
MYD88 
RBMX 
Overlap of high scoring  
positive regulators 
Overlap of high scoring 
negative regulators 
RAW G9 
NF-κB 
RAW G9 
TNF-α 
RAW G9 
TNF-α 
RAW G9 
NF-κB 
THP1   
TNF-α  
Figure 3.6: Shared hits across high scoring hits from three siRNA screens of the 
macrophage response to LPS.  
  
Venn Diagrams of the shared enrichments across the three siRNA screens for selected 
positive regulators (left) and selected negative regulators (right). Gene symbols of the 
shared regulators are tabulated below each figure. (High scoring regulators from the two 
mouse screens were converted to their human orthologue gene symbols for comparison.) 
Overlap across high scoring hits from three LPS 
siRNA screens 
THP1   
TNF-α  
Gene symbols of shared high scoring  
positive regulators 
Gene symbols of shared high 
scoring negative regulators 
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3.5 Overlap with hits from CRISPR/Cas9-based screen of the LPS response 
in dendritic cells is similarly limited 
A genome-scale study of the response to LPS in differentiated hematopoietic cells was also 
published by Parnas et al, 2015 (Parnas et al., 2015). While critical differences exist in the 
design and assay of their study and the three LPS studies I analyzed, such as cell type (Parnas 
and colleagues used primary bone marrow derived dendritic cells from mice) and gene 
perturbation methods (Parnas and colleagues used CRISPR/Cas9-based gene editing), the 
commonality of the TLR4 gene transcription response across these cell types would suggest 
that a significant enrichment of hits across these four studies would be expected.  The data 
provided by Parnas and colleagues had a normal distribution of Z-scores and a confidence 
measure of FDR that aligned with a ranking of the hits by Z-score. I used a similar approach 
for hit selection as with the three siRNA studies, assigning a cutoff for the top 2.5% of hits 
(Figure 3.7A; unlike the siRNA studies, the CRIPSR study by Parnas and colleagues had 
transformed the readouts to have a positive Z-score for putative positive regulators from the 
screen). Similar to the limited enrichment between the three siRNA studies, however, 
concordance between each individual siRNA screen and the CRISPR/Cas9 screen was likewise 
limited to a minimal fraction of hits. Two of the three comparisons crossed a threshold of 
statistical significance with the number of shared hits ranging from 13 to just over 20 (Figure 
3.7B). This comparison further highlights the limited agreement found in hit selection by 
different studies.  
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Parnas 
et al 
THP1   
TNF-α  
Parnas 
et al 
Parnas 
et al 
RAW G9 
TNF-α 
RAW G9 
NF-κB 
24 13 18 491 429 502 405 497 401 
A 
B 
Distribution of scores and hits selection in CRISPR study of 
LPS response in dendritic cells 
  
Overlap and enrichment across positive regulators from 
siRNA and CRISPR studies of the response to LPS 
  
Parnas et al. study Parnas et al. study Z score vs. FDR Parnas et al. study 
Figure 3.7: Enrichment and significance of overlap across high scoring hits from three 
siRNA screens of the macrophage response to LPS and high scoring hits from the 
CRISPR/Cas9 screen by Parnas et al.  
  
(A) Distribution of Z scores (left) and the Z-scores plotted across assigned FDR values (center) 
of the data from Parnas and colleagues. Assigning a cutoff for hits in the top scoring 2.5% 
(right) results in a cutoff of 1.3 and 515 hits. (B) 3 pairwise comparisons of the overlap between 
high scoring positive regulators for the CRISPR study by Parnas et al. and the siRNA THP1-
dual luciferase study (left), pairwise comparison of high scoring positive regulators for the for 
the CRISPR study by Parnas et al. and siRNA study using RAW G9 – GFP tagged NF-κB 
reporter (center), and  pairwise comparison of high scoring positive regulators for the for the 
CRISPR study by Parnas et al. and from the siRNA study using the RAW G9 – mCherry tagged 
TNF-α reporter cell line (right).  
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3.6 Heterogeneity of high scoring hits across parallel omic-scale studies 
suggest alternative approaches are required for hit selection 
The lack of concordance across the high-scoring hits from the four LPS-response studies align 
with a broad trend of limited overlap found in comparative omic analyses. Limited overlap of 
reported hits from high-throughput studies have been associated with screens of essential 
factors for influenza infection and early infection of HIV (as I reviewed in chapter 1 section 
1.6.1). Meta-analysis has suggested that the limited overlap is driven by the approaches to hit 
selection employed by the different research groups (Bushman et al., 2009; Hao et al., 2013). 
In addition to validating our findings in the comparative analysis of the LPS studies, the 
previously reported HIV screens provide datasets that can be studied for how alternative hit 
selection methods improve enrichment and error correction.  
I used the three studies of HIV Dependency Factors (HDFs) described in the introduction 
(section 1.6.3), the Brass et al. study (Brass et al., 2008), König et al. study (König et al., 2008), 
and the Zhou et al. study (Zhou et al., 2008). Applying normalization to the raw readout scores 
and appropriate cell viability corrections (described in detail in section 2.3.3) all three studies1 
generated normalized distributions of hits and rankings (Figure 3.8A). Reported hits from the 
three studies of HDFs were selected by combinations of subsequent analysis and validation 
approaches that varied from study to study. The similarities and differences in the design and 
hit selection of the three studies are tabulated in Table 3.2.  
To see how the post-validation hits from each study related to the highest scoring hits, I 
mapped the normalized Z scores and confidence scores for each study and highlighted the 
reported hits. The final lists of hits reported by each study differed substantially from the 
highest scoring hits (Figure 3.8B). The sets of highest scoring hits and reported hits from the 
 
1 Brass et al. and Zhou et al. performed two studies one at 48 hours post infection and another at a later 
timepoint. For comparative purposes I’m only comparing the first study from Brass and Zhou to the study of 
König et al. to focus on the candidates regulating early infection. 
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three HDF studies provide a testing set for how the measures of overlap are (and are not) 
improved by more circuitous and multi-step approaches, as compared to the direct hit selection 
process by screen score alone.   
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  Zhou et al. Brass et al. König et al. 
 Cell Type HeLa P4/R5 Cells HeLa-derived TZM-bl 
Cells 
293T Cells 
Experimental 
Conditions  
And 
Treatment HXB2 HIV- 1 HIV IIIB VSV-G pseudotyped 
HIV-1 reporter virus 
encoding 
luciferase 
Design Readout 1 Tat activation of 
expression of the b-Gal 
reporter 
p24 (product of gag 
gene) 
HIV-1 Vector encoded 
luciferase  
 Time point: 
Readout 1 
48h 48h 24h 
 Readout 2 Tat activation of 
expression of the b-Gal 
reporter 
b-Gal (Tat dependent) MuLV and AAV 
 Time point: 
Readout 2 
96h 72h 24h 
  Cell Viability 
Correction 
Decrease of cell 
viability by 2 SDs or 
more 
Decrease of cell 
viability by 2 SDs or 
more 
Cell toxicity screen 
Hit Selection, 
Bioinformatics, 
Z score cutoff 2 SSMD relative to the 
negative control 
2 SDs greater than the 
plate mean 
2 siRNAs with ³45% 
reduction in HIV 
infectivity 
and Secondary 
Screening 
Bioinformatics 
Used in Hit 
Selection 
In silico screening for 
expression in activated 
T cells and 
Macrophages 
None “evidence score” 
based on functional, 
biochemical, and 
transcriptional data. 
Yeast to hybrid protein 
interaction database, 
NCBI HIV-1 Protein 
Interaction Database, 
MCODE, Ontogeny-
based pattern 
identification algorithm 
 Secondary 
Screening 
Rescreening by 
independent siRNAS 
Rescreening of pooled 
siRNAs in single 
siRNA assay 
Rescreening of pooled 
siRNAs in single 
siRNA assay 
 
  
Table 3.2: Design and hit Selection methods for three siRNA studies of early HIV 
dependency factors by Zhou et al., Brass et al., and König et al. 
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A 
B 
Z score Distribution, Zhou et al. Z score Distribution, König et al. Z score Distribution, Brass et al. 
Median Score and Confidence, Zhou et al. Median Score and Confidence, Brass et al. Median Score and Confidence, König et al. 
Post validation selected hits 
Scores above the cutoff for Zscore and Cell Viability Correction 
Figure 3.8: High Scoring and Post-Validation Selected Hits from Three Studies of HIV 
Dependency Factors.  
 
(A) Distribution of normalized Z scores for siRNAs from the study by Zhou et al. (left) Brass 
et al. (center) and König et al. (right) B) Identifying the candidates selected by high score and 
those selected as post validation hits by the three studies. The post validation hits are in green 
and the area on the graphs where hits fall above the high scoring cutoff is highlighted in red. 
The density of hits at each point is represented by the blue color scale. Zhou et al. (left) and 
Brass et al. (center) used a cell viability count that was normalized to a Zscore. König et al. 
(right) used a p Value that was a combined “evidence score” that was plotted as a negative log 
p Value. 
Normalized scores and hit selection from three HIV HDF screens 
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3.7 Statistical enrichment, but not shared hits, is narrowly improved by 
commonly applied bioinformatic approaches to hit selection 
Utilizing the two hit selection sets (High scoring and Post-validation) identified in the previous 
section, I did a comparative analysis of statistical and shared enrichment across the three 
studies. When measuring the enrichment of Post-validation hits, all three comparisons crossed 
standard thresholds of statistical enrichment, while only one of the comparisons of hits selected 
only by high scores met the significance threshold (Figure 3.9A). This change reflects the 
significant improvement achievable by the bioinformatic and secondary validation methods 
used by the three studies beyond the high scoring results. When counting the absolute number 
of shared hits across the three screens, however, the numbers are very low and there is no 
discernible improvement between the high scoring hit sets to the post validation selected hit 
sets (Figure 3.10A-B).  To understand further how this dichotomy emerges, I did a comparative 
analysis of the two critical measurements of overlap that drive the calculation of statistically 
significant enrichment (described in detail in the introduction section 1.6.2).  
The number of shared hits between each comparison of two studies (corresponding to 
the measure of m in the hypergeometric testing equation (Figure 1.7)) remained nearly 
consistent between the sets of hits selected by high scores and the sets of hits selected by 
subsequent and secondary validation (Figure 3.9B).  When calculating the relative size of the 
selected hit sets, however, there is a clear reduction in the set size (n1 and/or n2) when moving 
between the sets of hits selected by high scores versus the sets of hits selected by the different 
analysis and validation pipelines (Figure 3.9C). These findings show that the increase in 
statistical enrichment gained by the post validation hits are largely driven by reducing the 
number of hits selected and eliminating hits that have lower likelihoods of being shared by 
comparative studies. These results further suggest that these methods are less effective when it 
comes to increasing the absolute number of hits that are identified across multiple studies. The 
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added bioinformatic and follow up analyses used for the hit selection of the reported hits from 
the three studies of HIV HDFs substantially reduced the number of false positives in the hit 
selection sets. The limited increase in overlap, however, shows that these approaches did not 
reduce the false negative rate as lower scoring hits missing the high score cutoff were not 
corrected for and considered as hits by the secondary analysis steps.     
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Figure 3.9: Measurements of shared enrichment and overlap in high scoring and post 
validation selected hits from three siRNA studies of HDFs.  
 
(A) Negative Log p Values of the statistical enrichment between the hit sets of the three siRNA 
HDF studies for, both, hits selected by high score cutoff (red) and hits selected by analysis and 
secondary screening (blue). The point at the y axis that corresponds to p = 0.05 is indicated with 
a dashed line across the graph. (B) Number of shared hits in two screen comparisons of the 
three siRNA studies of HDFs for hits selected by high score cutoff (red) and hits selected by 
analysis and secondary screening (blue). (C) Median size of the hit selection sets for each two 
way comparison of the three siRNA studies of HDFs for hits selected by high score cutoff (red) 
and hits selected by analysis and secondary screening (blue). 
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Shared genes in high scoring and post-validation hits from HIV 
HDF screens 
Figure 3.10: Overlap in high scoring and post validation selected hits from three siRNA 
studies of HDFs.  
 
Venn diagram of shared and unshared hits for the three studies of HIV HDFs selected by 
highest score (A) and from the post validation sets (b).  
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3.8 Summary 
The genome-scale screens for putative regulators of the TLR4 signaling pathway in 
macrophages provides a platform for the robust characterization of novel regulatory targets 
that go beyond the canonical and previously characterized members of the pathway. This 
approach is limited by the challenge of devising a hit selection method that overcomes the 
variation and noise intrinsic to studies with omic scale measurements. This challenge is 
reflected in the low level of commonality found across many comparative genome-scale studies 
and is similarly mirrored in my analysis of the described LPS response screens in differentiated 
hematopoietic cells. Devising a method for hit selection that is better at identifying shared 
enrichments has been a critical obstacle in genome-scale analyses, as a degree of expected 
concordance across studies is a critical metric to establish confidence in methodology and 
execution of high-throughput studies.  
My analysis of hit selection in three published studies of early HIV infection shows that 
the current practice of cutoff setting and supplementation through divergent enrichment 
analysis methods improves the statistical significance of screen overlap. These same analytical 
approaches, however, had no impact on the total number of hits identified across more than 
one study. The number of candidates identified by more than one genome-scale study remained 
nearly steady whether using a direct normalization and high score cutoff approach or if using 
the analysis and secondary validation selected by the three research groups. This suggested that 
robust hit selection from the three studies of the LPS response in macrophages would require 
the development of a new approach to increase the number of shared enrichments, while also 
reducing the number of candidates unlikely to appear in repeated assays. In the next chapter I 
again use the three studies of HIV HDFs as a testing dataset to assess alternative approaches to 
hit selection from high-throughput assays. 
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4 Developing a TRIAGE approach for hit selection from high-throughput data 
4.1 Introduction 
In the previous chapter I have shown that bioinformatic analysis approaches could improve 
screen concordance in the three studies of HIV HDFs. I have also shown that the improvement 
was largely concentrated in one metric, significance of overlap, and that it was driven by the 
strong removal of false positives by the added analyses. A different metric of hit selection 
confidence, number of shared hits, that is driven by low false negative rates, was not improved 
by the employed hit prioritization methods. The bias towards false positive correction methods 
is to be expected with secondary follow up studies. Secondary low-throughput follow up assays 
are designed to remove false positive hits and are critical to gaining confidence in the results 
from a screen. This approach, however, lacks a mechanism to correct for false-negatives. As I 
have argued in the introduction, many results and insights from high-throughput studies are 
compromised by high false negative error rates (citing examples in the literature from studies 
in influenza (Hao et al., 2013), HIV (Bushman et al., 2009), and β-catenin-active cancers 
(Rosenbluh et al., 2016)). Simply correcting false-negative rates by increasing the number of 
hits selected for follow up (such as lowering the score cutoff or selecting additional hits for 
secondary analysis) is costly and inefficient. There is a pressing need for hit selection methods 
that can correct for the false negative rates while also generating list of hits that can be 
reasonably validated in lower-throughput follow up experiments. 
In this chapter I propose an alternative method for how to assign hits vs. non hits from 
normalized readout scores (section 4.2). I show, using the HDF studies as an example, that 
pathway analysis and network analysis improve hit selection in different ways (sections 4.5-
4.8). I propose and validate a framework for integrating these approaches to get the optimal 
combined result from the different methods (sections 4.9-4.12). I name the framework 
Throughput Ranking by Iterative Analysis of Genomic Enrichment (TRIAGE). I then show 
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how TRIAGE analysis can also be used to reanalyze published studies using the previously 
validated hits (section 4.13).  
 
4.2 Segmentation of data by degrees of confidence is an alternative to the 
binary hit vs. non-hit approach 
The single cutoff approach bifurcates a dataset into hits and non-hits. This approach requires 
an irreversible compromise between false positive and false negative correction right at the 
outset of downstream data analysis. As an alternative, I set out to use a dual cutoff approach in 
hit selection. In the dual cutoff approach two cutoffs are selected, a stringent cutoff that assigns 
the score for what is considered a “high confidence” hit, and a more lenient cutoff score. 
Candidates whose scores fall between the lenient cutoff and stringent cutoff are considered 
“medium confidence” hits. As a result, you get a three-tiered data set of high confidence hits, 
medium confidence hits, and low confidence/non-hits (Figure 4.1A).  This approach can be 
used for data with a single readout (such as Z score or fold change) or for data with multiple 
readouts (such as Z score and cell viability, fold change and p value, etc.). Datasets with more 
than one readout can be segmented by assigning dual cutoffs to all readouts and then assigning 
as high confidence hits those that meet the stringent cutoff in two or more of the readouts and 
medium confidence as those that meet the stringent cutoff in only one readout. An alternative 
approach for datasets with more than one readout is to assign a single cutoff to one readout and 
a dual cutoff to another readout and require that all medium confidence and high confidence 
hits meet the criteria of the first cutoff (such as a critical cell viability metric or a similar 
confidence measure). 
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Figure 4.1: Segmenting data from high-throughput studies into three degrees of 
confidence. 
 
 (A) A schematic of the two data tiering approaches in high-throughput hit selection. A single 
cutoff approach (left) assigns a set of gene as hits and the rest as non-hits versus a dual 
cutoff approach (right) assigns a set of hits as high confidence, a secondary set of hits as 
medium confidence, and the rest as low confidence/non hits. (B) Scores from three genome-
wide studies of HDF. Normalized scores are plotted on the x-axis and secondary scores that 
were considered (such as cell viability and assigned p-values) are on the y-axis. Genes with 
both scores above the cutoff are in red and genes with Z scores above the secondary cutoff 
are in blue. The density of hits at each point is represented by the blue color scale. 
Hits 
Rest of genome non-hits 
Medium confidence hits 
Rest of genome non-hits 
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confidence hits 
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Normalized scores from 
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Medium confidence hit 
Single vs. dual cutoffs in high-throughput data 
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As an example of the three-tier data approach, I segmented the data from the three studies 
of HDFs introduced in chapter 3. The readouts of all three screens were normalized by Z score 
and each gene was assigned the median score of all its siRNAs. I then plotted those scores 
against the secondary scores used by the three studies (Zhou and Brass used cell viability 
readouts while König used a compiled “evidence score” p value). I assigned a single cutoff to 
the secondary scores of the three screens (as described in their respective publications; Zhou 
and Brass used a cutoff of -2 standard deviation for cell viability, König used a combination of 
scores and prioritized those with evidence scores of 0.05 or less). I then assigned dual cutoffs 
to the Z scores of the three screens. To make the set sizes comparable I assigned the genes with 
the 400 highest scores as high confidence hits. The gene candidates with the next 1000 highest 
scores (that were not included in the top 400 and also were above the threshold of the secondary 
readout cutoff) I assigned as medium confidence. The rest of the gene candidates were assigned 
as non-hits (Figure 4.1B). 
 
4.3 Hit selection and overlap in three genome-wide studies of HDFs  
In the previous chapter I have shown that the three genome-wide siRNA studies of HDFs 
demonstrate the gap between hits selected by normalized scores and hits selected by the 
respective research groups. These two hit selection approaches can be summarized as hit 
selection based on highest scoring hits versus user guided prioritization. The latter approach 
(as outlined in Table 3.2 in the previous chapter) is guided by a combination of different 
secondary analysis approaches that are applied to the highest scoring hits in different ways by 
different investigators. These supplementary analysis approaches include a combination of 
pathway analysis and network analysis applied to the selected hits, as well as adding in or 
removing hits based on user preferences. How these different analysis approaches are 
combined into a single set of selected hits also differs from study to study and is dependent on 
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the prioritization of the authors (Figure 4.2A). This approach differs from the direct and 
unbiased hit selection method of selecting the highest scoring candidates as hits (Figure 4.2D). 
These two approaches represent the two extremes of hit selection from high-throughput data, 
a direct and unbiased approach or a user guided combination of supplementary analysis 
approaches and follow up.  
As I have shown in the previous chapter for the three studies of HDFs, the user guided 
prioritization approach for reported post validation hits from each study only improves hit 
selection in one measure (p value of shared enrichment) while having only a marginal impact 
on the number of shared hits (Figure 4.2B-C and 4.2E-F). For this chapter I will be using these 
two analysis approaches as examples to compare against alternative methods. I continue using 
the quantitative measures of how significance of overlap and number of shared hits between 
the three studies are affected as assessments of false positive and false negative correction, 
respectively. 
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Figure 4.2: Hit selection by user guided prioritization or highest score. 
 
(A) Schematic of the user guided prioritization approach for hit selection. A combination 
of pathway analysis (PA), network analysis (NA) and user selected hits (US) are combined 
by the user to form a set of primary screen hit selection that are followed up on with 
validation studies. (B) statistical significance of the overlap across the three studies of HDF 
when comparing the reported hits from the studies. (C) Number of shared hits between the 
reported hits from each study. (D) Schematic of the hit selection approach by highest score. 
(E) statistical significance of the overlap across the three studies of HDF when comparing 
the highest scoring hits. (C) Number of shared hits between the highest scoring hits from 
each study.  
p Value of Shared  
Enrichments 
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4.4 Random permutation testing 
To evaluate how different bioinformatic approaches do or do not improve hit selection from 
high-throughput studies it is critical to first develop a test that can measure our confidence in 
these results. Bioinformatic approaches have intrinsic biases such as overrepresented groups 
and low resolution (Khatri et al., 2012). Given a sufficient number of hits to choose from it is 
possible that the biases within these analyses could lead to similar hits being selected from 
unrelated datasets. To increase confidence that the results represented in my findings are driven 
by the prioritization of biologically relevant candidates and not by the overrepresentation and 
annotation sets of the databases and methods used, I applied a random permutation testing 
approach. For each analysis and comparison that follows in this chapter I generated 1000 input 
files that have the same size of hits and non-hits (or high confidence hits, medium confidence 
hits, and non-hits where relevant) with the gene candidates assigned to different confidence 
groups at random. I ran each of the randomly generated inputs through the same analysis and 
cross-screen comparison as the non-random input. I then plotted the number of shared hits 
found in each run of the random input analysis. Using an empirical cumulative distribution I 
calculated what quantile in the distribution of random results the value from the non-random 
input corresponded to. (i.e. the frequency of different results in the randomly generated input 
was taken as a measure of how likely the results we found in our analysis was to be driven by 
the biases of the analysis method or by the size of our input versus being a non-random 
biologically relevant result.). 
To test the strength of this approach, I applied the random permutation test to the 
comparison analysis for hits selected by high scores. As no additional analyses were applied to 
the selection of these hits, the random permutation test results should align with results from 
the hypergeometric test (one-sided Fischer’s Exact Test). A comparison of the two tests found 
that the results were closely aligned (Figure 4.3). 
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Figure 4.3: Random permutation testing of highest score hit selection. 
 
(A) p values for shared enrichments across the studies of HDF as calculated by the 
hypergeometric test. (B-D) Distribution of shared hits by 1000 random permutation of 
equal size hits and datasets. Red arrow indicates where the number of shared hits from the 
non random dataset falls in the distribution. Blue arrow indicates where the median size of 
shared hits by random permutation falls in the distribution. Number is calculated by 1-
quantile. 
Random permutation test 
   117 
4.5 Hit selection by pathway analysis of high scoring hits improves statistical 
enrichment in some cases 
To test how the application of pathway analysis to high-scoring hits improves measures of 
overlap in hits from HDF studies, I applied pathway analysis to the high scoring hits of the 
three screens. I used the pathway membership list from the KEGG database, and applied a 
filtering only for pathways that are related to biological processes, and removed pathways that 
are related to disease networks (full process described in section 2.2.1 in Material and 
Methods). I then applied the hypergeometric test for enrichment of each pathway. High scoring 
genes that were in a pathway that had an enrichment score of p £ 0.05 were selected as hits, all 
high scoring hits not in an enriched pathway were reassigned as non-hits (Figure 4.4). 
  
Hits 
Non-hits 
Hit 
Selection PA 
Figure 4.4: Hit selection by pathway analysis. 
 
Schematic of the pathway analysis approach for hit selection. Candidates are divided by a 
single cutoff. Pathway analysis (PA) is applied to hits. Hits from enriched pathways are 
selected as final hits.  
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Statistical significance of overlap increased in two out of the three comparisons as 
compared to the significance of overlap in high scoring and post validation hits (Figure 4.5A). 
Number of shared hits, however, decreased in all cases as compared to the alternative analysis 
approaches. These results align with what would be expected from a direct pathway analysis 
approach. Pathway analysis is designed to filter the set of hits and remove false positives (as is 
reflected in the hypergeometric test results). Pathway analysis, however, does not include a 
false-negative correction mechanism and can in some cases increase false negative rates by 
biasing the results away from less annotated hits. This trade-off is reflected in the number of 
shared hits decreasing across all comparisons (Figure 4.5B). Pathway analysis is also uniquely 
sensitive to the setting of cutoffs, the noisier the dataset the less likely it is to find true 
enrichments. This sensitivity might explain why the improvement in enrichment significance 
in only observed in some cases. 
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Figure 4.5: Enrichment and overlap in hit selection by pathway analysis. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing 
hits selected by pathway analysis versus highest scoring hits and post validation hits. (B) 
Number of shared hits between the hits selected by pathway analysis from the three studies 
versus highest scoring hits and post validation hits. Random permutation test scores: ns = 
p > 0.05,  * = p ≤ 0.05,  ** = p ≤ 0.01 
Hit selection by pathway analysis 
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4.6  Hit selection by pathway analysis of three-tiered data has a stark impact 
on the statistical enrichment, but not commonality, of hits across studies 
of HDFs 
As an alternative approach, I ran pathway analysis on the HDF screens using a dual cutoff 
method applied to three-tiered data. Following analysis of the high confidence set to first 
establish enriched pathways, high confidence and medium confidence hits that were members 
of those pathways were brought into the hit set. Hits in either the high confidence or medium 
confidence set that were not part of these enriched pathways  
 were reassigned as non-hits (Figure 4.6). The strength of this approach is that it relies on the 
high confidence set of hits to guide the pathway analysis and then expands the hit selection to 
include lower scoring hits that are part of enriched-for biological processes.  
A comparison of the three studies of HDFs with hit selection by this approach shows that 
it strongly improves both measures of overlap (significance of enrichment and size of shared 
hits) in all screens as compared to the single cutoff pathway analysis approach (figure 4.5 A-B 
and Figure 4.7A-B). Comparison to hit selection by high scores and post validation, however, 
shows that the strength in pathway analysis is predominantly in the false positive correction 
(Figure 4.7A), and only marginally adds to the false negative correction (as measured by the 
commonality of hits across studies) (figure 4.7B). 
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Non hits 
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Hit 
Selection 
Figure 4.6: Hit selection by pathway analysis using dual cutoffs. 
 
Schematic of the pathway analysis approach for hit selection from a three-tiered dataset. 
Candidates are assigned to three groups based on hit confidence. Pathway analysis (PA) is 
applied to high confidence hits. High confidence and medium confidence hits from 
enriched pathways are selected as final hits.  
PA 
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Figure 4.7: Enrichment and overlap in hit selection by pathway analysis using dual 
cutoffs. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing 
hits selected by pathway analysis of three-tiered data versus highest scoring hits and post 
validation hits. (B) Number of shared hits between the hits selected by pathway analysis of 
three-tiered data from the three studies versus highest scoring hits and post validation hits. 
Random permutation test scores: ns = p > 0.05,  * = p ≤ 0.05,  ** = p ≤ 0.01 
Hit selection by pathway analysis using dual cutoffs 
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4.7 Hit selection by network analysis of three-tiered data has a strong effect 
on the number of shared hits, but not enrichment, between parallel studies  
The other commonly applied data analysis approach to improve hit selection from high-
throughput studies is network analysis. I applied network analysis to the dual cutoff datasets 
of the studies of HDFs. Using the protein-protein interactions curated by the STRING database 
and mapped back to gene IDs, I filtered the interactions for those based on published 
experimental evidence or curated databases (assigned “experimental” and “database” in the 
platform). Interactions were required to have a confidence score of medium or higher (full 
method described in section 2.2.2 in Materials and Methods). High confidence and medium 
confidence hits were entered into the network and searched for predicted interactions. The 
interactions were filtered to include only those between a high confidence hit and a medium 
confidence hit as a means to promote medium confidence hits to the high confidence set. All 
other medium confidence hits were assigned as non-hits (Figure 4.8). 
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Figure 4.8: Hit selection by network analysis. 
 
Schematic of the network analysis approach for hit selection. Network analysis (NA) is 
applied to high confidence hits. Medium confidence hits that have predicted interactions 
with high confidence hits are added to final hits.  
   123 
Hit selection by network analysis of high confidence and medium confidence hits led to 
a sharp increase in the number of shared hits across studies (figure 4.9B). Significance of 
overlap however was not improved (figure 4.9A) reflecting the expansion of the total number 
of hits selected and the increase in false positive hits. The testing by random permutation also 
found that the number of shared hits found by network analysis alone was only above a 
statistical threshold of significance in two out of the three comparisons (figure 4.9B) suggesting 
that the ‘catch-all’ approach of network analysis without any false positive correction is prone 
to the amplification of false positives. This suggests that hit selection by network analysis is a 
highly sensitive approach, but needs additional correction to increase the specificity of the hit 
selection set.  
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Figure 4.9: Enrichment and overlap in hit selection by network analysis. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing 
hits selected by network analysis versus highest scoring hits and post validation hits. (B) 
Number of shared hits between the hits selected by network analysis from the three studies 
versus highest scoring hits and post validation hits. Random permutation test scores: ns = 
p > 0.05,  * = p ≤ 0.05,  ** = p ≤ 0.01 
Hit selection by network analysis 
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4.8 Pathway and network enrichment analysis are complimentary and non-
overlapping in their solutions and hit selection methods 
Results from the previous two sections suggest that pathway and network analysis provide 
alternative solutions to hit selection. Pathway analysis has the strongest impact on false positive 
correction (Figure 4.7A) and network analysis’ impact is largely observed in false negative 
reduction (Figure 4.9B). These complementary solutions further suggest that an integrated 
framework that combines these two methods could be the optimal means to harness their 
combinatorial benefit to hit selection. 
 
4.9 An integrated serial approach to pathway and network analysis improves 
both statistical enrichment and number of shared hits  
To test a more integrated approach, I designed an integrated serial analysis framework for 
pathway and network analysis. I first identified enriched pathways from the high confidence 
hits  of the three HDF screens, then promoted medium confidence hits that were members of 
the enriched pathways to high confidence. All high and medium confidence hits that were not 
part of the enriched pathways became the new medium confidence set. I then applied network 
analysis to the newly assigned high confidence and medium confidence sets, and again 
promoted any medium confidence hit that had an established interaction with a high confidence 
hit. The expanded set of high confidence hits were assigned as the final hit set (Figure 4.10).  
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Figure 4.10: Hit selection by serial analysis of pathway and network analysis. 
 
Schematic of the serial analysis approach for hit selection. Pathway analysis (PA) is applied 
to high confidence hits. High confidence and medium confidence hits from enriched 
pathways are assigned high confidence hits. Network analysis (NA) is applied to new set 
of high confidence hits. Medium confidence hits that have predicted interactions with high 
confidence hits are added to final hits.  
PA NA 
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  Measuring the overlap of three screens of HDFs based on hit selection by the serial 
integrated approach led to improvements in both significance of overlap (figure 4.11A) and 
shared hits (figure 4.11B). While the improvements in significance and shared hit number were 
not as strong as with the respective exclusive use of pathway or network analysis, the 
improvement observed in both metrics when using the integrated serial framework suggests 
that it partially captures the combined error correction of the two methods.  
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Figure 4.11: Enrichment and overlap in hit selection by serial analysis of pathway and 
network analysis. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing 
hits selected by serial analysis versus highest scoring hits and post validation hits. (B) 
Number of shared hits between the hits selected by serial analysis from the three studies 
versus highest scoring hits and post validation hits. Random permutation test scores: ns = 
p > 0.05,  * = p ≤ 0.05,  ** = p ≤ 0.01 
Hit selection by serial analysis 
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4.10 An iterative method for the integrated approach further improves on hit 
selection 
In an attempt to amplify the combinatorial benefit of the integrated approach, I designed a 
framework that iteratively applies the two integrated analysis methods. In the iterative design, 
the same procedure as described above for the serial application of pathway and then network 
analysis is followed as a first iteration. Then, a second iteration repeats the pathway analysis 
step on the new set of high confidence hits, and the same procedure is followed to assign all 
high and medium confidence in the updated set of enriched pathways as high confidence hits. 
The same serial pathway-to-network analysis is applied to complete the second iteration.   
If the set of high confidence hits has not changed in this second iteration the analysis 
terminates and the new set of high confidence hits is assigned as the selected hits. If, however, 
the new set of high confidence hits is not the same as the set of high confidence hits from the 
previous iteration, a new iteration of pathway-to-network analysis is applied. The iterative 
analysis therefore terminates when it identifies a high-confidence and medium confidence set 
of genes that are no longer changed by further analysis cycles (Figure 4.12). (In testing this 
method with a range of gene sets from different screens, I found that the analysis usually 
reaches an equilibrium after 5-6 cycles. The first iteration involving a contraction of the set of 
high confidence hits and the second iteration leading to an expansion of hits when pathway 
analysis is applied to the newly assigned high confidence set. After the second iteration only 
small number of hits are added with each iteration and after a few cycles small additions to the 
hit set no longer impact the enrichment, leading to an equilibrium in the hit selection of each 
step. See next paragraph and Figure 4.13 for an example of this). This approach ensures that 
the set of selected hits is modified until neither pathway or network analysis can pull it in a 
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different direction, ensuring that the resulting set of hits is at the equilibrium between false 
positive correction by pathway analysis and false negative correction through network analysis. 
I then tested this iterative approach by applying the analysis to the three studies of HDFs. 
The three screens required 4 to 5 iterations before the set of high confidence hits no longer 
changed (Figure 4.13). I then ran the comparative analysis across the three screens using the 
hits selected by the iterative approach. Hit selection by the iterative integrated framework 
showed substantial improvements in both significance of overlap (Figure 4.13A) and size of 
shared hits (Figure 4.13B) across studies. Of note, the number of shared hits showed a marked 
improvement over the serial analysis method, suggesting that the repeated iterations are able 
to capture additional shared hits between screens that could be missed by a less rigorous 
analysis approach.  
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Figure 4.12: Hit selection by iterative analysis of pathway and network analysis. 
 
Schematic of the iterative analysis approach for hit selection.  
i = iteration 1 
Ai: Pathway analysis (PA) is applied to high confidence hits.  
Bi: High confidence and medium confidence hits from enriched pathways are assigned high 
confidence hits.  
Ci: Network analysis (NA) is applied to new set of high confidence hits. Medium 
confidence hits that have predicted interactions with high confidence hits are assigned as 
high confidence hits. 
Repeat steps A-C for i = iteration 2 
When i > 1 : 
If the set of high confidence hits at the end of the current iteration (HCi) is the same as the 
set of high confidence hits from the end of the previous iteration (HCi-1) high confidence 
this are used as hit selection from the study. If high confidence set of of hits are different, 
repeat iteration. 
Ci 
Ai 
PA 
NA 
Bi 
HCi-1 = HCi 
Hit 
Selection 
Mid Conf 
Non hits 
Hi Conf 
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Iterations and Hits Selection by Iterative Analysis of HDF Screens 
Figure 4.13: Iterations of integrated analysis of the three studies of HDF. 
 
0 on the x-axis represents the high confidence set of hits at the input. The high confidence 
hit sets are contracted and expanded through iterative analysis. Analysis terminates when 
high confidence sets are similar between two consecutive iterations.  
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p Value of Shared Enrichments 
Number of Shared Hits 
Hit selection by iterative analysis 
Figure 4.14: Enrichment and overlap in hit selection by iterative analysis of pathway 
and network analysis. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing 
hits selected by iterative analysis versus highest scoring hits and post validation hits. (B) 
Number of shared hits between the hits selected by iterative analysis from the three studies 
versus highest scoring hits and post validation hits. Random permutation test scores: ns = 
p > 0.05,  * = p ≤ 0.05,  ** = p ≤ 0.01 
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4.11 Iterative pathway enrichment followed by network analysis outperforms 
alternative framework combinations 
To ascertain whether the above design of the iterative framework is optimized to give the 
strongest improvements in hit selection, I designed and tested an iterative organization where 
the order of analysis methods is reversed, with network analysis done first followed by pathway 
analysis (Figure 4.15). The results of this analysis strongly aligned with the understanding of 
the complementary contributions of pathway and network analysis that I have outlined so far. 
While the same two analysis methods were applied, reversing the analysis order led to a 
decrease in both metrics of true positive hit selection (Figure 4.16A-B). The measure of 
confidence by the random permutation test was also low in two out of the three comparisons, 
suggesting that the noise of the false positive data was amplified in this hit selection approach. 
These results suggest that the preferred order for integrated analysis is a false positive 
correction (such as pathway analysis) followed by the false negative correction (as in network 
analysis), and that reversing the order greatly amplifies the noise of the results and blunts the 
power of the iterative approach. 
   
Figure 4.15: Hit selection by iterative analysis with reverse pathway and network order. 
 
Schematic of the iterative analysis as in Figure 4.12 with the order of pathway and network 
analysis reversed.  
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Number of Shared Hits 
Figure 4.16: Enrichment and overlap in hit selection by iterative analysis with reverse 
pathway and network order. 
 
(A) statistical significance of the overlap across the three studies of HDF when comparing hits 
selected by reverse iterative analysis versus highest scoring hits and post validation hits. (B) 
Number of shared hits between the hits selected by reverse iterative analysis from the three studies 
versus highest scoring hits and post validation hits. Random permutation test scores: ns = p > 0.05,  
* = p ≤ 0.05,  ** = p ≤ 0.01 
Hit selection by reverse iterative analysis 
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4.12 Throughput Ranking by Iterative Analysis of Genomic Enrichment 
(TRIAGE) 
In a summary figure of the approaches tested and comparisons measured, I show that the 
iterative framework for pathway and network analysis provides the strongest combinatorial 
benefit of the complementary analysis approaches (Figure 4.17). By incorporating data that 
uses two cutoffs, this approach makes it possible to triage the results of a screen using a 
combination of the initial gene rankings from the screen and the known gene characteristics 
and functions from curated databases. Since this approach is not unlike the principle of medical 
triage as developed by the French physicians Dominique Jean Larrey and Pierre-François Percy 
in 1806 (Nakao et al., 2017), I chose the name TRIAGE for this approach as an acronym for 
Throughput Ranking by Iterative Analysis of Genomic Enrichment.  
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Figure 4.17: Comparative analysis of different hit selection approaches. 
 
False positive correction measured by significance of overlap (red) and false negative correction 
measure by number of shared hits. Hit selection methods: (clockwise from top center): post 
validation hits, high scoring hits, pathway analysis using a two tiered dataset, pathway analysis using 
a three tiered dataset, network analysis, serial integration of pathway and network analysis, iterative 
integration of pathway and network analysis. 
Development of TRIAGE analysis 
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4.13 TRIAGE analysis can also be applied to post validation hits 
I also tested TRIAGE analysis on the post validation hits from the three HDF studies to 
determine if the screen concordance was affected. I assigned as high confidence the reported 
hits from each screen. and medium confidence hits as the top 1000 genes not selected as hits 
by the study (Figure 4.18A-B). I then ran this tiered dataset through TRIAGE and observed 
similar improvements both in the number of shared hits across the screens (Figure 4.19A) and 
in the significance of overlap (Figure 4.19B). These results show that the TRIAGE hit selection 
approach can also be used for prioritizing hits from already published and analyzed screens. 
Through the appropriate assignation of high and low confidence hits, TRIAGE analysis can be 
applied to prioritize newer hits from older studies guided by the results of the previous analysis.   
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Figure 4.18: Using post-validation hits for analysis by TRIAGE. 
 
(A) Scores from three genome-wide studies of HDF. Normalized scores are plotted on the x-
axis and secondary scores that were considered (such as cell viability and assigned p-values) 
are on the y-axis. Genes reported as post validation hits are in red and 1000 genes with the 
highest Z scores that were not selected as post validation hits are in blue.  (B) A schematic of 
the data tiering approaches using post validation hits. Reported post validation hits are 
assigned as high confidence. Highest scoring hits not selected by post validation are assigned 
as medium confidence. 
TRIAGE analysis with post-validation hits 
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Figure 4.19: TRIAGE analysis of highest scoring and post validation hits. 
 
(A) Venn diagram of the number of shared hits between hit selection sets by TRIAGE of highest 
scoring hits (left) and TRIAGE of post validation hits (right). (B) Analysis by hypergeometric 
test of shared enrichment across three studies of HDF by TRIAGE of highest scoring hits 
(bottom left) and by TRIAGE of post validation hits (top right). Shading represents –Log p value 
of the overlap. 
A 
B 
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4.14 Summary 
In this chapter I have proposed a framework for how pathway analysis and network analysis 
can be integrated for improved hit selection from high-throughput studies. I demonstrated how 
this approach outperforms the application of pathway and network analysis individually or in 
a non-iterative serial design. This approach is not without its limitations, some intrinsic biases 
of database dependencies and enrichment biases persist and remain largely unavoidable with 
current database genome coverage and data content. An element of hit selection will also 
always rely on the judgment and work of the researchers. This design expands the possibility, 
however, of using analysis methods to capture more lower scoring hits and increasing the 
number of true positive results. In chapter 6 I will use this method to reassess the three studies 
of the macrophage response to LPS. In the design of the TRIAGE method, however, I was 
aware that this framework for hit selection can be beneficial to the screening community 
beyond those working on the TLR4 response. In the next chapter I will show how I made this 
approach adaptable to other datasets and available to a wider community of researchers. 
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5 A publicly available web-interface for TRIAGE analysis of high-throughput data 
(triage.niaid.nih.gov) 
5.1 Introduction 
As shown in chapter 4, the Throughput Ranking by Iterative Analysis of Genomic Enrichment 
(TRIAGE) method integrates analysis from network databases of known interactions and 
associations with the shared membership of genes in functional pathways to correct for the 
false negative and false positive error rates that are associated with score based hit selection 
methods. While I ultimately developed TRIAGE for analysis of the genome-wide studies of 
the LPS response in macrophages, the approach is also applicable to prioritizing gene selection 
from essentially any genome-scale study. In this chapter I discuss how I built a publicly 
available web-based platform that enables other researchers to quickly and easily prioritize 
candidates from omics studies using the TRIAGE approach (sections 5.2-5.5). The platform 
can be accessed globally (https://triage.niaid.nih.gov) and requires no prior knowledge of 
computational languages. I focused on making the platform adaptable to different types of 
datasets and results (sections 5.6-5.10). In this chapter I describe the steps of uploading a 
dataset to TRIAGE and how the features of the platform can be used to explore the data 
(sections 5.11-5.14). I also propose an alternative approach for how to visually represent 
network and pathway results together and build into the platform an interactive feature that 
helps guide exploration into ‘missing links’ between enriched pathways (sections 5.15-5.16). I 
also discuss the steps I took to ensure security and privacy of the data uploaded to the platform 
(section 5.17).  
In developing the TRIAGE web interface, I collaborated with Dr. Jian Song from the 
Laboratory of Immune System Biology at the National Institute of Allergy and Infectious 
Disease (NIAID) of the National Institutes of Health (NIH) in Bethesda, Maryland, USA. In 
building the interactive network features on TRIAGE, I received assistance from Kyle Webb, 
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an NIAID Data Science Fellow. I also worked with the NIAID Office of Cyber Infrastructure 
and Computational Biology (OCICB) to secure the hosting and security measures for the site. 
 
5.2 A Shiny driven web interface for TRIAGE analysis 
I developed and designed the TRIAGE analysis pipeline using the “R” computer language. R 
is a computer language and environment designed for statistical analysis and data visualization 
(R Core Team, 2014) and is one of the top three most commonly used platforms in 
computational biology (together with the Unix shell Bash and Python) (Carey & Papin, 2018). 
Data analysis solutions created with R can be reproduced by either shared code or through the 
sharing of “packages”, units of self-contained reproducible code that can be integrated into the 
workflow of other environments (Wickham, 2015). Despite these advantages, however, there 
remains a critical need within the omics community to make analysis pipelines available to 
researchers across the spectrum of computational literacy. One such path is utilizing the R 
package “Shiny” which makes R based scripts run as interactive web interfaces that can be 
used without having to interact with or manipulate computational code (Winston Chang, 2019). 
Examples of R based analysis pipelines that have utilized the Shiny platform to create widely 
used web-based interfaces include the Comprehensive Analysis for RNAi Data (CARD) 
platform (B. Dutta et al., 2016) and the Pathway Coexpression Network (PCxN) platform (Pita-
Juárez et al., 2018). 
To build a Shiny powered interface for TRIAGE and broaden the utility of the platform, 
I separated what choices can be provided to each user and what features are preset to apply to 
all analyses. A table of the preset conditions versus user provided inputs is listed (Table 5.1). 
Based on these settings I built a Shiny powered interface that can record the user provided 
inputs as parameters for running the analysis. (Figure 5.1) 
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Pre-set User-selected 
Organism  Human or Mouse 
Pathway Database KEGG Biological process pathways, 
disease pathways, or all 
pathways, 
Network Database STRING Which ”evidence source” 
interactions to include. 
Which confidence level of 
interactions to include. 
Criteria for high confidence, 
medium confidence and non-
hits 
 
Selected from a drop-down 
menu created from the input 
fields in the user’s upload file  
Cutoffs  Numerically assigned by the 
user 
Statistical threshold for 
enrichment 
Within the TRIAGE analysis 
the cutoff is set at p = 0.05 
Following analysis, user is 
provided with p values, FDR, 
Bonferonni score for all 
enrichments 
  Table 5.1: Pre-set and user selected conditions in TRIAGE interface. 
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Figure 5.1: triage.niaid.nih.gov interface. 
 
The landing page of triage.niaid.nih.gov. 
(A) Users selects the organism relevant to the dataset (human or mouse). (B) a drop down menu 
to select the relevant pathway types from the KEGG database. (C) The default setting for 
network analysis uses experimental and database sourced connection. The user can also select 
“advanced options” which creates a list of all the possible interaction types that the user can 
select from.  (D) The user can select the confidence cutoff for network interactions based on 
the scores from STRING. Default is set to medium confidence. (E) .csv files can be uploaded 
to the platform by clicking the browse button and selecting the file. (F) Field for entering the 
cutoff or assigned value for high confidence hits. (G) Field for entering the cutoff or assigned 
value for medium confidence hits. 
A 
B 
C 
D 
E 
F 
G 
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5.3 Unique IDs can be assigned by either EntrezID or HGNC Gene Symbol 
Commonly used gene names in the scientific literature use the familiar “Gene Symbol” 
nomenclature. While a gene symbol is often more familiar and intuitive to interpret, the NCBI 
EntrezID numeric nomenclature is a more reliably unique identifier with a one-to-one matching 
of gene to ID. The TRIAGE analysis uses EntrezID to ensure consistent and accurate gene 
matching between databases and user input files. The front facing information in TRIAGE, 
however, uses GeneSymbol to make the information more interpretable by the user. To that 
end, the files uploaded to TRIAGE for analysis must include a column assigned either 
“EntrezID” or “GeneSymbol”, with the appropriate ID matched to each input (Figure 5.2). 
Both ID systems, however, do not need to be included in the upload. If only one is included, I 
designed the platform to identify the missing one and generate a column of the missing ID type. 
 
5.4 KEGG pathway database for human and mouse is integrated and adapted 
in the TRIAGE platform 
To adapt the KEGG database to the TRIAGE platform I included the pathway membership 
data from the KEGG Application Program Interface (API). I filtered the pathways into two 
groups “Biological Processes” and “Disease Pathways”. In the TRIAGE interface, the user can 
select whether to use one or both of these groups when querying the data for enrichment (Figure 
5.1B) 
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  GeneSymbol EntrezID PercInfected.Zscore CellNumber.Zscore assigned.value 
CXCR4 7852 -4.96623446 0.755277194 1 
C1orf52 148423 -3.637572822 1.925896515 1 
MED14 9282 -3.435696475 0.976086257 1 
ADAM10 102 -3.435673997 1.513583032 1 
GCK 2645 -3.223640638 1.920937941 1 
GPR21 2844 -3.201246647 -0.096137148 1 
ZNF831 128611 -3.20098761 -0.243515999 1 
CD4 920 -3.162525347 1.767687649 1 
EGFR 1956 -3.162525347 1.487870985 1 
WNT1 7471 -3.140163554 1.674727332 1 
USP6 9098 -3.114415882 1.238823011 1 
PLEKHA7 144100 -1.920126088 -1.705268716 0.5 
DPH3 285381 -1.919642212 -0.473272261 0.5 
NA 284861 -1.919642212 -0.200375892 0.5 
PNMA6A 84968 -1.917641072 -1.574602053 0.5 
EIF3G 8666 -1.917428352 -1.51997327 0.5 
TFDP2 7029 -1.916264377 1.3078323 0.5 
CLNS1A 1207 -1.915660931 0.543313511 0.5 
MMP19 4327 -1.90908986 1.426094148 0.5 
RECQL4 9401 -1.90908986 1.167972495 0.5 
ZNF536 9745 -1.909010831 -0.111569716 0.5 
NMUR2 56923 -3.690591512 -2.63385185 0 
SMU1 55234 -3.686455305 -3.076050904 0 
LSM8 51691 -3.62462392 -2.307921727 0 
NAT10 55226 -3.460889184 -2.681841646 0 
SGO1 151648 -3.435116303 -4.066983289 0 
DHRS13 147015 -3.38711184 -2.495038806 0 
XAB2 56949 -3.327710602 -3.064859872 0 
HEG1 57493 -3.291433863 -2.728928693 0 
COPB2 9276 -3.28475593 -4.284378793 0 
PSMB6 5694 -3.261635121 -3.280551426 0 
Figure 5.2: A sample input file for TRIAGE. 
 
A sample dataset prepared for TRIAGE analyses using the data from the Brass et al. 
of study of essential factors for HIV infection. Gene column IDs are labeled as 
“EntrezID” and “GeneSymbol” (either one is sufficient for upload). The 
“PercInfected.Zscore” column includes the normalized Z scores and can be used to 
set cutoffs for in the high confidence and medium confidence fields on the TRIAGE 
platform. To include the “CellNumber.Zscore” to consider what is a high confidence 
and what is a medium confidence hit, a new column is created “assigned.value”. Hits 
assigned as high confidence by both criteria are given a value of 1, hits assigned as 
medium confidence are given a value of 0.5. Hits that don’t meet the two criteria are 
assigned a value of 0. 
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5.5 STRING database interaction networks and criteria are integrated into the 
TRIAGE platform 
Adapting the STRING database for use by TRIAGE required first an alignment of the IDs, as 
STRING uses Ensemble protein IDs and TRIAGE uses gene EntrezIDs. Using the Biomart 
converter table, I transformed the STRING network data by mapping the proteins IDs to 
EntrezIDs (Durinck et al., 2009). I then segmented all interactions based on their evidence 
source and divided the confidence cutoffs into three tiers; 0.15-0.4 as low confidence, 0.4-0.7 
as medium confidence, and 0.7-1 as high confidence. This allows the user to choose and 
compare different networks and confidence levels for their analysis. As the preferred settings 
for high-throughput hit selection are interactions in STRING that are based on experimental 
and database evidence of at least medium confidence, I set these as the default TRIAGE 
settings. I also included as an advanced option the ability for users to select their preferred 
evidence sources and confidence level (Figure 5.1C-D). The filtered network set by the user at 
the outset of the analysis is used throughout all of the subsequent analysis steps. 
 
5.6 TRIAGE platform can perform analysis with human or mouse datasets 
To broaden the utility of the TRIAGE platform I designed the analysis with a built-in capability 
to run analysis for mouse or human datasets. When setting the analysis, the user selects the 
appropriate organism in which the data was generated, and all the subsequent database 
selections are matched accordingly (Figure 5.1A).  
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5.7 Uploading a data set to the TRIAGE platform for analysis 
The TRIAGE platform reads files in the .csv format. The file must contain a column either 
titled “GeneSymbol” that has HGNC gene symbols in all the rows or, alternatively, a column 
titled “EntrezID” with NCBI EntrezID in all the rows. The file must also contain a column with 
a numeric value that can be used to separate high confidence, medium confidence, and non-
hits. This column can be titled according to the user’s choosing. A sample dataset is shown in 
Figure 5.2. After the file is uploaded a message appears with the number of IDs in the list that 
have been successfully mapped to gene IDs with a warning of the number of IDs that are 
unmatched 
 
5.8 Criteria for high confidence and medium confidence cutoffs are set by the 
upload file and user 
After the user’s file has been uploaded a dropdown option appears under ‘Cutoff Type’ 
containing the names of all the columns in the upload file (Figure 5.3A). The user can then 
select the name of the column that contains the numeric values to be used for setting the high 
confidence/medium confidence cutoffs. For the rest of the analysis only the columns containing 
the gene IDs and the selected “Cutoff Type” column will be considered by the platform, any 
additional columns in the upload file are ignored and added back only in the download file that 
the user saves at the termination of the analysis. 
 
5.9 Dual cutoffs in TRIAGE platform can be set by assigned values or as 
greater-than or less-than values 
For simplicity, I designed TRIAGE to consider the input of only one column when measuring 
what is a high confidence hit and what is a medium confidence hit. In a straightforward way 
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this column can be used for a measure like Z score, fold change, or p value. The user then 
places the numeric cutoffs for high confidence and medium confidence hits in the appropriate 
field of the interface. TRIAGE then automatically calculates, based on the difference between 
the cutoffs for high confidence and medium confidence, whether it should be using a greater-
than or less-than approach when segmenting the data by cutoff.  
This design, however, does not preclude using the inputs from multiple criteria to assign 
targets to high confidence or medium confidence groups. When determining what should be 
designated as high confidence and medium confidence, a user might want to consider a primary 
readout (such as Z score or fold change) together with a secondary readout (such as including 
cell viability measures, p values, off target analysis, etc.). Some user may also want to combine 
datasets from different studies to create confidence designations based on the scores form 
different assays. To consider more than one criterion a user can do the confidence assignation 
before uploading the dataset to TRIAGE (such as seeing which hits meet more than one 
criterion, which hits appear in more than one assay, etc.) and assign all of the high confidence 
hits a single value (such as 1 for example). The user then assigns a value that is below the value 
chosen for high confidence hits (such as 0.5) to all the hits that would be considered medium 
confidence. The user then assigns a value below both of these values to all other hits (such as 
0). The user then uploads the file and enters “1” as the high-confidence cutoff and “0.5” as the 
medium confidence cutoff (Figure 5.1F-G). This will group all the hits curated from the 
different criteria in the proper confidence designations. Examples of these different approaches 
are shown in the sample dataset in Figure 5.2. 
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A 
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C 
Figure 5.3: Running TRIAGE analysis. 
 
(A) After a file is uploaded a dropdown menu with all the column names containing numeric 
values appears. The user selects the preferred column for setting cutoffs. (B) When selected, 
“Add genome background” adds in a ‘rest of genome’ background of non-hits for analysis of 
the dataset. (C) Analysis can be run and reset within the same session. 
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5.10 TRIAGE can add a “genome background” for datasets that only include 
hits 
Many high-throughput assays are now outsourced to core facilities within institutions and then 
sent to research groups to analyze and follow up on. These resources often supply in return a 
list of selected candidates and do not include the full range of scores for the entire genome 
being measured. These restricted lists preclude the possibility of running enrichment statistics 
that measure the number of hits against the entire set from which they were selected from. To 
not exclude the analysis of those list’s formats on TRIAGE, I added a feature where the user 
can add in a “genome background” against which the enrichment analysis will be done (Figure 
5.3B). When selected, the “add genome background” feature adds genes to the list that aren’t 
included in the upload file to be used as a background for statistical enrichment analysis. The 
added background “genes” will not appear as suggested hits by the TRIAGE analysis, the 
background genes are only used as a means to have more robust statistics on the enrichment of 
pathways. The background genomes use only the known protein coding genes of the selected 
organisms that are not in the upload file. TRIAGE uses the difference between the size of 
selected hits and the number of known protein coding genes as the number of “non-hits” for 
enrichment statistics.  
 
5.11 Running TRIAGE analysis with a single click and in less than 30 seconds 
To run TRIAGE analysis, the user clicks “Analyze my data” and the iterative analysis process 
begins (Figure 5.3C). A progress bar appears once the analysis has begun and makes half step 
leaps after every iteration so that the user can see the progress. In my testing, a majority of 
datasets complete the analysis in less than 30 seconds. When the analysis has run, the window 
switches to the results panels (see following sections). An added benefit of the fast speed of 
the analysis processes is that it allows a user to experiment with different cutoffs for the high 
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and medium confidence settings to compare and contrast outputs. To encourage this approach, 
I included a “Reset” icon that, when clicked, resets the input settings and allows the user to 
easily run a new analysis with different parameters (Figure 5.3C). 
 
5.12 TRIAGE has built-in recognition for contingencies and outlier datasets 
It is impossible to predict all the different ways a web-based analysis tool will be used. Not all 
of the directions provided will be followed and there are a myriad of ways in which input files 
may vary from the ones for which I originally built this platform. For situations that may arise 
when some of the input and upload criteria are not fully followed, I took the approach of 
building a warning message system that alerts the user as to how an input setting led to an 
incomplete result. This approach has the benefit of guiding the user through their attempts to 
correct their input settings. Table 5.2 lists the anticipated situations and the associated warning 
messages I included. 
While testing multiple randomly generated datasets on TRIAGE, I identified rare cases 
where the enrichment set is so small, that the statistics for enrichments are extremely sensitive 
to small additions to the sets of hits. These situations lead to the set never fully converging to 
the same set of hits but instead fluctuating between two sets of hits. To anticipate the possible 
emergence of these cases I added in a contingency whereby the iterations of TRIAGE first 
check to see if the set has converged and if it hasn’t it looks for a repeated pattern. If the 
iterations are found to oscillate between the same repeated selections of sets, it looks for the 
largest most inclusive set in the pattern and terminates the analysis at that juncture. 
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5.13 TRIAGE analysis identifies robust enrichment and illustrates annotated 
KEGG pathway maps 
Once an analysis has run the window switches to the “Enriched Pathways” tab. This tab 
provides a list of statistically enriched pathways found in the selected set of hits by TRIAGE 
analysis.  The list includes all pathways that have a statistical score of 0.05 or less in a 
hypergeometric test. While a 0.05 p value is a lenient cutoff for pathway enrichment, this is 
only the minimum requirement a pathway must meet to be included in the list. Values for more 
stringent statistical tests are included in the table and allow the user to rank pathways based on 
different standards and cutoffs (Figure 5.4). 
The names of the enriched pathways can also be clicked on. Clicking on the pathway 
name will open a new tab from the KEGG website showing a schematic of the genes in the 
pathways with the gene hits from the TRIAGE analysis highlighted. Genes that were marked 
as high confidence at the start of the analysis are highlighted in blue and those marked as 
medium confidence are highlighted in red. This feature makes it possible to further explore if 
the genes that are driving the enrichment of the pathway are spread across the pathway or 
concentrated in a particular segment (Figure 5.5) 
Anticipated Error Warning Message 
Wrong organism selected or 
wrong Gene Symbol convention 
used 
Either check the organism or 
update your GeneSymbols to 
match the official HGNC symbols 
if you want to include ALL in this 
analysis. 
One or more input genes have no 
matching EntrezID due obsolete 
GeneSymbol 
Warning: X GeneSymbols have 
mapped EntrezIDs and will be 
used in this analysis! 
Criteria generate too small 
datasets for network analysis 
Warning: Criteria produced 
empty network. Session will 
restart. 
Table 5.2: Anticipated user errors with built in responses. 
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Figure 5.5: Results from TRIAGE analysis mapped onto a KEGG pathway map. 
 
Focal adhesion pathway map overlaid with the results from TRIAGE analysis of the 
Brass et al. of study of essential factors for HIV infection. Hit genes selected by 
TRIAGE that were in the input high confidence group are in blue, hit genes selected by 
TRIAGE that were in the input medium confidence group are in red. 
Figure 5.4: triage.niaid.nih.gov results. 
 
A table of enriched pathways following TRIAGE analysis of the Brass et al. study of essential 
factors for HIV infection. Hit genes selected by TRIAGE that were in the input high confidence 
group are in blue, hit genes selected by TRIAGE that were in the input medium confidence 
group are in red. 
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5.14 TRIAGE output provides prioritized hits from high-confidence and 
medium confidence sets 
Following the interactive enrichment tab, the “Gene Hits” tab contains a series of tables that 
list the genes that were selected by the TRIAGE process and can guide the further prioritization 
of hits for follow up. The lists are divided under different sub tabs:  
 
TRIAGE Gene Hits: This table provides a list of prioritized hits selected by TRIAGE analysis 
with supporting information on interacting genes (based on the user -selected network criteria) 
and membership in enriched pathways. I designed these tables to best guide further analysis. 
The “interacting gene” column lists which other hits each selected hit has predicted interactions 
with. An additional column lists the pathways that those interacting genes are members of. This 
can be particularly useful when the specific gene hit is not yet annotated as part of a pathway. 
Using the pathway memberships of its interacting genes can help guide hypotheses about its 
function. 
  
Gene Hits by Iteration: A table with the input document and the genes added or dropped out 
at each iteration is listed in each column. Genes counted assigned as high confidence in a 
specific iteration are indicated as “HighConf”, genes counted as medium confidence are 
indicated as “MedConf”. The “TRIAGEhit” column indicates the gene hits that are counted as 
final hits in TRIAGE. The top row highlighted in orange indicates the total number of hits 
considered high confidence at the end of each iteration. The table also includes columns with 
information about the pathways, interactions with other hits, and the pathway membership of 
the interacting genes as in the TRIAGE Gene Hits table described above. 
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Graph: Gene Hits by Iteration: A graph showing the number of medium confidence hits and 
high confidence hits that are selected as TRIAGE hits at each iteration of the TRIAGE analysis. 
(starting with all the initial high confidence genes from the input and 0 medium confidence 
genes. Medium confidence hits are added during the iterations). 
 
High Confidence Hits not in TRIAGE Hits:  This table includes a list of hits that were 
assigned as high confidence in the input but were not selected as hits by the TRIAGE analysis. 
I added this table so that user can easily review the high-confidence hits that were dropped out 
by TRIAGE to see if any of those should be added back in. This is an important feature in the 
context of under studied genes that have no previously reported pathway annotations or 
interactions, but could be an important novel regulator of the biological process being studied.  
  
Pathway Enrichments: This table lists the enriched pathways from the analysis with statistical 
cutoffs and the gene candidates that drive the enrichment. 
 
The enrichment and hit prioritization tables are all available to download by the user. 
This ensures that the data is securely saved by the user after the analysis is removed from the 
server. The “Download all files” icon under the “Download” tab provides a zipped folder of 
the analysis files generated by the TRIAGE platform. 
  
5.15 Using Hierarchical Edge Bundling (HEB) to simultaneously visualize 
pathway and network enrichment 
In building the TRIAGE platform I encountered the challenge of how to visually represent the 
results from the combined pathway and network analysis. To build a solution I adapted a 
network visualization approach called Hierarchical Edge Bundling (Holten, 2006). 
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Hierarchical Edge Bundling is based on the design principle of all the nodes in the network 
being organized in a circle and separated into different groups (the hierarchical part), the edges 
connecting different nodes to one another across groups are then “bundled” such that you can 
observe both the individual node and edge origin. This visualization also enables you to see 
which groups are often connected (the edge bundling part). For this context I utilized the 
Hierarchical Edge Bundling method to group network nodes (which in this context would be 
genes or proteins) that are part of enriched pathways into individual groups. I assigned another 
group as the “novel gene” group to place all the gene hits that are not annotated as part of the 
selected pathways. For visual clarity, I filtered out the often seen intra-group connections 
within a given pathway, but kept them for the group representing the “novel genes”. This 
method allowed for easier visualization of genes driving suggested interactions between 
pathways. This approach also makes it possible to explore interactions between genes in the 
same pathway through a common interacting ‘novel’ gene (Figure 5.6). 
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  Pathway 2 
Pathway 1 Pathway 3 
TRIAGE hits not annotated in pathways 1-3  
Figure 5.6: A hierarchical edge bundling for pathway and network visualization. 
 
TRIAGE hits that are annotates of part of selected pathways are grouped together and 
highlighted by different colors (red, brown, and blue). TRIAGE hits that are not annotated as 
part of the selected pathway based on the pathway database but have predicted interactions 
with pathway genes based on the network databases are added to a new group (green). 
Interactions are colored based on the group it originates from. Only interactions between the 
groups and within the group of added genes (green) are shown. 
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5.16 An interactive version of pathway and gene hierarchical edge bundling 
To enable further exploration of the datasets in TRIAGE I developed an interactive version of 
the integrated pathway and network graph within the platform. The user can select up to three 
pathways from the list of enriched pathways and TRIAGE will generate an HEB graph of all 
the TRIAGE hits that are part of the selected pathways as well as all the TRIAGE hits that have 
predicted interactions with the ‘pathway’ genes (Figure 5.7). The visual parameters of the 
graph can be adjusted by the user. For example, hovering with a cursor over a specific gene 
(“node”) highlights all the predicted interactions (“edges”) of that gene. Clicking on this gene 
‘fixes’ the interactions, so that the user can then click on one of the predicted interactions to 
observe the interactions from the second node. A panel at the side of the graph provides 
information about the interaction, such as the evidence source for the interaction and its 
confidence score from the STRING database. After clicking through a string of interacting 
genes the user can click the “Highlight Clicked Pathway” icon and all the genes clicked through 
in the exploration, together with their predicted interactions, are highlighted (Figure 5.7). The 
clicked genes, and the pathways they are members of are tabulated in a separate table that can 
be downloaded with the rest of the analysis at the download tab. 
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Figure 5.7: Interactive interface for data exploration of pathway and network connections. 
 
After selecting up to three enriched pathway an interactive network figure is generated. 
Showing the results following the selection of the “RNA transport”, “Ribosome biogenesis in 
eukaryotes”, and “N-Glycan biosynthesis” pathways in the TRIAGE analysis of the Brass et 
al. study of essential factors for HIV infection. Information about different nodes and edges 
appear in the window at top right. Aesthetic parameters can be controlled by the sliders on the 
right. “Highlight Clicked Pathway” highlights the clicked on genes and their reactions, as 
shown in this figure. 
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5.17 Steps taken towards data security on triage.niaid.nih.gov 
TRIAGE uses a secure encrypted HTTPS connection. To further increase security, when a file 
is uploaded a new directory is created where the input file and all the subsequently generated 
analysis files are temporarily saved, ensuring that only the user generating the connection can 
access the directory with their files. The directory is kept on the server only for the duration of 
the session (i.e. as long as the user is using the site). Once the sessions ends (i.e. close of 
browser window or move to a new site) the directory and all its files are removed from the 
TRIAGE server. This decreases the security risk for the user and ensures that the results are 
only stored locally after the analysis. Data collected for each session is limited to the country 
where the request comes from and the time spent using the site (and specific pages). File names, 
analysis choices, user IDs, and results are neither collected nor stored.  
 
5.18 Summary 
The development of a robust hit prioritization method for high-throughput studies of the LPS 
response in macrophages led me to the identification a novel bioinformatic approach 
employing iterative analysis of pathway and network databases (TRIAGE). Recognizing that 
this approach has utility beyond the study I designed, I chose to broaden its access. To ensure 
accessibility and ease of use, I built a web interface that guides the user through straightforward 
steps of the TRIAGE analysis. I also built the analysis results interface to enable further 
exploration of the data via interactive features and integrated information from selected 
databases. The TRIAGE URL (triage.niaid.nih.gov) is currently hosted by the National 
Institutes of Health (NIH). 
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6 TRIAGE analysis of LPS screen data identifies a critical and broad regulatory role 
for spliceosome and proteasome related genes in macrophage activation 
 
 
6.1 Introduction 
Following the development and testing of TRIAGE, I applied the analysis pipeline to the three 
genome-scale siRNA studies of the macrophage response to LPS I introduced at the beginning 
of this thesis in chapter 3. The three studies included an siRNA screen using THP1 cells with 
a luciferase reporter tagged to a TNF-a promoter (Human-TNF-a study), an siRNA screen 
using RAW G9 cells tracking GFP-tagged p65 (Mouse-NFkB study), and an siRNA screen 
using RAW G9 cell measuring an mCherry reporter tagged to a TNF-a promoter (Mouse-TNF- 
a study). (The different reporter cell lines and the design of the three studies are described in 
detail in Figures 1.6 and 1.7.) All three studies have been previously reported with a number 
of observations selected for in-depth follow up analysis (John et al., 2018; Ning Li et al., 2017; 
J. Sun et al., 2017; J. Sun et al., 2016). With the development of TRIAGE, I reanalyzed these 
datasets to find hits and enrichments beyond the highest scoring genes. In this chapter, I begin 
by describing segmentation of the data into high and medium confidence hits, and then apply 
the TRIAGE analysis pipeline to all screens individually. I show that the discordance between 
the studies that I observed in chapter 3 is largely overcome by TRIAGE analysis (section 6.2). 
The TRIAGE selected hits also show a more robust enrichment for canonical TLR pathway 
genes (section 6.3). Looking beyond individual hits, I show how TRIAGE enriches for many 
immune-related pathways, as expected, as well as two critical biological processes; the 
proteasome and the spliceosome. Using the integrated pathway and network approach, I also 
show how the dataset is enriched for hits that provide interaction links between the TLR 
pathway and the proteasome and spliceosome (section 6.4). As a further validation for a broad 
role of the proteasome and spliceosome in macrophage activation, I show two experiments 
using chemical inhibitors of the relevant processes and report on their impact on the LPS 
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response (section 6.5-6.6). I follow up these studies with an enrichment analysis between an 
RNA-seq study of the LPS response and the hits from the LPS screens (section 6.7). While 
alternatively spliced isoforms of TLR pathway genes have been reported before, a critical 
question to address in this context is to what extent dynamic splicing events occur within the 
rapid time frame of macrophage activation. I address this question by PCR analysis, using 
primers flanking alternatively spliced exon boundaries of canonical TLR genes, and 
demonstrate their alternative engagement within the window of early macrophage activation 
(section 6.8). By the combined analysis and follow up studies in this chapter I show how the 
TRIAGE analysis can identify novel regulatory mechanisms by which macrophages may use 
proteasome-targeted negative regulators to set thresholds for activation, and dynamic 
alternative splicing to promote and sustain an inflammatory response. 
 
6.2 Analysis by TRIAGE of three LPS screens 
To conduct TRIAGE analysis of the three studies of the LPS response, I began by using the 
normalized datasets I created in chapter 3. The data was already normalized with a cell viability 
correction (section 3.1). In deciding how to prioritize hits for high or medium confidence, I 
considered possible additional metrics to the normalized readout scores. siRNAs (and as is 
being discovered, CRISPR/Cas9 guides studies as well) can have off-target effects (A. L. 
Jackson & Linsley, 2004; Aimee L. Jackson & Linsley, 2010; Mohr et al., 2010). In these cases, 
though the perturbation reagents are designed to target a specific gene, they may through weak 
binding affinities with alternative sequences interfere with the expression of a different gene. 
These off-target activities can lead to the observed phenotype being erroneously attributed to 
the incorrect gene. A widely used bioinformatic solution for RNAi is using Common Seed 
Analysis (CSA) (Marine et al., 2012). Common Seed Analysis looks at all the possible high 
and low affinity bindings of the siRNA oligonucleotide and compares the readout score of its 
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target gene versus the scores of its possible off-target partners. CSA provides a statistical score 
for how likely the observed result is caused by an off-target effect. When prioritizing the hits 
from the siRNA studies I assigned a cutoff to each study (corresponding to its Z score inflection 
point) and applied CSA. Genes that were above the cutoff and were not estimated by CSA to 
be a possible off target effect were assigned as high confidence, genes that were above the 
cutoff but were flagged as possibly being driven by off target effects were assigned as medium 
confidence. Similarly, hits that had a score between the set cutoff and a Z score of 1 standard 
deviation from the mean yet had a low score for possible off-target effects were also considered 
medium confidence (Figure 6.1A). 
Having established the method for ranking the LPS screens into three tiers, I proceeded 
with TRIAGE analysis. Each of the three screens cycled through 3 to 4 iterations of hit 
prioritization until the analysis converged on a final set of hits. Though the three studies had 
different distributions, the analysis by TRIAGE found similar sized sets for the Human-TNFa 
and the Mouse-NFkB studies. The mouse-TNFa study started with a very small set of hits with 
analysis by TRIAGE broadening it to include more lower scoring hits (Figure 6.1B). 
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Normalized scores from 
Human-TNFa study  
Normalized scores from 
Mouse-NFkB study 
Normalized scores from 
Mouse-TNFa study  A 
B Iterations and Hits Selection by Iterative Analysis of LPS Screens 
Human-TNFa Mouse-NFkB Mouse-TNFa 
Figure 6.1: TRIAGE analysis for three siRNA studies of the response to LPS. 
 
(A) Normalized distribution of the readout scores for the human TNF-α study (left), mouse NF-
κB study (center), and the mouse TNF-α study (right). High-confidence assigned hits are in red, 
medium confidence in blue. (B) Iterations of TRIAGE analysis of the three LPS response studies.  
High confidence and medium confidence hits from  
three siRNA studies of the LPS response 
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As an initial test of confidence in the selected hits I compared the overlap across the three 
studies. As I have shown in chapter 3, overlap between the highest scoring hits from the three 
studies is quite low. Hit selection by TRIAGE, however, identifies a very strong shared 
enrichment between the studies. The overlap across the studies also have a strong statistical 
significance (Figure 6.2) suggesting a robust true positive rate. 
 
6.3 Enrichment for canonical TLR pathway genes in the three screens of the 
LPS response are shared and divergent 
Following analysis by TRIAGE I used the Ingenuity Pathway Analysis (IPA) program to test 
the selected hit sets for enrichment of established TLR pathway components. In contrast to the 
enrichments found in the high scoring hits in chapter 3 (Figures 3.2-3.4), hits selected by 
TRIAGE showed enrichment for canonical TLR pathway components across all the major 
signal transduction junctures (Figure 6.3-6.5). Critically, the three studies show enrichment in 
all three “modules” of the TLR pathway (encoder, transmission, and decoder, described in the 
introduction section 1.5.2, Figure 1.5). The encoder module (TIRAP, TICAM1, and TOLLIP, 
in addition to CD14, MyD88, and TLR4), the transmission module (TAB2, TAK1, TRAF6, 
IKKa), and the decoder module (NFkB, c-Fos, MAPK, p38). Of interest, TRAF6 only came 
up as critical in the Mouse-NFkB screen, suggesting that the TNFa response is less sensitive 
to TRAF6 perturbation than NFkB. TAB2 and TAK1 were only hits in the two TNFa studies, 
suggesting that the MAPK p38 and Jnk responses downstream of TAK1 are critical to support 
the TNFa readout (Figure 6.3 and Figure 6.5).  
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THP1   
TNF-α  
RAW G9 
NF-κB 
THP1   
TNF-α  
RAW G9 
NF-κB 
RAW G9 
TNF-α 
RAW G9 
TNF-α 
17 21 73 436 401 432 398 345 344 
Shared enrichment of high scoring hits from three LPS screens. A 
Figure 6.2: Shared enrichment of TRIAGE selected hits from three siRNA studies of the 
response to LPS. 
 
(A) Number of shared hits and significance of overlap between the highest scoring 2.5% of hits 
from three screens of the macrophage response to LPS. (B) Number of shared hits and 
significance of overlap between hits selected by TRIAGE from the three screens of the 
macrophage response to LPS. p value of overlap is calculated by the hypergeometric test. 
Human   
TNF-α  
Mouse 
NF-κB 
Human  
TNF-α  
Mouse 
NF-κB 
Mouse 
TNF-α 
Mouse 
TNF-α 
116 76 190 839 719 879 479 645 356 
Shared enrichment of TRIAGE selected hits from three LPS screens. B 
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  Enrichment of TLR pathway genes in TRIAGE selected hits 
from the THP1 TNF-α study  
Figure 6.3: Enrichment of canonical toll-like receptor pathways genes in TRIAGE 
selected hits from THP1 TNF-α genome-wide studies.  
 
Overlaying TRIAGE selected hits from the THP1-dual luciferase study over the 
canonical pathway map curated by Ingenuity Pathway Analysis (IPA, Qiagen) 
Putative Positive Regulators 
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  Enrichment of TLR pathway genes in TRIAGE selected hits 
from the Raw G9 NF- κB study  
Figure 6.4: Enrichment of canonical toll-like receptor pathways genes in TRIAGE 
selected hits from Raw G9 NF- κB genome-wide studies.  
 
Overlaying TRIAGE selected hits from the from the RAW G9 – GFP tagged NF-κB 
study over the canonical pathway map curated by Ingenuity Pathway Analysis (IPA, 
Qiagen) 
Putative Positive Regulators 
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  Enrichment of TLR pathway genes in TRIAGE selected hits 
from the Raw G9 TNF-α study  
Figure 6.5: Enrichment of canonical toll-like receptor pathways genes in TRIAGE 
selected hits from Raw G9 TNF-α genome-wide studies.  
 
Overlaying TRIAGE selected hits from the from the RAW G9 – mCherry tagged TNF-
α study over the canonical pathway map curated by Ingenuity Pathway Analysis (IPA, 
Qiagen) 
Putative Positive Regulators 
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6.4 Immune, spliceosome, and proteasome pathways are critically enriched in 
the three studies of LPS response 
For pathway analysis of the three LPS screens, I prioritized enrichments that were found in at 
least two out of the three studies. In addition to the p-value threshold, I added a False Discovery 
Rate (FDR) test and set the threshold at FDR = 0.1. The pathways identified included, as 
expected, the TLR pathway itself, integral sub-components of the TLR response (including 
NFkB and MAPK) and many other immune related pathways in the top scoring and shared 
enrichments (Figure 6.6). Two pathways that are not primarily immune related but appear as 
strong enrichments in the study are the proteasome and spliceosome (Figure 6.6). Though the 
proteasome is to be expected as critical for TLR signaling, given the necessity of proteasomal 
degradation for removing negative inhibitors (as I described in the introduction, section 1.3.1), 
the strong enrichment of multiple proteasomal factors suggested the possibility that there is an 
even broader requirement for the proteasome in TLR activation. As I have shown in the 
previous section of the TLR enrichment of the three screens, hits from the TNFa screens 
indicate a signaling pathway independent of NFkB. The strong enrichment of proteasome 
factors in the Mouse-NFkB and the Human-TNFa screens, suggests that the function of the 
proteasome in enabling macrophage activation goes beyond relieving inhibition of NFkB 
translocation. There are similar considerations with the enrichment of the spliceosome 
pathway. Though the core components of the spliceosome are critical for basic cell function, 
the enrichment of splicing related hits even after applying a critical cell viability correction 
(section 2.3.3), suggest a possible function beyond cell homeostatic requirements that is 
specific to TLR signaling. To further highlight these enrichments, I followed up the pathway 
analysis with an integrated pathway and network analysis to identify the hits from the screen 
that aren’t annotated as part of the TLR, proteasome, or spliceosome pathways, yet have 
predicted interactions with gene members of at least one of those pathway sets. The enrichment 
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found further representation of splicing and proteasome related genes, many with known 
interaction to TLR components (Figure 6.7). In all three LPS studies, HNRNPH1 and NXF1 
were identified as hits. Though not formally annotated in the spliceosome pathway by KEGG, 
their enrichment suggests a path for the engagement of its main components. 
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Human - TNFα Mouse - NFκB  
KEGG Pathway Enrichment of TRIAGE Hits in LPS Response Studies 
Mouse - TNFα  
Pathway Enriched in all 3 studies 
Pathway Enriched in 2 studies 
Immune related pathway 
Spliceosome and proteasome pathway 
Figure 6.6: Pathway enrichment by TRIAGE of three studies of LPS response. 
 
KEGG pathway enrichment analysis of the human TNF-α study (left), mouse NF-κB study 
(center), and mouse TNF- α study (left). Only showing shared enrichments. Red bars indicates 
pathways enriched in all three studies. Orange indicates enriched in two out of three studies. 
Significance indicates a cutoff of FDR < 0.1, Figure truncated at –Log(pValFDR) = 5. 
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  Network analysis of TRIAGE selected hits linking the TLR pathway with mRNA 
splicing and protein degradation 
Figure 6.7: Network and pathway integrated analysis of TLR, spliceosome, and proteasome 
related hits. 
 
Integrated pathway and network analysis of the TRIAGE selected hits from the human- TNF- α 
study. The network shows hits from the study in the TLR pathway (red), spliceosome pathway 
(brown), proteasome pathway (blue), and hits not annotated as part of the three pathway, yet have 
predicted network interaction with hits in the three pathways. 
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6.5 Inhibition by MG132 shows proteasome degradation is critical for 
signaling in multiple branches of the TLR pathway 
To investigate further the possible basis for the strong enrichment of proteasome components 
in the LPS screens, we investigated the effects of proteasome inhibition on LPS-induced 
signaling in macrophages. MG132 (carbobenzoxy-Leu-Leu-leucinal) is a proteasome inhibitor 
that has been used previously in macrophage cells (Ortiz-Lazareno et al., 2008; Perry et al., 
2010). For this assay I worked with Dr. Jing Sun at the National Institutes of Health (NIH), and 
we sought to determine whether the proteasome is required for LPS signaling beyond the 
known requirement for degradation of IkB and p105 (Ciechanover et al., 2001; Coux & 
Goldberg, 1998). We identified a juncture in the downstream signaling of LPS that is 
independent of these two factors. p38 MAPK is a signaling pathway independent of NFkB and 
it is also a key contributor to the LPS-induced TNF response (Gottschalk et al., 2019; J. Sun et 
al., 2016). We chose this juncture in addition to two factors from the NFkB and p105 signaling 
pathway, IkB and Erk respectively. Using antibodies for IkB, phospho-Erk, and phospho-p38, 
we find that the LPS-induced degradation of IkB as well as the activating phosphorylation of 
Erk and p38 are all substantially diminished in the presence of MG132 (Figure 6.8A-C). This 
suggests that proteasomal function is critical in the activation of all the signaling branches 
tested (NFkB, Erk MAPK and p38 MAPK), and further indicates that the strong enrichment 
for proteasome components in all three screens could be due to a pervasive requirement for 
protein degradation to activate numerous signaling events downstream of TLR4 activation. 
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Figure 6.8:  Changes in phosphorylation of TLR effectors following proteasomal inhibition. 
 
(A) Western blot of Total IκB following 15 minutes, 30 minutes, and 60 minutes of LPS 
treatment shows only small changes in Total IκB following proteasomal inhibition. (B) Levels 
phospo-Erk (a factor downstream of p105) following LPS treatment with and without MG132 
inhibition of the proteasome. (C) Levels of phopho-p38, which signals independently of the 
NFκB pathway, in the absence and presence of proteasomal inhibition by MG132. Bar graphs 
show the results of two or more experiments. Western blot gels show representative samples.  
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, multiple t test. 
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6.6 Inhibition of splicing by Madrasin blocks transcriptional response to LPS 
To first test in an overarching manner whether engagement of the spliceosome is essential for 
the activation of LPS signaling, I used a chemical inhibitor of splicing to observe its impact on 
signal transduction. The current model of signal transduction in TLR4 involves the recruitment, 
conformational alteration, degradation, and translocation of proteins that lead to pro-
inflammatory transcription and cytokine expression. While it can be assumed that the 
expression of pro-inflammatory cytokines would require the essential machinery of mRNA 
splicing and translation, it would be a novel finding if the signaling upstream of pro-
inflammatory transcription actively depends on the engagement of the spliceosome to facilitate 
and maintain signal transduction.  
To test this hypothesis, I utilized the RAW G9 reporter cell line from the LPS screen together 
with a chemical inhibitor of splicing. The RAW G9 cell line contains an mCherry reporter that 
is tagged to the single exon promoter of TNF-a (Figure 1.4C). The expression of the single 
exon promoter does not require any splicing to activate the reporter activity, therefore this 
system can be used as a way to measure splicing activity required upstream of the initiation of 
TNFa transcription. The mCherry reporter is tagged to a PEST sequence which has an 
approximate 1 hour half-life (Sung et al., 2014). The short half-life provides a dynamic readout 
of continued activation of the TNF-a promoter from the measured fluorescence.  Several 
chemical inhibitors of splicing have been identified (Effenberger et al., 2017), however, many 
are derived from bacteria and sources that lead to trace levels of contaminants that can be 
recognized by PRRs and activate macrophages. Madrasin (2-((7methoxy-4-methylquinazolin-
2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-one RNAsplicing inhibitor) is a synthetic inhibitor 
of splicing (Pawellek et al., 2014) (Figure 6.9A) which makes it a better candidate for use in 
immune cells such as macrophages. Madrasin targets the A complex of the spliceosome, 
blocking the SN2 reaction between two proximal exons junctions. At the outset, I first tested 
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that the treatment by Madrasin did not affect the basal expression of the TNF promoter-driven 
mCherry reporter (Figure 6.9B). I then did a dose response assay of 4-hour pretreatment with 
increasing concentrations of Madrasin followed by treatment with LPS. Measuring mCherry 
expression in the RAW G9 cells with increasing dosage of Madrasin showed a clear dose 
response curve of inhibition (Figure 6.9C). I paired this assay with a cell viability assay 
measuring the levels of Lactate Dehydrogenase (LDH) compared to a cytotoxic control. Pre-
treatment by Madrasin did not significantly increase cell death, reducing the likelihood that the 
observed effect on the TNFa response is driven by a decrease in viable cells (Figure 6.9D). I 
followed up these assays with a time course assay. Pre-treatment with Madrasin completely 
attenuated the LPS response, as measured by the Tnf promoter-driven mCherry expression 
(Figure 6.10). These results further support our finding from the enrichment analysis of the 
LPS studies that the spliceosome is required for LPS signaling upstream of the transcriptional 
response. 
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Figure 6.9: Dose response and cytotoxicity of splicing inhibition and TNF reporter response. 
 
(A) Structure of 2-((7methoxy-4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-
one RNAsplicing inhibitor (Madarasin) (from Sigma-Aldrich). (B) Measurement of basal 
expression of the mCherry TNF –α reporter in RAW G9 cells treated with pretreated with 
Madrasin (MDS). (C) Dosage response of Madrasin pretreatment and LPS (10ng/mL) shows 
staggered impact on mCherry TNF- α  reporter. (D) Cytotoxicity assay measuring LDH release 
as compared to cell lysis control. All experiments were done in triplicates, with error bars 
representing deviation of the samples. Experiments were repeated two times, data shown are from 
representative sample. 
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Figure 6.10: Time course assay of splicing inhibition effect on LPS response. 
 
Time course assay of RAW G9 cells pretreated for 4 hours with 100uM Madasin showing ablation 
of the LPS response by splicing inhibition. TNF –α  expression was measured by expression of 
mCherry tagged reporter. Untreated cells were given similar concentrations of DMSO as treated 
cells. All timepoints were done in triplicates, error bars represent deviation across replicates. 
Experiment was repeated two times, data shown is from a representative sample. 
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6.7 LPS screen hits are enriched for predicted interactions with alternatively 
spliced genes of the TLR4 pathway 
To consider alternative splicing as a regulatory mechanism for the activation of macrophages, 
it is essential to also determine whether effectors of the TLR pathway are alternatively spliced 
within the time frame of the LPS response. As a first step evaluation, I analyzed an RNA-seq 
dataset generated by Dr. Sinu John and Dr. Mani Narayanan at the NIH. The RNA-seq dataset 
used RNA from wildtype THP1 cells as well as THP1 cells with the expression of UBL5 
knocked down by shRNA (shUBL5). UBL5 is a factor involved in pre-mRNA splicing (Oka 
et al., 2014), and it was selected by Dr. John for further analysis as one of the strongest hits in 
the THP1 LPS screen dataset. The dataset measured differential exon usage following 
stimulation by LPS for 0.5, 1, 2, and 4 hours. I conducted an analysis of their dataset to look 
for TLR pathway genes that have changes in exon usage following LPS treatment, and found 
that many canonical genes from the TLR pathway show relative changes in exon levels in 
wildtype THP1 that were diminished in shUBL5 cells (Figure 6.11). These results suggest that 
many effectors of the TLR pathway are alternatively spliced in response to treatment by LPS 
and that some of the changes depend on a specific splicing factor. 
To further illustrate the enrichment of potential regulatory splicing factors, I analyzed by 
network analysis the hits from our Human-TNFa screen together with the TLR pathway genes 
that showed differential exon usage following treatment of LPS (Figure 6.12). I used the 
splicing network categories described by Papasaikas which separates the splicing network into 
core, hnRNPs, SR proteins, and splicing support to categorize the spliceosome related hits 
found in the screen (Papasaikas et al., 2015). The network analysis found enrichment in the 
Human-TNFa screen for all four groups of splicing factors as well as predicted interaction 
between hits and TLR genes that show differential exon usage in the RNA-seq dataset (Figure 
6.11). These results further suggest that both the measurement of alternative splicing in TLR 
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factors and the engagement of the splicing network could shed insight into how the TLR 
pathway utilizes alternative splicing in the transition to inflammatory activation. 
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  Canonical TLR genes showing significant exon variation in 
RNA-seq of LPS Time course 
WT Xhr vs WT 0hr WT Xhr vs UBL5 KD Xhr 
X hrs  
post LPS 0.5 1 2 4 0 0.5 1 2 4 
Padj ≤ 0.1 
Figure 6.11: Differential exon usage by TLR genes in WT and UBL5 knockdown cells, 
following treatment by LPS. 
 
Relative exon usage was measured by comparing reads from WT cells vs UBL5 KD cells at the 
same time point after LPS treatment (left panel) or WT at a specific time after LPS treatment as 
compared to untreated WT cells. Exon usage was calculated by DexSeq. Fold change 
measurements that have an FDR of 0.1 or less are highlighted by a black border. TLR genes with 
a fold change that crossed the FDR threshold of 0.1 in at least one time point were included. 
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alternative splicing 
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siRNAs, with spliceosome 
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Network analysis of TLR genes with differential exon usage and TRIAGE 
selected hits linking core and supporting spliceosome genes 
Figure 6.12: Network analysis of TLR factors showing differential exon usage by RNA-seq 
and spliceosome network hits from LPS response study. 
 
Network analysis using curated interactions from the STRING database. (Evidence source = 
Experimental and score ≥ 700). The TLR genes were selected based differential exon usage by 
RNA-seq. The splicing factors were selected as hits from the Human TNF –α study. The splicing 
factors were grouped based on the categories outlined by Papasaikas, 2015.  
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6.8 Examples of alternative splicing in response to LPS treatment 
Alternative splicing acting as a regulatory mechanism for TLR activation relies on the 
possibility that the splice variant repertoire of TLR pathway components changes dynamically 
soon after LPS stimulation. To further interrogate whether such changes are observed, I 
selected two TLR factors from the RNA-seq dataset that have known splice variants. IRAK1 
has reported variants that lack exon 11 (Rao et al., 2005). TMED7-TICAM2 is a gene whose 
alternative splice variants lead to the expression TMED7, TRAM, and TAG genes (Doyle et 
al., 2012). To assess whether these events occur within the timeframe of the LPS response, I 
designed sets of primers that span the alternatively spliced regions in the genes and sets of 
primers that sit outside of it. I then ran a polymerase chain reaction (PCR) using RNA from 
THP1 cells treated with LPS for 2 or 4 hours, alongside RNA from untreated cells. Running 
the PCR products from the IRAK1 set of primers on a gel showed that the sets of primers that 
bound outside of alternatively spliced region stayed consistent from 0 to 4 hours of LPS 
treatment. The PCR product from the reaction using the set primers that bound to the 
alternatively spliced region decreased with 2 and 4 hours of LPS treatment (Figure 6.13).  
Results from the TMED7-TICAM2 reactions show an interesting discrepancy. Reactions 
with primers that bound to either the TMED7 gene exclusively or the TICAM2 gene 
exclusively show a consistent PCR result across the hours of treatment with LPS. The set of 
primers that bound across the span of TMED7-TICAM2, however, showed an observable 
decrease following treatment with LPS (Figure 6.14). Suggesting that the mRNA of the 
TMED7-TICAM2 gene is transcribed and spliced differently in response to LPS treatment, and 
that its change is observable in the early stages of LPS stimulation. 
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Figure 6.13: cDNA amplification by primer pairs of IRAK1 following treatment by LPS. 
 
(A) Primers were designed to align with different exons of IRAK1. Primer sets including exon 
11-exon 12 (S2-A2, S1-A2) show a decrease following 4 hours of LPS treatments. Primer sets 
outside of the exon 11-exon 12 range (S3-A3) shows a slight increase with treatment by LPS. (B) 
A schematic of IRAK1 exons (based on the NM_001569 NCBI sequence) and the primer 
sequence placements. 
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Figure 6.14: cDNA amplification of TMED7-TICAM2 gene following treatment by LPS. 
 
(A) Primers were designed to align with different exons spanning different segments of the 
TMED7-TICAM2 gene. Primer sets that span only the range of TMED7 (S1-A1) or only the 
range of TICAM2 (S3-A4) shows consistent expression following LPS treatment. The primer set 
spanning the combined gene transcript (S1-A3) shows a consistent decrease following treatment 
by LPS. (B) A schematic of TMED7-TICAM2 cDNA sequences (based on the NCBI sequences: 
NM_001164469 (TMED7-TICAM2), NM_181836.6 (TMED7), NM_021649.7 (TICAM2)) with 
the primer sequence placements. 
TMED7-TICAM2 
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6.9 Summary 
Analysis by TRIAGE identified robust shared enrichment between the three screens of the 
macrophage response to LPS. An analysis of the pathway enrichments in the selected datasets 
show that, in addition to the immune related factors, pre-mRNA splicing and proteasomal 
factors have a key role in facilitating TLR activation in response to LPS treatment. I followed 
up this observation with assays to further investigate the roles of the proteasome and mRNA 
splicing in response to LPS. Treating macrophages with a proteasome inhibitor showed a broad 
dependency of multiple branches of the TLR pathway on stimulus-induced proteasomal 
degradation to permit signal transduction. Further validation and studies are still needed, 
however, to establish how many branches of the pathway it effects and to determine if there 
are additional unappreciated targets of proteasomal degradation in the LPS signaling cascade. 
Treating macrophages with an inhibitor of splicing also showed that upstream of cytokine 
transcription, an active spliceosome is required to support and sustain the LPS response. 
Analysis of RNA-seq data and follow up by PCR shows that alternative splicing of TLR factors 
occur within the rapid time frame of innate immune activation. These combined results in 
alternative splicing and spliceosome inhibition suggest that the engagement of the spliceosome 
is a critical mechanism in the activation of the inflammatory response. How these dynamic 
changes occur and what are the impacts on signaling of alternatively spliced factors of the TLR 
pathway remain to be explored. 
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7 Short read and long read RNA-seq characterizing alternative splicing in response 
to LPS 
 
7.1 Introduction 
With the identification of a regulatory role for the spliceosome (chapter 6), a critical question 
to address is whether the macrophage transcriptome is dynamically changed in response to a 
challenge by LPS. I have shown isolated examples of such changes in chapter 6 (section 6.8), 
yet to address how such changes are driven by LPS, and what role they could potentially play 
in the activation of macrophages, requires a broader approach. The next generation sequencing 
(NGS) method RNA sequencing (RNA-seq) provides a platform where the characterization of 
cellular RNA can be done on an omic scale (Z. Wang et al., 2009). Advances in bioinformatic 
analysis pipelines have further expanded the capacity of these analyses to discriminate between 
different kinds of alternative splicing events (Shen et al., 2014). Third generation sequencing 
approaches make it further possible to read transcripts end-to-end, eliminating the need to rely 
on a reference genome to reconstruct transcripts thereby enabling the identification of 
completely novel isoform variants (Eid et al., 2009). In this chapter I describe the application 
of these approaches to compare the transcriptome of unstimulated macrophages to the 
transcriptome of macrophages treated with LPS. For this analysis I utilize the RNA of 
macrophages differentiated from primary and immortalized monocytes (section 7.2). Using 
Illumina Iso-seq analysis I show how differential isoform expression is induced by treatment 
with LPS (section 7.3). Utilizing the rMATS analysis pipeline I show how different forms of 
alternative splicing are similarly induced in the different cells sequenced (section 7.4). Despite 
modest overlap on the gene level, I show how the enrichment for TLR signaling pathways in 
LPS induced alternative splicing is shared in human and mouse (section 7.5). I also show how 
long read RNA-seq by SMRT Pacific Biosciences more thoroughly identifies the variant 
changes driven by LPS stimulation (section 7.6). I was assisted in the work of this chapter by 
the Center for Cancer Research Sequencing Facility (CCR-SF) at Frederick National 
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Laboratory for Cancer Research (FNLCR) and the NIAID Collaborative Bioinformatics 
Resource (NCBR) group. 
 
7.2 RNA extraction of primary and immortalized macrophages treated with 
LPS 
To increase the likelihood that the variants identified illuminate the LPS response in human 
health and disease, and to also have a pipeline for experimental validation in mouse models 
and cell lines, I ran the sequencing using macrophages derived from human and mouse cells. I 
included macrophages derived from human peripheral blood monocytes from healthy donors, 
macrophages differentiated from mouse bone marrow, and macrophages differentiated from 
the human THP1 cell line. I also included macrophages derived from THP1 cells which had 
the splicing factor UBL5 knocked down (described in section 6.7 and section 2.5.4). I 
differentiated the different sourced monocytes using the relevant differentiation factors (GM-
CSF for human PBMCs, MCSF for mouse BMDMs, and PMA for THP1s). Following 
differentiation, I treated a subset of cells with LPS for four hours while leaving a subset of cells 
untreated. I prepared three independent biological replicates for every condition and extracted 
total RNA from the cells to be sequenced. A schematic of the experimental design is in Figure 
7.1. I also tested to confirm that the LPS treatment worked by measuring the relative induction 
of TNF-a mRNA by qPCR in the treated versus untreated cells (Figure 7.2). 
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RNA 
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Figure 7.1: RNA extraction from 4 macrophage cell types treated with LPS. 
 
Cells were collected from four sources. (L-R) Human peripheral blood monocytes collected 
from three screened healthy donors, bone marrow derived monocytes from C57BL/6 mice, 
THP-1 cells, and THP1 cells with UBL5 knockdown by siRNA. Cells were differentiated to 
macrophages in culture. Following differentiation, cells were split into LPS treated and 
untreated subsets. Following four hours of LPS treatment all cells were lysed and the RNA 
extracted. Three replicates of each condition and cell type was collected. 
  
Sample preparation for RNA-seq of the LPS induced transcriptome 
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Figure 7.2: PCR of TNF transcription in LPS treated samples selected for RNA-seq. 
 
PCR reaction of the three replicates from each cell type treated with LPS and selected for 
RNA-seq. The LPS treated cells (100ng/ml, 4h) are compared to the LPS untreated cells. The 
change in TNF-α expression between the treated and untreated samples were measured and 
normalized to the expression of HPRT in treated and untreated samples. Each biological 
replicate was run as three technical replicates. Error bars represent the standard deviation of 
the three technical replicates. 
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7.3 LPS induces differential gene expression within and beyond the canonical 
TLR4 Pathway 
To first observe how the replicates and different samples compare to each other, together with 
my collaborators at CCR-SF and the NCBR, we did a gene expression concordance analysis. 
Calculating the level of overlap in gene expression across the different replicates and samples 
showed strong agreement across replicates and critical divergence between treated and 
untreated cells (Figure 7.3A-D). Of note, the replicates of mouse BMDMs showed the highest 
level of overlap as compared to intra-condition replicates of the other macrophage cell types. 
While this is to be expected (BMDMs were collected from same age mice of the same genetic 
background, housed in the same facility, and collected on the same day), it portends that many 
of the fold change differences that can be measured are more likely to cross thresholds of 
significance in the BMDM samples as compared to samples with less comparable replicates 
(Figure 7.3C-D).  
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Figure 7.3: Concordance of gene expression profiles as measured by RNA-seq. 
 
Overlap of raw counts of gene expression by RNA-seq. LPS treated cells are denotated as 
”plus” and untreated cells as “minus”. (A-B) Human primary cells derived macrophages (H), 
THP1 macrophages (T), and UBL5- KD THP1 macrophages (U) are compared. Visual 
representation of concordance and calculated values are in the left and right panel, 
respectively. (C-D) Concordance of gene expression in mouse BMDMs (M) samples and 
replicates. Visual representation of concordance and calculated values are in the left and right 
panel, respectively. 
  
H = Human Primary Macrophages. T = THP1 derived macrophages.  
U UBL5- KD THP1 derived macrophages. M = Mouse BMDM. 
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Mapping the differentially expressed genes in untreated versus LPS treated cells shows 
that, in all macrophage samples, LPS induces differential gene expression in a sizable selection 
of the genome. More than 2000 of the genes with differentially expression in response to LPS 
are shared across all wildtype macrophage types (Figure 7.4A). Comparison between the 
wildtype THP1 cells and UBL5 knockdown THP1 cells also shows that more than half of the 
differentially expressed genes in THP1 macrophages require UBL5 to support the differential 
expression (figure 7.4B). This provides further support for the importance of dynamic splicing 
to promote and sustain the LPS-induced gene expression program. Comparison of differentially 
expressed canonical TLR pathway genes shows a similar trend. Human primary macrophages, 
BMDMs, and THP1 macrophages show differential gene expression in many of the canonical 
TLR pathway genes, with 68 out of 186 genes changed in macrophages from human, mouse, 
and immortalized human monocytes (Figure 7.4C). Similar to what we saw with global gene 
expression, when comparing wildtype THP1 macrophages to UBL5 knockdown macrophages 
a substantial portion of canonical TLR genes did not show LPS induced differential gene 
expression in the absence of UBL5 expression (Figure 7.4D). Since LPS induces gene 
expression alteration for such a large proportion of the signaling components of the pathway, 
this already implies that the ‘state’ of the TLR4 pathway in naïve cells is substantially altered 
after macrophage activation. It is tempting to surmise that an important theme of this change 
in state could involve the expression of different splice variants that have altered signaling 
properties that serve to maintain the post-LPS state of the cells.  
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  Divergence and scale of LPS induced differential expression in 
macrophages of diverse origin. 
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Figure 7.4: Differential gene expression in LPS treated macrophages. 
 
(A)  Scale of shared and divergent counts of differentially expressed genes in LPS treated 
human primary cells derived macrophages (H), Mouse BMDMs (M), and THP1 macrophages 
(T). (B) Scale and overlap of differentially expressed genes in LPS treated wildtype THP1 
macrophages (T) and UBL5- KD THP1 macrophages (U). (C-D) Canonical TLR pathway 
genes that have differential expression in response to LPS treatment. 
A B 
C D 
H = Human Primary Macrophages. T = THP1 derived macrophages.  
U UBL5- KD THP1 derived macrophages. M = Mouse BMDM. 
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7.4 Diversity of splicing events are consistent across species and cell type 
To investigate the alternative splicing events induced by LPS I worked with Dr. Justin Lack 
and Dr. Cihan Oguz from the NCBR group to apply the replicate multivariate analysis of 
transcript splicing (rMATS) analysis pipeline to our data. The rMATS analysis pipeline uses 
the comparison of two sequencing samples to map the type of alternative splicing events that 
explain the transcript differences between them (Shen et al., 2014). rMATS curates splicing 
events into five alternative splicing event types. Skipped exon (SE) which involves the skipping 
of an exon between two transcripts. Alternative 5’ splice site (A5SS) which involves variation 
in the 5’ region by the preference for alternative splice sites near the 5’ site. Alternative 3’ 
splice site (A3SS) which involves variation in the 3’ region by the preference for alternative 
splice sites near the 3’ site. Mutually exclusive exons (MXE) which occurs when two exons 
are interchangeably included in transcripts. Retained introns (RI) which is when an intronic 
sequence is included by alternative splicing in a transcript. (Figure 7.5). 
 
 
  Figure 7.5: Classification of 
alternative splicing event types. 
 
Alternative splicing event types and 
their abbreviations as defined by the 
rMATS analysis platform. From top 
to bottom) Skipped exon (SE), 
Alternative 5’ splice site (A5SS), 
Alternative 3’ splice site (A3SS), 
Mutually exclusive exons (MXE), 
and Retained intron (RI).  
From Park, J. W., Tokheim, C., Shen, S., & Xing, Y. (2013). 
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A cursory analysis of splicing events induced by LPS treatment in the four samples I 
measured found that all five splicing events occurred in near similar proportions in the 
differently sourced macrophages. Splicing events were dominated by skipped exon events with 
smaller proportions of the other four event types. These ratios were, interestingly, not effected 
by the knockdown of the splicing factor UBL5 (Figure 7.6). The most observable difference 
between the different macrophage samples were the number of splicing events in response to 
LPS treatment. BMDMs and THP1 macrophages showed the greatest number of alternative 
splicing events in response to LPS treatment. Human primary macrophages and UBL5 
knockdown THP1 macrophages show only about half as many splicing events in response to 
LPS treatment as THP1 wildtype and BMDMs (Figure 7.6). Looking at the genes associated 
with those splicing events reveals that a substantial number of the genes undergoing alternative 
splicing are shared across samples (Figure 7.7A). Across the wildtype sample (Human primary, 
BMDMs, THP1) 32 genes with alternative splicing events are shared (Figure 7.7B). A list of 
the 32 genes reveals several TLR pathway related genes, such as IRAK1, TANK, and CASP8. 
The regulatory factor MBNL1 that was found to be critical for macrophage differentiation and 
regulating splicing events (H. Liu et al., 2018) is also found on the list as undergoing alternative 
splicing in response to LPS (Figure 7.7C). The mitochondrially targeted NDUFAF6 is also 
listed amongst the genes undergoing alternative splicing in response to LPS suggesting a 
mitochondrial and metabolic regulatory link. (Alternatively spliced variants of this gene have 
also been associated with a form of Fanconi Syndrome a chronic kidney disease associated 
with pulmonary interstitial fibrosis (Hartmannová et al., 2016)).  
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MXE
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U+ vs. U-
SE A5SS A3SS MXE RI
798 events 
Diversity of LPS driven splicing events across macrophage 
samples 
Figure 7.6: Splicing events in different macrophage cell types treated with LPS. 
 
Characterization of splicing events as found in rMATS analysis of RNA-seq data from human 
primary cells derived macrophages (H), Mouse BMDMs (M), THP1 macrophages (T), and 
UBL5 KD THP1 macrophages (U). Proportion of each event type represented in the Venn 
diagram and number of total events observed listed below. 
H = Human Primary Macrophages. T = THP1 derived macrophages.  
U UBL5- KD THP1 derived macrophages. M = Mouse BMDM. 
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  Genes with alternatively spliced mRNA in response to LPS 
Number of genes with alternatively 
spliced mRNA 
A B Number of genes with alternatively 
spliced mRNA  
(Wildtype cell types only) 
Genes with alternatively spliced mRNA 
in all cell types (WT) 
C 
Figure 7.7: Alternative splicing events in shared genes following treatment with LPS. 
 
(A) Number of genes with observed splicing events in response to LPS treatment found in 
human primary cells derived macrophages (H), Mouse BMDMs (M), THP1 macrophages (T), 
and UBL5- KD THP1 macrophages (U). (B) Number of genes with observed splicing events 
in response to LPS treatment found in the wildtype cell line derived macrophages. (C) Table 
of shared genes with measured splicing events. Score is calculated by the splicing event with 
the highest “inclusion level difference”. 
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7.5 In human and mouse macrophages, genes related to LPS signaling are 
alternatively spliced in response to LPS 
The extent of conservation between human and mouse TLR4 signaling architecture has been 
the subject of much study and debate (Godec et al., 2016; Seok et al., 2013; J. Sun et al., 2016; 
Takao & Miyakawa, 2015) (Figure 1.3). While some core signaling factors are conserved 
across species, other factors have been shown to be species specific (such as IRAK1 and 
IRAK2, (J. Sun et al., 2016)). Alternative splicing has also been shown to operate in a species 
specific manner, with conserved genes generating different isoform variations across species 
(Pan et al., 2005). In the previous section I have shown that in response to LPS many genes are 
alternativly spliced in macrophages from primary human and mouse monocytes. (The higher 
proportion of genes with observed alternative splicing events in mouse versus human may in 
part be driven by the closer similarity of its replicates. As discussed in section 7.3, Figure 7.3). 
Genes undergoing alternative splicing in response to LPS only modestly overlap across human 
and mouse (Figure 7.8A). An analysis of pathway enrichment, however, shows that in both 
species the genes undergoing alternative splicing in response to LPS are in pathways related to 
TLR signaling (Figure 7.8B). In human, of the 70 pathways identified as enriched for in the 
alternatively spliced genes, 34 are in TLR related pathways. In mouse, of the 136 pathways 
enriched for in the alternatively spliced genes, 52 are in pathways associated with TLR 
signaling. Critically, the 12 pathways that are enriched for in both species are dominated by 
TLR related signaling pathways (Figure 7.8B). These findings suggest that the engagement of 
alternative splicing in response to LPS is conserved across species, and that its activation 
effects a broad range of TLR signaling genes.   
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Human Mouse 
108 1262 555 
Human Mouse Enrichment score 
Genes undergoing alternative 
splicing in response to LPS 
LPS induced alternative splicing in human and mouse 
macrophages 
Pathway enrichment in genes undergoing 
alternative splicing in response to LPS 
Figure 7.8: Shared enrichments in human and mouse macrophages of LPS induced 
alternative splicing. 
 
(A) Number of genes with observed splicing events in response to LPS treatment found in 
human primary cells derived macrophages and Mouse BMDMs. (B) Reactome pathway 
enrichments (p<0.05) of genes in human and mouse macrophages that undergo alternative 
splicing events in response to LPS.  
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7.6 Long read sequencing identifies LPS driven differences in repertoire of 
mRNA transcripts 
The power of short read bulk RNA-seq is that it provides a quantitative measure for the mapped 
splicing events it detects. This approach, however, relies on the short reads (usually of about 
150 base pairs (bp)) being mapped onto a known reference genome so that the expressed 
transcripts can be reconstructed. The dependency on the reference genome means that short 
read RNA-seq is hindered from identifying novel transcripts that are as yet not curated in the 
reference genome and its variants. An alternative approach is long read RNA-seq methods that 
can read upwards of 5000bp at a time, thus requiring no reconstruction of splice junction to 
infer transcript variants. A table of the differences between short and long read approaches are 
listed in table 7.1. To complement the short read RNA-seq analysis, I collaborated with the 
CCR-SF group to conduct long read RNA-seq by SMRT PacBio Sequencing (Table 7.2). A 
representative single replicate RNA sample set from the short read analysis was selected for 
long read sequencing. To compare the various macrophage samples, in the context of novel 
isoforms, PacBio results were analyzed by the Structural and Quality Annotation of Novel 
Transcript Isoforms (SQANTI) pipeline (Tardaguila et al., 2018). The SQANTI pipeline still 
uses the reference genome, not as a way to map and reconstruct transcripts, but to categorize 
how the identified transcripts relate to known transcripts. SQANTI categorizes transcripts as 
full splice match (FSM), incomplete splice match (ISM), novel in catalog (NIC), novel not in 
catalog (NNC), genic intron, and genic genomic (Figure 7.9).  A SQANTI analysis of the 
treated and untreated macrophages I selected showed high levels of FSM and ISM transcripts, 
with lower levels of the other categories. Of interest, the number of incomplete splice matches 
was substantially higher in the treated and untreated UBL5 knockdown samples, further 
suggesting that a segment of the alternatively spliced variants we observe in macrophages 
depend on UBL5 (Figure 7.10). 
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Illumina short read 
sequencing 
SMRT Pacific 
Biosciences (PacBio) 
Base pairs/read ~150 >5,000 
Novel isoforms not in 
the reference genome 
Relies on matching to 
reference genome 
Can identify novel 
isoforms 
Scale Affordable to scale to 
multiple conditions 
and replicates 
Expensive to expand 
to multiple conditions 
and replicates 
Table 7.1 Short read versus long read RNA-seq methods. 
 
 
 
 
 
  
Illumina short read 
sequencing 
SMRT Pacific 
Biosciences (PacBio) 
Cell types H, M, T, U H, M, T, U 
Conditions LPS-/LPS+ LPS-/LPS+ 
Replicates 3 1 
Table 7.2 Sample and replicate conditions for short read and long read RNA-seq.   
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Novel Not in Catalog,  
novel isoforms using novel junctions.  
Incomplete Splice Match,  
matches reference partially.  
Novel In Catalog,  
novel isoform using known junctions.  
Intronic sequence,  
entirely within intron. 
Intronic sequence,  
overlapping introns and exons. 
Full Splice Match,  
matches reference perfectly.  
Categorization of isoforms from long read RNA-seq 
Figure 7.9: Novel isoform categorization by SQANTI analysis of long read RNA-seq. 
 
A schematic of the categorization of isoforms from long read RNA-seq. Visual mapping is of 
how the different isoforms map onto the reference isoform (black). Image adapted from  
https://www.pacb.com/wp-content/uploads/2018-SMRT-Leiden-Iso-Seq-Method-Human-
Diseases-Elizabeth-Tseng-MainTalk.pdf 
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Figure 7.10: Classification of transcripts identified by long read RNA-seq of LPS 
treated and untreated macrophages. 
 
LPS treated samples are indicated as “plus” and untreated as “minus”. Numbers reflect total 
different transcripts identified. Categories follow SQANTI categorization (see figure 7.8)  
H = Human Primary Macrophages. T = THP1 derived macrophages.  
U UBL5- KD THP1 derived macrophages. M = Mouse BMDM. 
Transcript classification of LPS treated and untreated 
macrophages. 
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7.7 Summary 
The identification of the spliceosome as a regulatory signaling mechanism in the context of 
macrophage activation implies a dynamic macrophage transcriptome in the early stages of the 
LPS response. To elucidate how these changes in mRNA transcripts activate and sustain LPS 
signaling requires a robust characterization of the alternative splicing events and novel 
transcripts induced by TLR4 signaling. In this chapter I have demonstrated the creation of such 
a dataset by creating complimentary short read and long read RNA-seq analysis. The diversity 
of macrophage samples used in the dataset further enables cross-species and cell line 
comparison for identifying variant changes that are relevant in human disease. Critical 
interrogation of these datasets, paired with rigorous follow up studies, is still required. These 
datasets outline a path towards further characterizing the novel regulatory mechanism I have 
shown in chapter 6.  
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8 Discussion 
 
8.1 Outline 
Taken together, the findings that I have presented in the preceding chapters suggest two parallel 
sets of insights. First, a framework for analysis of genome-scale data that goes further than 
previous methods in identifying lower scoring true positive hits. Second, a regulatory role for 
the spliceosome and proteasome in initiating and sustaining macrophage activation on a more 
detailed scale than has been previously appreciated. In this chapter I discuss some of the 
implications of these two findings. I begin with a summary of the different findings of this 
thesis (section 8.2). I discuss some of the questions and possible follow up studies that the two 
major findings suggest (section 8.3 and section 8.4). Based on the latter finding from this thesis 
I also propose a new model for how stimulated macrophages sustain TLR4 signaling against a 
background of active regulatory expression (section 8.5). As proposed by the model, a role for 
alternative splicing in the regulation of inflammatory signaling would elucidate some of the 
innate immune signatures that are observed in diseases associated with splicing-related 
mutations and differential isoform expression. In the final section I present one such example 
and how the work of this thesis can be built upon to expand our understanding of the 
mechanism behind a specific disease pathology (section 8.6).  
 
8.2 Summary of the work presented in this thesis. 
The work I have presented in this thesis support three hypotheses about high-throughput data 
analysis and the regulation of TLR4 signaling. First, that pathway and network approaches to 
hit selection are complimentary in the solutions they provide, and a systemic integration of 
these approaches would yield cumulative results. Second, that a robust analysis of genome-
scale studies that goes beyond the highest scoring and recognizable hits would reveal novel 
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regulatory mechanisms of macrophage activation. Third, that the spliceosome and alternative 
splicing play a dynamic and potentially critical role in macrophage activation.  
Using previously published datasets for HIV HDFs, I first developed and tested a novel 
integrated and iterative framework, coined TRIAGE, for using curated databases in hit 
selection from genome-scale screens. By measuring the statistical significance of enrichment 
and the size of overlap across parallel omic studies, I showed that pathway and network-based 
approaches are indeed complimentary with strengths in false positive and false negative 
correction respectively (Sections 4.1-4.9). I then showed how the TRIAGE framework for 
integrating pathway and network-based hit selection to prioritize hits from a two cutoff dataset 
leads to the strongest combined error correction (Sections 4.10-4.13).  
Applying the TRIAGE approach to hit selection from three genome-scale siRNA studies 
of the response to LPS in macrophages I identified many shared putative regulators with a 
strongly improved enrichment of TLR and other expected innate immune pathways (section 
6.3). The analysis also identified a robust enrichment of splicing and proteasome factors 
(section 6.4). The integrated approach further identified putative regulatory and interacting 
candidates of these processes that are currently outside of the annotated spliceosome and 
proteasome groups (section 6.7). Using a proteasome inhibitor, I showed how the proteasome 
is more broadly required in the downstream signaling branches of the TLR pathway than has 
previously been appreciated (section 6.5). Using a splicing inhibitor, I also showed how the 
activation of the TNF-a promoter by LPS requires an active spliceosome (section 6.6). I further 
demonstrated that TLR factors with known variants show differential exon usage in response 
to LPS stimulation (section 6.8). To expand the capacity for characterizing the role of 
alternative splicing in macrophage activation I generated and mapped a set of RNA-seq 
datasets from human and mouse macrophages treated with LPS (section 7.2). Initial global 
analysis of alternative splicing and the increase in splicing events in response to LPS 
   213 
complemented my earlier finding of the likely important role of the spliceosome in macrophage 
activation, especially considering the high frequency of TLR pathway components among the 
spliced transcripts (sections 7.4-7.5). Long read RNA-seq broadens this dataset by identifying 
novel transcripts not currently annotated in the reference genome (section 7.6). These two 
datasets suggest a pathway through which the quantitative data from the short-read RNA-seq 
can be integrated with the robust transcript detection of the long-read approach to achieve a 
more comprehensive characterization of the changes that occur in the macrophage 
transcriptome in response to LPS.  
In the processes of developing the above analysis, I also recognized that the TRIAGE 
pipeline has a utility for the high-throughput biology research community beyond the innate 
immune context for which I developed it. To broaden its accessibility, I built a publicly 
available web-based interface of the analysis pipeline (chapter 5). A version of the interface 
was first made publicly available in February 2018. Since then, triage.niaid.nih.gov has had 
more than 1,000 unique visitors, with the majority returning for repeat visits. The most 
common question raised by users has been the challenge in how to tier the high confidence and 
medium confidence datasets in different contexts. The ease of use and speed of analysis by 
TRIAGE is designed to make it possible to address the above issue through repeat analysis 
with different cutoffs to compare and contrast different analysis outcomes (section 5.11). The 
findings of this thesis also raise critical questions and suggest paths for further exploration both 
in bioinformatic solutions to high-throughput guided discovery and in determining the role of 
alternative splicing in the context of inflammatory signaling and disease. In this chapter I 
address some of the possible paths that follow from this analysis.  
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8.3 Persistent challenges in database-driven omics exploration  
In the development of TRIAGE, I have focused on the twin challenges of incomplete genome 
annotation by pathway databases and lack of false positive correction in network analysis 
approaches. TRIAGE addresses these issues and optimizes the use of databases to more 
thoroughly identify biologically significant lower scoring hits from omic-scale studies. 
TRIAGE was designed and tested using the first-generation methods of pathway and network 
analysis (over representation analysis and direct neighbor, respectively). While the framework 
of the complementary iterative design of TRIAGE can in principal be extended to other forms 
of pathway and network analysis, it remains to be tested whether the design can be similarly 
applied to those analysis methods.   
Some of the intrinsic challenges of relying on curated databases persist even in the 
TRIAGE design. In the context of using pathway enrichment for hits prioritization, the 
statistical approach used to assess significant enrichment (a hypergeometric test with FDR) 
favors a specific range of pathway sizes. Best practices in the use of pathway enrichment 
statistics suggest that the analysis works best in pathways that contain member genes in the 
range of 20 to 400 (Ramanan et al., 2012). This range limits the possibility to explore broader 
pathways such as metabolic processes which have higher gene membership counts. There is 
also a lot of redundancy and overlap in pathway annotation which can lead to unrelated 
enrichments being identified, though some bioinformatic solutions for this have already been 
proposed (Pita-Juárez et al., 2018; Vivar et al., 2013). Network analysis driven data exploration 
also has a set of persistent challenges. Notably, network analysis databases such as STRING 
are cell type and treatment agnostic (Ma et al., 2019), making some of the imputed interactions 
irrelevant or misleading for analysis in different contexts. The latter challenge could be 
addressed by more cell or disease specific protein-protein interaction networks being 
generated, but this will require a substantial investment from the research community to 
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develop and generate such resources. I designed the TRIAGE R code such that it can be adapted 
to more bespoke analysis pipelines when such datasets are available. Recently developed 
search engines such as GADGET have used thoroughly sensitive text mining algorithms to 
map abstracts in PubMed to specific gene IDs, metabolites, and disease keywords (Craven, 
2015), an expansion of these methods to map interactions from the literature to the cell types 
and treatments they were identified in could address some of the current network database 
blindspots. Additional creative bioinformatics, however, will also be necessary to infer across 
which cell types and conditions observed protein-protein interactions can be extrapolated to, 
and in what contexts comparisons are less likely to be informative. 
  
8.4 Alternative splicing as a regulatory mechanism for macrophage activation 
The short and long read RNA-seq datasets I described in chapter 7 provide an opportunity to 
explore many critical questions of how alternative splicing might actively regulate 
macrophages following stimulation by LPS. The comparative data in human and mouse 
primary macrophages make it possible as a first step to first characterize how many of the genes 
that undergo alternative splicing in response to LPS are shared across human and mouse. Of 
those shared genes, an essential follow up question that these datasets can reveal is if the 
alternative splicing sites and mechanisms are shared or different between species. This will 
shed light if gene expression conserved in mouse and human TLR4 response also correlates 
with shared isoform expression. Another essential path of inquiry is to characterize and validate 
by PCR the novel isoforms and the differential alternative splicing identified by both RNA-seq 
methods. Commercially available antibodies are often not effective at differentiating between 
different isoforms (as a recent study exploring the different isoforms of TMEM173, the gene 
transcribing the STING protein, found (Rodríguez-García et al., 2018)), thus validation by 
qPCR may be the prudent method to validate the candidates from the RNA-seq findings. 
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Targeting the 32 shared candidates identified as alternatively spliced in wildtype macrophages 
(Figure 7.7) by siRNA knockdown could serve as an initial test for a regulatory role in the LPS 
response. Exogenous expression of specific variants in the knockdown cell lines could be 
further used to delineate the comparative roles of different splice variants. 
The prevalence of alternatively spliced signaling factors raises the question of what the 
mechanistic effects of differently spliced variants imply. The diversity of alternative splicing 
events identified in the datasets (Figure 7.6) could serve as a starting guide for exploratory 
analysis. A number of recent papers, for example, have suggested that intron retention by 
alternative splicing is a cellular mechanism of inducing nonsense mediate decay of a protein 
and thereby decreasing its abundance (Ge & Porse, 2014; Jacob & Smith, 2017). Looking at 
this mechanism from a different angle raises questions of how contextual alternative splicing 
events are guided and selected for. Studies have shown that splice sites are often selected based 
on relative GC nucleotide richness, and GC vs AT richness is reflective of a “splice site 
strength” (Amit et al., 2012; M. Wang & Marín, 2006). A computational tool to asses predicted 
splice strength has been developed (Yeo & Burge, 2004).  
The TRIAGE analysis of the three LPS screens also provides an additional approach 
through which to elucidate the alternative splicing regulatory mechanism. Analysis of the three 
LPS screens identified a network of splicing and spliceosome supporting factors, many of 
which function as RNA-binding proteins (RBPs) (section 6.7). Computational methods have 
been developed to predict binding between specific sequences and RBPs (Paz et al., 2014). 
These methods could be used to prioritize candidates from the LPS siRNA screen based on 
their predictive binding with alternatively spliced isoforms from the LPS RNA-seq studies. 
Identified regulatory candidates could then be experimentally tested by the use of siRNA 
knockdown in THP1 cells and measuring its impact on the abundance of the targeted 
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alternatively spliced isoform. These parallel approaches are a path by which the effect and 
mechanism of alternative splicing on TLR4 signaling can be systemically mapped. 
 
8.5 A model for context specific sensitivity in macrophage activation 
The critical dependency of TLR signaling activation on an active spliceosome and proteasome, 
as I have shown in chapter 6, suggests a possible model by which macrophages switch to 
sustained inflammatory activation from its homeostatic state of robust transcription of factors 
that suppress activation. Alternative splicing of inhibitory factors in a way that selectively 
targets them for degradation by the proteasome can sustain inflammatory activation even in the 
context of robust inhibitory transcription.  Alternative splicing can also blunt the inhibitory 
effects of negative regulators of TLR by shifting its isoform selection to non-functioning 
variants. The explanatory potential of this model for macrophage activation dynamics is that it 
provides a novel avenue through which activation sensitivity, response duration, and rapid 
resolution can be tuned in a context specific manner. Both proteasome activation and 
alternative splicing have been previously shown to confer tissue specific behavior in different 
contexts (Badr et al., 2016; Grosso et al., 2008; Kniepert & Groettrup, 2014; Morozov & 
Karpov, 2019) (also discussed in section 1.4.3). Context specificity is critical for TLR signaling 
sensitivity, as encounters with different levels of endotoxin in different tissue contexts signal 
different levels of danger. In this understanding, the TLR pathway is maintained under tonic 
negative regulation by the robust transcription of factors that suppress its activation. When a 
contextually appropriate threshold of danger is sensed, the proteasome and spliceosome alter 
the mRNA profile and protein abundance of pathway effectors allowing signaling to 
successfully proceed down the pathway uninhibited.  
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8.6 A mechanism for inflammatory dysregulation in myelodysplastic 
syndromes  
Myelodysplastic syndromes (MDS) is a premalignant hematological disease that is associated 
with chronic TLR signaling. As I review in section 1.4.4, patients with MDS have a high 
prevalence of mutations in various core splicing factors. A model of spliceosome and 
proteasome driven regulation of inflammatory activation would suggest a possible mechanism 
for the dysregulated inflammation found in patients with MDS. Two studies looking at MDS 
patients with spliceosome mutations found that patient cells expressed different isoforms of 
critical TLR pathway effectors. Analysis of IRAK-4 expression found that MDS patients with 
mutations in the splicing factor U2AF1 express a long form of IRAK-4 (IRAK4-L) that 
constitutively activates NFkB (Smith et al., 2019). In the context of the findings I have 
presented, and the proposed model for TLR regulation, this could suggest that in the non-
disease state macrophages toggle between the activating and non-activating isoforms of IRAK-
4 to control the inflammatory response. In MDS patients with splicing related mutations this 
capacity may be compromised, leading to the dysregulated TLR signaling that is observed.  
Another study of MDS patients found that hnRNPA1, an auxiliary splicing factor 
(discussed in section 1.4.3), leads to alternative splicing of ARHGAP1 which then activates 
the GTP-binding Rho family protein Cdc42 and is associated with dysregulation in HSC of 
MDS patients (Fang et al., 2017). This finding further shows how dysregulation of a splicing 
factor is correlated with aberrant innate immune signaling. Intriguingly, close observation of 
the targets I identified by TRIAGE analysis of genome-scale studies of the response to LPS 
suggests a possible mechanism that can fill in some of the steps that such a process might take. 
In Figure 6.7 (p. 151) I mapped the canonical TLR pathway and spliceosome pathways hits 
from the screen together with hits from the screen that have predicted interactions with the 
pathway members. A study of the resulting network shows that PTKB which is activated by 
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LPS interacts with Paxillin which also interacts with GIT1, both of which are hits identified in 
my analysis of the screens by TRIAGE. GIT1 interacts with another hit identified in the screen, 
ARHGEF6. ARHGEF6 is a reciprocal modulator of ARHGAP1 and functions as a GTPase 
exchange factor with Cdc42. ARHGAP1 and Cdc42 are the two factors that the study in MDS 
patients found to be effected by the splicing factor and associated with dysregulated HSC. This 
analysis suggests a pathway by which the findings I have shown in this thesis can be used to 
further elucidate the mechanism of inflammatory signaling in health and disease. Building on 
this work, I have begun a collaboration with Dr. Neil Young at the National Heart Lung and 
Blood Institute at the NIH to compare the RNA-seq data from macrophages derived from the 
cells of MDS patients with the findings I have shown in Chapter 7 of this thesis.  
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